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I. - INTRODUCTION 
Bluetongue (BT) is a non-contagious, insect-transmitted disease of certain species of 
domestic and wild ruminants that is caused by BT virus (BTV), (MacLachlan & 
Pearson, 2004; Verwoerd & Erasmus, 2004). BTV infection of ruminants occurs 
throughout much of the temperate and tropical regions of the world, coincident with 
the distribution of specific species of Culicoides biting midges that are biological 
vectors of the virus (Gibbs & Greiner, 1994; Tabachnick, 2004). BT typically occurs 
when susceptible sheep are introduced into areas where virulent strains of BTV 
circulate, or when virulent strains of BTV extend their range into previously 
unexposed populations of ruminants. The global distribution of BTV has historically 
been between latitudes of approximately 40-50°N and 35°S but the virus recently 
(since 1999) has spread northward in parts of the Mediterranean Basin and appeared 
in North-Western Europe in 2006 (far beyond its prior known upper northern limits 
anywhere in the world). Palearctic region of Europe is the only continent other than 
Antarctica currently free of BTV infection. 
From 1998 the incursion of BTV into the Mediterranean Basin is causing great 
economic losses, partly due to the disease itself, but mostly linked to the total ban of 
ruminant trade between the infected and non infected areas.  
During a BTV-2 epidemic in Italy in 2000-2001, approximately 263.000 diseased 
sheep and goats were reported and 48.000 sheep and goats died. During a second 
epidemic in 2001-2002, approximately 251.000 diseased sheep and goats were 
reported and 73.000 sheep and goats died. In 2007 BTV-8 outbreaks occurred on 
over 20.000 farms in Germany with disease in ca, 35.000 cattle, sheep or goats. 
In Sardinia BT was first reported on 18 August 2000 in a flock located in the south-
western part of the island in the Cagliari Province. Serological confirmation of BT 
was obtained on 24 August and BTV-2 was isolated by the National Reference 
Centre for Exotic Diseases (CESME - Centro Studi Malattie Esotiche) on 1 
September and identified subsequently by the Onderstepoort Veterinary Institute. In 
September 2003 circulation of BTV-4 was detected in Sardinia. In January 2004 
circulation of  BTV-16 was found by virus neutralisation test in 7 sentinel animals in 
the north-eastern part of Sardinia. Serotype 1 was first notified on 15 October 2006 
in the south-western part of the island. 
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The indirect costs associated with bluetongue can be much greater than the direct 
costs. Bluetongue is a "List A" disease of the Office of International Epizootics 
(OIE). List A diseases are those diseases which can spread rapidly and that have a 
considerable impact on the health of livestock. List A diseases are notifiable to the 
OIE, and often used as non-tariff trade barriers to prevent livestock from moving and 
potentially spreading disease. Livestock from bluetongue endemic areas, or regions 
where there are outbreaks, can be prevented through regulatory policy from moving 
to regions considered bluetongue-free. The economic impact in reducing livestock 
movement and trade can be considerable.  
In an attempt to reduce direct losses due to disease and indirect losses due to the 
trade embargo caused by virus circulation, the Italian government has, since 
February 2002, been carrying out a compulsory BT vaccination campaign of all 
domestic ruminants using modified-live virus vaccines (MLV) produced by 
Onderstepoort Biological Products (OBP), South Africa. Based on the serotype/s 
present in a given area, various MLV monovalent serotype formulations were used.  
Aim of this work was to evaluate the safety and the efficacy of BTV serotype 1 MLV 


















Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
4 
 
II. - HISTORY 
The disease of BT was first described as ‗malarial catarrhal fever‘ and ‗epizootic 
catarrh of sheep‘ in the original written descriptions by investigators in South Africa. 
The name of ―bluetongue‖ was later used to describe the distinctive cyanotic tongue 
of some severely affected sheep. The first descriptions of BT, an arboviral disease of 
ruminants, were published in the late 19
th
 and early 20
th
 centuries, although farmers 
in South Africa recognised the disease soon after the introduction of fine-wooled 
European breeds of sheep to that region of the world (Erasmus, 1975; Spreull, 1905). 
Prior to the 1940s, BT was thought to be confined to southern Africa. There is some 
evidence for the occurrence of bluetongue in Cyprus in the 1920s but the disease was 
not officially recognized outside of Africa until 1943, when a significant epidemic 
occurred in Cyprus and Palestine (Gambles, 1949). Bluetongue was soon recognized 
in several countries of the Middle East. In 1952 there was an extensive epidemic of 
blue tongue in California but this was eclipsed by an epidemic in Portugal and Spain 
in 1956/57 that killed about 180.000 sheep. The rapid spread of this potentially 
devastating disease prompted the publication by the Food and Agriculture 
Organization of the United Nations (FAO) of a book on Emerging Diseases of 
Animals in 1963, and the disease was added to List A of the World Organisation for 
Animal Health (OIE), thereby restricting the trade in animals from affected countries. 
Bluetongue viruses continued to spread, being found in Australia in 1977 and 
tropical America in the 1980s, but the worldwide absence of any significant losses to 
clinical bluetongue led in the 1990s to a reassessment of its significance. By the end 
of 2001 at least 10 Mediterranean countries have been affected by bluetongue, 
including six (France, Italy, Bulgaria, Macedonia, Yugoslavia and Tunisia) that had 
never previously experienced the disease and two within which hit her to unaffected 
areas (mainland Greece and the Balearic islands of Spain) have now been affected. 
The epidemic, which may not yet be over, has already claimed more than 250.000 
sheep and this is, therefore, the largest epidemic of bluetongue yet seen. Despite this 
statistic, however, the real significance of the epidemic lies elsewhere.  
In the Old World, bluetongue viruses are primarily transmitted by a single species of 
biting midge, Culicoides Imicola (Mellor et al., 2000). This species also transmits the 
closely related African horse sickness virus. Between the late 1960s and 1998, there 
were several outbreaks of bluetongue and African horse sickness in the 
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Mediterranean region and all were in countries that had also been affected in 
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III. - AETIOLOGY 
III.1 - BT VIRUS, TAXONOMY AND STRUCTURAL BIOLOGY  
BTV belongs to the genus Orbivirus of the family Reoviridae, wich currently 
contains twelve genera of multi-segmented dsRNA viruses, including pathogens of a 
wide range of insects, reptiles, fish, crustaceans, mammals (including humans), 
plants and fungi, many of which are of economic, veterinary or medical importance, 
(Mertens, 2000). These viruses can be distinguished and identified by a number of 
different characteristic features, including capsid structure, number and size 
distribution of genome segments, host range, serological properties, protein 
composition, disease symptoms and most recently by sequence analyses and 
comparisons of individual  genome segments (Tables I and II).  
The orbiviruses (which are classified as members of the genus Orbivirus, within the 
family Reoviridae) characteristically have a ten-segmented dsRNA genome that is 
packaged as one copy of each segment within an icosahedral protein capsid (~85 nm 
diameter). The viruses are resistant to lipid solvents, which is typical of 
nonenveloped viruses. The viruses are relatively acid-labile, and slow freezing at -10 
to -20 °C is deleterious to the virus. BTV is the prototype species of twenty-one 
different Orbivirus species now recognised by the International Committee for the 
Taxonomy of Viruses (Mertens, 2004).  
 
Table I. Virus genera of the family Reoviridae 
Genera of viruses with genomes composed of 10-12 segments of dsRNA (Mertens, 2004). 
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Table II. The Orbivirus species (Mertens, 2004). 
 
 
BTV virions are architecturally complex structures composed of 7 discrete proteins 
that are organised into two concentric shells, the outer and inner capsids, and a 
genome of 10 dsRNA segments (Fig. 1). The inner capsid consists of the structural 
protein VP3 which forms the sub-core upon which the VP7 containing "rings" or 
capsomers are located (Huismans et al., 1987a; Hyatt et al., 1988). There are 780 
molecules of VP7 which form 260 triangular spikes and protrude 5 nm from the base 
of the inner capsid (Prasad et al., 1992). The arrangement of the trimers are such that 
there are 132 channels on the surface of the inner shell and are termed Types I, II and 
III. Type I channels are located along the icosahedral 5-fold axes and terminate 
inside the inner shell where they and the Type II channels, which surround the 5-fold 
axes, form indentations on the sub-core. Type III channels are located around the 
icosahedral 3-fold axes and traverse the inner-shell and into the sub-core where the 
minor structural proteins VP1, VP4 and VP6 are located (Fig. 2). A possible function 
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of these Type III channels may be associated with the passage of metabolites and 
RNA into and from the core. Such a function would be consistent with the report by 












Fig. 1. Schematic diagram illustrating the structure of the bluetongue virus particle derived from 







Fig. 2. The overall cryoEM 3-D recon-
struction of the core of BTV-10. (a) 
Surface represent-tation of the core 
showing the trimers of VP7 in yellow, 
with an enlarged portion highlighting the 
protomeric unit of the viral capsid. The 
icosahedral axes are marked as are 
channels II and III in the layer of VP7. In 
the enlarged section, the five quasi-
equivalent trimers are marked P (closest 
to the fivefold) to S (closest to the twofold 
axis) through to T (the trimer on the 
icosahedral threefold axis). (b) Close-up 
of a transverse view of a trimer of VP7 
sitting on the inner layer of VP3, with the 
density coloured radially inward from 
yellow through to blue. (c) Figure of the 
cryoEM reconstruction of  he core of 
BTV (radially cut at 260 Å), showing the 
smooth featureless inner layer of VP3 
coloured in blue. The viral icosahedral 
axes and the positions of the channels II 
and III in the layer of VP7  are marked 
(Grimes, 1997). 
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The outer capsid of BTV and other orbiviruses has been described as fibrillar. The 
outer-shell is composed of the major structural proteins VP2 and VP5. The outermost 
layer is composed of 180 copies, ‗sail-shaped‘ VP2 protein, arranged as trimeric 
‗triskellion‘ structures, together with 360 copies of an inter-dispersed and underlying 
VP5 protein, which also appears to be arranged as 120 trimers. The outer capsid, is 
involved in cell attachment and virus penetration during the initial stages of 
infection. In addition to the seven structural proteins, three non-structural (NS) 
proteins, NS1, NS2, NS3 (and a related NS3A) are synthesised in BTV-infected 
cells. Of these, NS3/NS3A is involved in the egress of the progeny virus. The two 
remaining non-structural proteins, NS1 and NS2, are produced at high levels in the 
cytoplasm and are believed to be involved in virus replication, assembly and 
morphogenesis.  
The components of the BTV outer capsid, proteins VP2 and VP5, are the most 
variable of the viral proteins. VP2, in particular, contains neutralising epitopes and 
by controlling the specificity of virus particle interactions with neutralising 
antibodies, determines the identity of the 24 BTV serotypes that are currently 
recognised using serum neutralisation (SN) assays. Sequence analyses of genome 
segment 2 (Moss et al., 1992; Hewat et al., 1992; Huismans et al., 1987a) and 
segment 6 (Eaton et al., 1992) from representative isolates of all 24 BTV serotypes 
have recently been completed. Phylogenetic comparisons have demonstrated that 
variations in the nucleotide sequences of segment 2 and 6 and in the amino acid 
sequences of VP2 and VP5 show a high correlation with virus type as determined by 
SN assays (Moss et al., 1992; Hewat et al., 1992; Huismans et al., 1987a; Eaton et 
al., 1992).  
Importantly, there is considerable variation amongst field strains of BTV, even those 
of the same serotype, which reflects differences in the nucleotide sequence of each of 
the 10 distinct dsRNA segments of the BTV genome (Bonneau et al., 1999; Pritchard 
et al., 2004; Bréard et al., 2007). Genetic heterogeneity of field strains of BTV 
occurs as a consequence both of genetic drift and genetic shift, the latter as a result of 
reassortment of viral genes during mixed infections of either the vertebrate or 
invertebrate hosts of the virus (Bonneau & MacLachlan, 2004; Pierce et al., 1998; 
Samal et al., 1987a, 1987b). Variation in the nucleotide sequence of individual genes 
occurs through a complex process of genetic drift and founder effect during 
alternating passage of BTV in its ruminant and insect hosts (Bonneau et al., 2001). 
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III.2 - BT VIRUS REPLICATION 
BTV interacts with the target cell surface via VP2 trimers binding to cell surface 
glycoproteins and possibly to other receptors. BTV core particles can also bind to 
cells (particularly insect cells) via VP7 trimers. The BTV particle is then internalized 
in endosomes via a clathrin-dependent endocytosis pathway (Hyatt et al., 1988). VP2 
dissociates from the outer capsid layer in early endosomes. Acidification induces 
VP5 fusion with the endosomal membrane (Huismans et al., 1987), delivering the 
transcriptionally active core into the cell cytoplasm. Like other members of the 
Reoviridae family, BTV replicates within the cytoplasm of infected cells. Within the 
BTV core, the VP1 molecules transcribe positive sense ssRNA copies from each of 
the ten BTV genome segments (Studdert et al., 1966). These mRNA molecules are 
capped by the guanylyl-transferase and transmethylase activities of VP4 (De Mattos 
et al., 1994) and leave the particles via channels situated at the five fold axes of the 
core particle (Della Porta et al., 1979). The viral mRNA serve as templates for 
translation in viral proteins, starting within two hours post infection (Murphey et al., 
1971). Viral positive RNA are directed to viral inclusion bodies (VIB) where the 
correct encapsidation of the different segments (nature and numbers) within the VP3 
shell may involve interactions with the helicase VP6 (Pedley et al., 1988), the 
ssRNA binding NS2 protein (Mertens et al., 1985), and the VP1 and VP4 proteins. 
VP1 then synthesizes the negative strand RNA to produce dsRNA (Studdert et al., 
1966; Fig 3). It has been proposed that each dsRNA segment independently 
associates with a different transcription complex (VP1, VP4 and VP6) located at the 
inner side of VP3 along a five fold axis, making a ‗flower shape‘ in 
cryoelectromicroscopy (Della Porta et al., 1985). 
Exchanges of dsRNA segments can occur when two different BTV (serotypes or 
strains) infect the same cells, contributing to the evolution of BTV through the 
process of reassortment. The process of reassortment may involve fusion of VIB 
formed with different viral particles. For unknown reasons, some segments are more 
often exchanged than others (Browne et al., 1967). 
The VP3 subcores are relatively fragile and unstable structures (Gould, 1987) that 
serve as a scaffold for the addition of VP7 trimers, giving rise to more rigid and 
stable cores. The outer capsid proteins VP2 and VP5 appear to be added to the 
progeny core particle surface at the periphery of the VIB as they enter the host cell 
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cytoplasm. Mature progeny virus particles are transported within the cytoplasm on 
microtubules involving VP2/vimentin interactions (Wade-Evans et al., 1992). 
Release of virions from the infected cell occurs via cell membrane destabilization 
mediated by the NS3 viroporin activity (Lecatsus, 1968), in some cases via budding, 






















Fig. 3. Schematic diagram representing the lytic replication cycle of bluetongue virus (Mertens, 2004). 
 
III.3 - SUSCEPTIBLE SPECIES 
The generally accepted premise is that BTV is able to infect and replicate in all 
species of ruminant, domestic and wild, and there is a significant amount of 
information to support this assertion (Jessup 1985; House et al., 1982; Stallnecht & 
Howerth 2004; MacLachlan, 2004).  
Of the domestic species, sheep are the most severely affected. Indigenous South 
African breeds are less susceptible than the Merino, while most exotic breeds such as 
the European mutton breeds are more susceptible than the Merino. Susceptibility 
may also vary among individuals of a breed. Selected breeds as European fine 
wooled Merinos are highly susceptible to the virus while, Asian and African breeds 
are the most resistant. Sheep breeds from the temperate countries of the world are 
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more susceptible to the development of clinical disease than breeds adapted to the 
tropics. Older sheep are considered to show more severe disease than younger sheep. 
Goats are susceptible to infection although clinical disease is rarely encountered. 
Cattle are frequently infected with BT virus (BTV), but clinical disease is rare 
(Erasmus, 1975). The absence of BT in sheep does not necessary imply the absence 
of BTV or viral activity in a particular region or country at a time. Sheep could 
therefore be regarded as merely an indicator of the presence of the disease. 
In the case of wild ruminants, clinical disease seems to be common only in North 
America where mortality and morbidity have been documented in white-tailed deer 
(Odocoileus virginianus), mule deer (O. hemionus), pronghorn antelope, 
(Antilocapra americana), Elk (Cervus elaphus), mountain goat (Oreamnos 
americanus) and bighorn sheep (Ovis canadensis) (Stallknecht & Howerth 2004). 
Antibodies have been detected in wild carnivores in Africa, and cross-contamination 
between bluetongue and canine vaccines during vaccine manufacture has resulted in 
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IV. - EPIDEMIOLOGY 
Bluetongue is biologically transmitted by Culicoides midges, but only a limited 
number of Culicoides species are efficient vectors. Cattle are the main amplifying 
hosts and are probably also important maintenance hosts. The competent Culicoides 
vector species feed more abundantly on cattle. The incidence and geographical 
distribution of bluetongue infections are determined largely by the distribution of 
insect vectors. The central role of the insect in BT epidemiology ensures that 
prevalence of the disease is governed by ecological factors and climatic, temperature, 
humidity and soil characteristics, which favour insect survival. In many parts of the 
world therefore, the disease has a seasonal occurrence, generally in late summer and 
early autumn.  
IV.1 - DISTRIBUTION OF BTV  
Although BTV infection occurs throughout extensive portions of the tropical and 
temperate regions of the world (Fig. 4), there are marked regional differences in the 
occurrence of virulent BT influenced by several factors, most importantly, 
geographical location, climate and vaccination history. There also are profound 
differences in the virus serotypes and/or principal species of Culicoides vector that 
occur within specific regions (Gibbs & Greiner, 1994; Tabachnick, 2004; 
MacLachlan & Osburn, 2006; Fig. 5; Table III). Both vector insects and ruminant 
animals are essential to the lifecycle of btv. 
IV.1.1 - BTV GEOGRAPHICAL DISTRIBUTION IN EUROPE AND 
MEDITERRANEAN BASIN 
An unknown disease of sheep was first reported from Cyprus in 1924. This disease 
was confirmed as being BT in 1943 (Gambles, 1949; Mellor & Pitzolis, 1979). 
Subsequently in Israel BT was first reported in 1943/44 and then with increasing 
frequency since that time (Shimshony, 2004). 
Between 1956 and 1960, a large outbreak in Spain and Portugal caused the deaths of 
approximately 179.000 sheep (Manso-Ribeiro et al., 1957; Lopez & Botija, 1958). 
More recently an outbreak of serotype BTV-4 has involved the Greek islands of 
Rhodes and Lesbos in 1979 and 1980 (Vassalos, 1980; Dragonas, 1981). Greece was 
then declared BTV free in 1991, but in the October of 1998 a new outbreak involved 
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the islands of Rhodes, Kos, Samos and Léros (serotype BTV-9) (Mellor & 
Wittmann, 2002; Calistri et al., 2004; OIE, 1998). 
From 1999 BTV infection spread progressively across most of the Mediterranean 
Basin, Balkan areas and more recently in north west Europe. Until now, 7 serotypes 
have been detected in the current outbreak in the Mediterranean Basin: BTV-1, BTV-
2, BTV-4, BTV-8, BTV-9, BTV-15 and BTV-16 (Mellor & Wittmann, 2002; 
www.reoviridae.org /dsRNA_virus_proteins/outbreaks.htm). 
 
Table III. Recent global distribution of BTV serotypes and vectors (MacLachlan & Osburn, 2006). 
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Fig. 4. Geographical distribution of bluetongue virus and clinical disease. The three zones are depicted 
to simplify analysis of the epidemiology; they are dynamic and represent parts of a spectrum of virus 
activity dependent upon climate, altitude and other factors. They should not be considered 
geographically accurate; e.g., no clinical disease has been recorded in Australia or South America. 
One would normally expect that in the endemic zone, most ruminants have antibody to the virus; in 
the epidemic zone, the percentage of animals with antibody to the virus varies and is focal, although 
herds/flocks with antibody can be found; and in the incursive zone, no ruminants with antibody can be 

















Fig. 5. Global distribution of BTV serotypes and vector species. The Culicoides species identified in 
bold are considered the principal vector of BTV in each region (MacLachlan & Osburn, 2006). 
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IV.1.1.1 - ROUTES OF INTRODUCTION OF BTV SEROTYPES 
Routes of introduction of such vector-borne diseases into EU are often not clear. 
There is a need for a multi-disciplinary approach to identify the source, ranging from 
tracing of animal/product movements to more sophisticated knowledge of virus and 
vector biology. Knowledge of vector biology and ecology is fundamental to the 
understanding of how these diseases behave and may become established in the EU. 
Genetic analysis of BT viruses isolated in Europe has shown that six serotypes of the 
virus (1, 2, 4, 8, 9 and 16) have entered the region since 1998. There are four 
apparently distinct routes by which these viruses have arrived: from the east via 
Turkey/Cyprus; from the eastern part of north Africa (Algeria, Tunisia) into Italy and 
the western Mediterranean Islands; from Morocco into southern Spain and Portugal 
and via an unknown route into North Western Europe BTV-15 was identified in 
















Fig. 6. Map of the possible routes of introduction of the different BTV serotypes isolated in Europe 
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IV.1.1.2 - BTV SEROTYPES IN EUROPE AND MEDITERRANEAN BASIN  
IV.1.1.2.1  BTV-1 GEOGRAPHICAL DISTRIBUTION 
Serotype 1 was first notified in the north-western part of mainland Greece 
(Panagiotatos, 2004) and in the island of Lesbos and Rhodes in 2001. For a long 
period of time BTV-1 was not detected in other countries in the region, until 2006 
when in October it was recorded in Sardinia (OIE, 2006a). It has also been reported 
in 2006 in Algeria, in Morocco,  in 2007 in Spain, in France, in Tunisia, in Portugal, 
in Libya and in Gibraltar (OIE 2006 and 2007 various Disease information Reports). 
Phylogenetic analyses of segment 2 sequences of BTV serotype 1 Greek isolate and 
Algerian and Moroccan isolates showed that they are distinct, belonging to different 
‗eastern‘ and ‗western‘ lineages respectively (www.iah.bbsrc.ac.uk/dsRNA_virus 
_proteins /BTV1-segment2-tree.htm). 
The initial strain of BTV-1 in Greece is related to eastern viruses from India and 
Malaysia and is thought to have entered Europe from the east 
(www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/ ReoID/btv-1.htm).  
This strain only persisted for a relatively short period in Greece and apparently did 
not spread to other European Countries. In 2006 BTV was detected in northern 
Africa and was shown by RT-PCR and sequence analysis to be caused by BTV type 
1 (www.iah.bbsrc.ac.uk/ dsRNA_virus_proteins/ReoID/btv-1.htm). 
The strain involved is most closely related to other western type 1 isolates from sub-
Saharan Africa, but is clearly distinct from the South African vaccine strain. It is also 
distinct from the earlier Greek isolates of BTV-1 (www.iah.bbsrc.ac.uk/dsRNA_ 
virus_ proteins/ReoID/btv-1.htm).  
IV.1.1.2.2  BTV-2 GEOGRAPHICAL DISTRIBUTION 
In December 1999 BTV-2 was identified in Tunisia, along the east coast of the 
country (OIE, 2000a). During the summer of 2000 new outbreaks of the same 
serotype appeared in the whole northern part of Tunisia and in Algeria (OIE, 2000b). 
During the summer and autumn of 2000, Italy experienced the largest BT epidemics 
in Europe (OIE, 2000c; Calistri et al., 2004). Three regions were involved (Sardinia, 
Sicily and Calabria), inhabited by 54.7% of the entire Italian sheep and goats 
population. 
Phylogenetic analyses of Seg-2 sequences of Tunisia isolate identified the virus as 
BTV serotype 2, belonging to a western lineage (www.iah.bbsrc.ac.uk/dsRNA_ 
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virus_proteins/BTV2-segment-2- tree.htm). The virus is related to other BTV-2 
strains from Nigeria and South Africa, although it is distinct from the South African 
BTV-2 vaccine strain. The initial Tunisian isolates of BTV-2 are also almost 
identical to subsequent isolates made in Corsica and Sardinia indicating that BTV-2 
managed to spread northwards, from north Africa into Italy and the western 
Mediterranean islands (www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/ReoID/btv-
2.htm). 
In the early autumn of 2000 the disease was notified in the Spanish Balearic islands 
(OIE, 2000d) and in the French island of Corsica (OIE, 2000e). In the following 
years BTV-2 infection spread through the southern and central regions of Italy 
(Calistri et al., 2004). 
IV.1.1.2.3  BTV-4 GEOGRAPHICAL DISTRIBUTION 
In 1999 BTV-4 spread in several islands of the Greek. Later the same year the 
serotype spread also into the northern and eastern mainland areas of Greece. Western 
regions of mainland Greece were also involved in 2000, and western and central 
areas in 2001 (Panagiotatos, 2004; Nomikou, 2006 personal communication), and, 
almost at the same time, it appeared in Calabria region, the most southern region of 
mainland Italy (Calistri et al., 2004). 
Phylogenetic analyses demonstrated that the Greek virus is similar to earlier isolates 
from Cyprus and Turkey (www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/btv4-
segment-2-tree.htm). It is also closely related to the Reference strain of BTV-4, 
which is also believed to have been originally derived from Cyprus 
(www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/ReoID/btv-4.htm and http://www.iah. 
bbsrc.ac.uk/dsRNA_virus-proteins/ReoID/BTV-mol-epidem.htm). This suggests that 
the BTV-4 strain which invaded Greece and the Eastern Mediterranean region since 
1999, has been circulating in the region, on the borders of Europe, for some time. 
Indeed several isolates of BTV-4 have subsequently been made in Israel. 
Phylogenetic analyses show that these European BTV-4 strains belong to a western 
lineage but are distinct from the South African vaccine strain 
(www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/ReoID/btv-4.htm and http://www.iah. 
bbsrc.ac.uk /dsRNA_virus-proteins/ReoID/BTV-mol-epidem.htm). 
In September 2003 circulation of BTV-4 was detected in Sardinia (OIE, 2003a). The 
virus spread also to the province of Nuoro, Sassari and Oristano (April, 2004). 
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Further to the notification of an outbreak of BT in Cognocoli-Monticchi, by the south 
Corsica Department dated 31 October 2003, BTV-4 was identified at the laboratory 
of the French Agency for Food Safety (AFSSA) (OIE, 2003b). In the same year 
(2003) BTV-4 was also identified from the Spanish Balearic islands. 
A vast epidemic of BTV-4 in 2004 involved also the northern part of Morocco (OIE, 
2004a), spreading from there into the southern part of the Iberian Peninsula (OIE, 
2004b; OIE, 2004c). The phylogenetic analyses of BTV detected in the Spanish 
island of Menorca showed that this was also a western strain of BTV-4, although it is 
clearly distinct from strains that had previously caused outbreaks in the eastern 
Mediterranean region (www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/ ReoID/btv-
4.htm and http://www.iah.bbsrc.ac.uk/dsRNA_virus-proteins/ReoID/BTV-mol-
epidem.htm). These conclusions were confirmed by Zientara et al., (2006) working 
with Corsican isolates at Maisons Alfort in France. This virus is believed to have 
entered Europe from North Africa. The same strain of BTV-4 subsequently caused 
outbreaks and was isolated in Morocco and then spread to the Iberian peninsula in 
2004, where it persisted through into 2005. 
IV.1.1.2.4  BTV-8 GEOGRAPHICAL DISTRIBUTION 
Serotype 8 had not been detected in Europe and the Mediterranean Basin before 
2006, when it was the cause of a large epidemic involving five Northern Western 
European countries: Belgium (OIE, 2006b), The Netherlands (OIE, 2006c), Germany 
(OIE, 2006d), France (OIE, 2006e), Luxembourg (OIE, 2006f), United Kingdom, 
Denmark, Switzerland, Czech Republicc, Spain and Portugal (www.reoviridae.org 
/dsRNA_virus_proteins/outbreaks.htm). Multiple isolates of the virus were made 
from isolates across this region. Sequence analyses of Seg-2 from Dutch isolate 
demonstrated that the virus is from a western lineage from sub Saharan Africa, but is 
distinct from the BTV-8 vaccine strain (www.iah.bbsrc.ac.uk/dsRNA_ 
virus_proteins/BTV-8-Seg-2-tree.htm). It is uncertain exactly how BTV-8 arrived in 
Northern Western Europe, but the absence of BTV-8 outbreaks in southern Europe 
suggests that it did not involve simple linear extension of earlier outbreaks and is 
likely to reflect a distinct entry route and mechanism.  
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IV.1.1.2.5  BTV-9 GEOGRAPHICAL DISTRIBUTION 
In the autumn of 1998, clinical and serological evidence of BTV-9 was recorded on 3 
islands of Greek Dodecanese archipelago (Leros, Rhodes, Kos) and Samos, adjacent 
to the Anatolian Turkish coast (Mellor & Wittmann, 2002). During 1999 the virus 
was also recorded in south eastern Bulgaria (OIE, 1999), in European Turkey, 
western Anatolian Turkey, North-East and eastern mainland Greece (Mellor & 
Wittmann, 2002). In 2000 and 2001, BTV-9 was again detected in mainland Greece, 
initially in the northern areas and then in the NW near the Albanian and Former 
Yugoslav Republic of Macedonia (FYROM) borders (Panagiotatos, 2004). 
New outbreaks of BTV-9 also occurred in southern Bulgaria in September 2001, and 
in the same month BTV-9 appeared for the first time in Serbia (OIE, 2001a) and in 
FYROM (OIE, 2001b). In October the infection was detected also in Kosovo (FRY) 
(OIE, 2001c) and, in December, in southern Croatia, Dubrovnik district (OIE, 
2001d). 
In September 2002 the National Veterinary Office of Bosnia and Herzegovina 
reported BTV-9 outbreaks in the Republic of Srpska and subsequently ruminants 
have been found seropositive in the Federation of Bosnia and Herzegovina (OIE, 
2002). In the same period of time outbreaks again occurred in Bulgaria. In December 
2002, Albania experienced for the first time one outbreak of BT in Librazhd, in the 
eastern part of the country (OIE, 2003c). After years of absence, in October 2006 
BTV-9 reappeared in south eastern regions of Bulgaria (OIE, 2006g). 
Sequence data for genome segment 2 of the BTV isolated in 1998 in Greece was 
compared to other isolates of BTV held in the reference collection at IAH Pirbright 
from around the world (www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/ReoID/btv-
9.htm). 
The resulting analysis shows that this is an ‗eastern‘ virus, related to strains from 
Indonesia and Australia (www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/btv9-segment-
2-tree.htm). 
IV.1.1.2.6  BTV-15 GEOGRAPHICAL DISTRIBUTION 
A sample of a virus-isolate that was made in Israel from outbreaks of disease in 2006 
was typed as BTV-15, by RT-PCR assays using serotype specific primers targeting 
genome segment 2.  Subsequent phylogenetic analyses confirm the virus serotype 
and indicated that it belongs to a western lineage (www.reoviridae.org/ 
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dsRNA_virus_proteins/BTV15-Seg2-tree.htm).  The number of BTV-15 isolates that 
are available is very limited. So it is difficult to be more precise about the origins of 
this virus strain. However, the existing data suggest that it is new to the region and 
may therefore represent a further threat to Europe in the future.    
IV.1.1.2.7  BTV-16 GEOGRAPHICAL DISTRIBUTION 
BTV-16 was first detected in 1999 in the Greek Dodecanese islands and in northern 
mainland Greece and in 2000 it was also detected in western Anatolian Turkey 
(Mellor & Wittmann, 2002) and on the Greek Island of Lesbos (Nomikou 
unpublished results). Since September 2003, a surveillance programme has been in 
place in Cyprus, and BTV-16 seroconverted sentinel animals were found in October 
2003 (OIE, 2004d). The affected area was in Famagusta (Ammochostos) district, in 
the eastern part of the country. Moreover, in February 2004 a new outbreak of BT 
occurred in Larnaca district, also in the eastern part of the country, about 20 km 
south-west from the first outbreak. 
In January 2004 circulation of BTV-16 in Sardinia was detected by virus 
neutralisation test in 7 sentinel animals (Calistri et al., 2004). In the summer of the 
same year BTV-16 was detected also in Corsica (OIE, 2004e). 
The sequence analysis of Seg-2 and phylogenetic analysis 
(www.iah.bbsrc.ac.uk/dsRNA_virus_ proteins/btv16-segment2-tree.htm) of the 
initial European strain of BTV-16 isolated in Greece during 1999, show that this 
virus is from an eastern lineage and is very similar to strains of BTV-16 from Turkey 
and the South African reference strain of BTV-16 (www.iah.bbsrc.ac.uk/ 
dsRNA_virus_proteins/ReoID/btv-16.htm and http://www.iah.bbsrc.ac.uk/dsRNA_ 
virus-proteins /ReoID/BTV-mol-epidem.htm). The similarity between the Greek and 
Turkish strains and the South African reference strain of BTV-9 may seem surprising 
but the reference strain was originally derived from an outbreak in Pakistan. This 
suggests that the virus arrived in Europe from the east. Phylogenetic analyses have 
shown that the original European field strain of BTV-16 is closely related, although 
distinct from the BTV-16 vaccine strain. BTV-16 also appeared in Cyprus during 
2004, and was a strain of this serotype which is similar to the earlier eastern 
Mediterranean isolates. 
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IV.2 - MODES OF TRANSMISSION  
Bluetongue virus is transmitted by biting midges in the genus Culicoides. Other 
Culicoides species can also transmit the virus and may be important locally. Ticks or 
sheep keds can be mechanical vectors but are probably of minor importance in 
disease transmission. Cattle are the major amplifying host due to their prolonged 
viremia and the feeding preferences of many Culicoides species. The virus is not 
transmitted by direct contact, or by indirect means, between animals in the absence 
of insect vectors. Animals can be infected experimentally by inoculation with 
infected blood. Therefore, iatrogenic transmission by needle transfer is considered 
possible but unlikely. Rarely, virus may be excreted in the semen when males are 
viraemic. Excretion is more likely if there is inflammation of the genital tract and if 
the animal is aged. Contaminated semen may infect recipient females, but this will 
not initiate a cycle of transmission unless competent insect vectors are abundant. 
Introduction of BTV from an area into another can occur in 4 ways: through animal 
movement (domestic and wild ruminants) or animal product transport (semen, 
embryos); by infected vector Culicoides spp. carried by various living (plants, 
animals) or inanimate (airplanes, ships) means; through the active flight of infected 
vector Culicoides spp. (local propagation); and through passive flight of infected 
vector Culicoides spp. on the wind (responsible for long-distance dissemination). 
IV.3 - THE CULICOIDES 
Culicoides (Diptera: Ceratopogonidae) are small biting flies, 1-3 mm in size; 96% of 
the more than 1.300 species known world-wide are obligate bloodsuckers attacking 
mammals (including humans), birds, reptiles and even other insects. In some parts 
their attacks are legion, causing nuisance to humans or an acute allergic dermatitis in 
Horse, and have earned them names such as damnosus, diabolicus and irritans. They 
are distributed from the tropics to the tundra and from sea level to 4.200 m (in Tibet). 
Approximately 120 species of Culicoides occur in Europe; this diversity declines 
markedly towards the Arctic with only about 25 species living beyond the 60th 
latitude.  
Fortunately, only a very small fraction (2.5%) of the Culicoides described world-
wide have a proven involvement in the transmission of viral pathogens injurious to 
livestock; these pathogens include BTV, African horse sickness virus (AHSV), 
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epizootic haemorrhagic disease of deer virus (EHDV), Akabane virus (AKAV) and 
equine encephalosis virus (EEV). Furthermore, adults Culicoides also transmit 
several parasites of veterinary importance, as for example hemoparasites 
(Haemoproteus sp. in birds; Hepatocystis kochi in monkeys) and filariasis 
(Onchocerca sp. in horses and cattle). 
Around the world approximately 32 species of Culicoides are considered to be 
involved in the transmission of BTV; these are listed in Table IV (adapted and 
updated from Meiswinkel et al., 2004) according to subgenus and species complex. 
In sub-Saharan Africa C. Imicola and C. Bolitinos transmit BTV and also other 
orbiviruses including equine encephalosis virus (EEV) and African horse sickness 
virus (AHSV). In South Africa at least 14 serotypes of BTV have been isolated from 
C. Imicola alone (Nevill et al., 1992) one of these being BTV-8, the serotype 
affecting Northern Western Europe in 2006. In the Mediterranean Basin C. Imicola 
(Fig. 7) is the principal vector of BTV; however, within southern Europe an 
additional four species are also implicated: C. Pulicaris, C. Scoticus, C. Obsoletus 
and C. Dewulfi. The latter three species are probably the most important vectors in 
northern Europe, where C. Imicola does not occur. In western North America the 
major vector of BTV is C. Sonorensis, which is replaced by C. Insignis in the south-
eastern USA; in Central and South America C. Insignis and C. Pusillus are the 
known vectors. In south-east Asia and Australia the major vector is C. Brevitarsis 





















Fig. 7. A gravid female Culicoides Imicola collected from a location near bluetongue outbreaks in 
Sardinia in 2007. 
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Table IV. The 32 species of the genus Culicoides (Latreille, 1809), that play a greater or lesser role in 
the transmission of bluetongue disease across the world. These are assigned to their correct subgenus 
and species complex (where known); the species given in bold are those more clearly implicated in 
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IV.3.1 - THE CULICOIDES LIFE CYCLE 
Adult female Culicoides use a protein-rich blood meal to mature the ovaries and to 
develop between 30-450 eggs (measuring 350-500 μm in length and 65-80 μm in 
breadth) which are laid (oviposited) in batches. One batch of eggs is matured from 
each blood meal. Midges need to survive only five days to lay the first egg mass, but 
they must survive 10 days to transmit a virus during which time they may lay two to 
three egg masses. In general Culicoides eggs usually hatch in 4- 5 days at 25 ºC but 
in one northern European species (C. Grisescens) hatching was reported to take 7-8 
months (Parker, 1949). For the tropical C. Imicola at 30 °C the eggs hatch within 2-3 
days with the egg to adult cycle being rapid (9-10 days). However, low temperatures 
affect egg viability and in the case of C. Imicola below 6.5 °C viability decreases 
after 7 days with none hatching after 37 days (Nevill, 1967). 
Culicoides have four larval instars. All 4 larval instars are slender and almost 
―hairless‖, which facilitates their characteristic ―serpentine‖ movement through the 
semi-solid media they inhabit. The length of the larval development is regulated by 
temperature and nutritive richness of the breeding sites varying from a week in 
tropical species like C. loxodontis (Meiswinkel, 1992) to nearly two years in some 
Arctic species (Downes, 1962). The lengthening of the larval cycle across latitudes 
appears related to falling average annual temperatures and to the number of daylight 
hours; at 8 hours of light or less the larvae of many temperate species go into 
diapause and development is resumed the following spring when warmer, longer 
light, conditions return. Water content determines the suitability of a breeding habitat 
because the larvae and pupae will die when the habitat dessicates unless they are able 
to migrate to a joining areas that are still moist. The pupa is a short-lived, non-
feeding stage from which the adult midge hatches 2 days to 4 weeks later (Fig. 8). 
The longevity of adult Culicoides has not been measured precisely but it is likely that 
it lasts from a few weeks or less (usually) to several months (rarely). Nevill found 
also that at temperatures as low as -1.5 °C only 15% of C. Imicola adults lived 
beyond 15 days. From field data it has been estimated that the optimal temperatures 
for C. Imicola range between 18 and 38 ºC (Ortega et al., 1998); for C. Obsoletus 
these have been calculated to be between 11-27.5 °C (Dzhafarov, 1964). Before 
Culicoides are able to mate both sexes require several days to reach sexual maturity. 
Mating occurs mainly around sunset but has been described for only a few species 
during which swarms of males are detected by single females, which then enter the 
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swarms to be mated. Males feed exclusively on sugar sources such as plant nectar; 
while females feed principally on blood they have been reported to also visit flowers 
to obtain nectar.  
It is widely assumed that Culicoides are generally crepuscular and may continue to 
be active throughout the night; however, many species are also (in particular those 
found at more northerly latitudes) troublesome in the day displaying two biting 
peaks: one after sunrise the other close to sunset. In general Culicoides disperse only 
short distances from their breeding sites. It is postulated that in the Mediterranean 
region C. Imicola can be passively carried for distances of over 100 km on winds 
(Sellers, 1975; Sellers et al., 1977, 1978, 1979; Sellers & Pedgley, 1985; Sellers & 
Maarouf, 1989, 1991; Braverman & Chechik, 1996) and recent outbreaks of BT in 
the Spanish Balearics and in absence of animal movements onto the islands have 
been highlighted as an example of this (Alba et al., 2004), in Sardina and in Corsica 
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IV.3.2 - VIRUS-VECTOR INTERACTIONS 
Vector Culicoides become persistently infected with BTV for their entire lifespan 
after acquiring infection through feeding on an infected ruminant, whereas infection 
of the ruminant host is transient and the virus does not persist in a geographic region 
in the absence of competent insect vectors (Gibbs & Greiner, 1994).  
BTV is ingested by adult female Culicoides during the course of blood feeding on a 
viraemic host and is deposited in the hind part of the insect‘s mid-gut along with the 
ingested blood. If the individual that has ingested the virus is a competent vector then 
the virus particles attach to the luminal surface of the mid-gut cells, penetrate into the 
cytoplasm of these cells by a process of endocytosis, and replicate in them. Progeny 
virus particles exit into the haemocoel of the vector through the abluminal surface of 
the gut cells, probably by a process of budding and disseminate through the body 
cavity suspended in the haemolymph. Secondary target tissues that include fat body, 
neural cells and the salivary glands may be infected during the course of this 
dissemination. In the case of the salivary gland cells, these are infected and a second 
cycle of replication ensues with fresh progeny virus particles exiting into the salivary 
ducts where they collect, sometimes in para-crystalline arrays and so are available for 
transmission during subsequent biting activity. The time interval between ingestion 
of virus and transmission is called the extrinsic incubation period and is temperature-
controlled decreasing in duration as temperature rises. The high concentration of 
virus in the salivary ducts of infectious vectors means that BTV transmission is 
extremely efficient and in most cases the bite of a single midge will result in the 
infection of a susceptible host (O‘Connell, 2002). However, transmission from an 
infected host to the vector is much less efficient and experimental work indicates that 
even at peak viraemia <2% of feeding individuals become infected (O‘Connell, 
2002). The blood of an infected animal is more infectious when virus titres are high, 
soon after infection (before antibodies develop). Nevertheless, experimental evidence 
suggests that even at peak viraemia with titres in excess of >5 log10 TCID
50
 of 
virus/ml, it can be difficult to persistently infect more than 1% of feeding vectors 
(O‘Connell, 2002; Baylis et al., 2004). As the titre of viraemia drops there is less 
chance of a biting midge imbibing an infectious dose of virus. However, midges can 
sometimes be infected even when the virus titre is too low to be recorded by 
conventional tests (i.e. <0.5 log10 TCID
50
 of virus/ml), (Bonneau et al., 2002). This 
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suggests that any titre of viraemia may be infectious for some vector midges should 
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V. - PATHOGENESIS 
The pathogenesis of BTV infection is similar in sheep and cattle, and most probably, 
all species of ruminants (Barratt-Boyes & MacLachlan, 1995; MacLachlan, 1994; 
Mahrt & Osburn, 1986; Pini, 1976). There are marked differences in the severity of 
disease that occurs in different ruminant species after BTV infection, however, with 
cattle being especially resistant to expression of BT disease. After initial replication 
in the lymph nodes draining the sites of inoculation, BTV disseminates to secondary 
sites, principally the lungs and spleen, where it replicates in endothelium and 
mononuclear phagocytes (Barratt-Boyes & MacLachlan, 1994). BTV can 
disseminate via lymph (Barratt-Boyes & MacLachlan, 1994) or/and via blood 
(Brodie et al.,1998). BTV infects monocytes both in vivo and in vitro. In vivo, 
infectious BTV can be retrieved transiently (<1 week) from monocytes (minimum 
10
5
 cells) (Brodie et al.,1998; Whetter et al.,1989). 
Monocytes also express BTV antigens in vivo at low frequency (four NS2 antigen-
positive monocytes per 2×10
5
 peripheral blood mononuclear cells (Whetter et 
al.,1989). In vitro, around 15% of monocytes express BTV VP7 after 36 h in culture 
(Barratt-Boyes & MacLachlan, 1995) and they produce low amounts of infectious 
BTV in vitro (Whetter et al.,1989). Conversely, resting T lymphocytes are not 
efficient at supporting BTV replication (Whetter et al.,1989) unless they are 
activated by mitogens (Barratt-Boyes & MacLachlan, 1995). Interestingly, γδ T cell 
lines can be productively infected in vitro (Takamatsu et al., 2003) and blood γδ T 
cells from infected sheep (3–13 days post infection) have been induced to produce 
infectious BTV when cocultivated with skin fibroblasts (Takamatsu et al.,2003). 
However, it is unclear how monocytes and possibly blast T cells are involved in vivo 
in the pathogenesis of BTV. Last but not least, infectious BTV can also be detected 
in the intracellular vesicles of erythrocytes, in which it does not replicate but persists 
in invaginations of cell membrane (MacLachlan et al., 2004; Whetter et al., 1989). 
The association of infectious BTV with erythrocytes is detected very early after 
infection (24 h) (Brodie et al., 1998) and persists throughout viraemia (MacLachlan 
et al., 2004; Shad et al., 1997).  
In sheep, the incubation period is usually 5 to 10 days, while in cattle can become 
viremic starting at 4 days post-infection. BTV infection in ruminants is characterized 
by a prolonged cell-associated viraemia that can persist in the presence of high titres 
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of neutralizing antibody, although recovered animals are immune to re-infection with 
the homologous serotype of BTV. In sheep and cattle, infectious BTV can be 
detected in the blood for 35 to 60 days (Barratt-Boyes & MacLachlan, 1994) and 
viral structures for up to 160 days (Katz et al.,1994). It has been proposed that 
particles associated with erythrocytes are protected from early immune clearance. 
Furthermore, detection of BTV RNA up to 145 days after infection is remarkably 
similar to the lifespan of the ruminant erythrocytes, suggesting that erythrocytes are 
likely to be the critical mechanism that allows cattle to serve as natural reservoir 
hosts of BTV (Brewer et al., 1994). Some other work indicated that BTV RNA can 
be detected even up to 222 days (Bonneau et al., 2002).  
In enzootic areas, BT usually appears in late autumn after long periods of quiescence 
(8-12 months), a phenomenon called overwintering (Takamatsu et al., 2003). 
However, conventional models for the transmission of BTV suggest that if adverse 
winter conditions last for more than 100 days, the virus should be unable to survive 
from one year to the next. Persistence of BTV in the larvae of vector Culicoides is 
considered to be highly improbable (Mellor, 1990) although it cannot be ruled out 
(White et al., 2005). Some authors have postulated that persistently infected γδ T 
cells, recruited by midge biting, could facilitate the transmission of BTV for periods 
as long as nine weeks post infection in Dorset sheep (Fig. 9) (Takamatsu et al., 
2003). However, this finding was not confirmed in another study using a different 
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Fig. 9. The figure shows how, on being bitten by an infected adult Culicoides vector, ruminant hosts 
become infected with BTV (a). In some infected hosts, the virus establishes a persistent infection of  T 
cells. Surviving animals will be seropositive and aviraemic, but will still carry BTV in their  T cells 
(b). In such apparently recovered animals the virus persists, covertly, over the cold vector-free winter 
months (c). In the following spring, new vectors emerge and commence biting ruminants, some of 
which are persistently infected (d). Vector biting causes localized skin inflammation, which initiates 
the recruitment of inflammatory cells, including infected  T cells, into the inflamed areas (e). In the 
skin, interactions between the skin fibroblasts and the  T-cell-specific surface molecule WC-1, causes 
growth arrest in the infected  T cells and, through a mechanism that is not fully understood, converts 
the BTV persistent infection to a productive, lytic infection. This results in BTV replication, cell death 
and release of the virus into the skin at locations where the vectors are biting (f). The released virus is 
ingested by the vector Culicoides, infecting the vector (g) and initiating a new transmission cycle (h) 
(Adapted from Takamatsu et al., 2003). 
 
V.1 - CELLULAR RESPONSE TO BTV 
Viral haemorrhagic diseases are not only a consequence of direct viral damage to the 
cells but also the result of intense and sometimes deregulated inflammatory 
processes. BTV reduces endothelial electrical resistance in vitro associated to p38 
MAP kinase-dependent cytoskeletal rearrangements (Chiang et al., 2006). In 
addition, BTV infections induce cell death in many cell types and an important 
inflammatory cell response. 
In mammalian cells, BTV induces cell death (apoptosis and/or necrosis) in cell lines 
(Mortola et al., 2004), microvascular ovine and bovine endothelial cells (De Maula et 
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al., 2001), monocytes (Barratt-Boyes et al., 1992) and in WC1-activated γδ T cells 
(Takamatsu et al., 2003). In mammalian cell lines, uncoating of BTV, but not BTV 
replication, is required to trigger apoptosis (Mortola et al., 2004). Extracellular 
treatment with a combination of the viral outer capsid proteins VP2 and VP5, and the 
cell penetration protein VP5 is sufficient to trigger apoptosis, involving activation of  
NF-κB (Mortola et al., 2004). However, some cell types that support the replication 
of the virus do not demonstrate a cytopathic effect to BTV, such as insect cells 
(Mortola et al., 2004), γδ T cell lines (Takamatsu et al., 2003) and activated blood 
lymphocytes (Barratt-Boyes et al., 1992). The budding versus the viroporin-mediated 
viral exit mechanism might partially explain this difference (Wirblich et al., 2006). 
Infection of bovine and ovine microvascular endothelial cells induces the 
transcription of interleukin 1 (IL-1), IL-8, IL-6, cyclooxygenase-2, and inducible 
nitric oxide synthase (De Maula et al., 2001). These mediators have been involved in 
the pathogenesis of severe viral haemorragic fevers. Infection of sheep and cattle 
with BTV induces a plasmatic increase of prostacyclin and thromboxane (De Maula 
et al., 2001). Thromboxane is a strong pro-coagulant factor whereas prostacyclin is a 
potent vasodilatator and inhibitor of platelet aggregation. There is a much higher 
prostacyclin/thromboxane ratio in cattle, which may explain the lower sensitivity of 
cattle to BTV induced microvascular injury and thrombosis (De Maula et al., 2001). 
BTV is also a strong inducer of type I IFN in vivo, in sheep (Foster et al., 1991), 
cattle (MacLachlan et al., 1985a) and mice (Jameson et al., 1978). A strain of BTV 
serotype 8 was shown to be an extremely potent inducer in vivo in mice, even when 
UV-irradiated. Strains of many BTV serotypes have been reported as IFN inducers 
but they may differ in their ability to induce IFN depending on the cell context 
(Fulton et al., 1982). A wide variety of cells produce type I IFN after BTV 
stimulation in vitro, including mouse embryo cells (Huismans, 1969), human 
leucocytes (Jameson et al., 1978), leucocytes from adult sheep (Rinaldo et al., 1975). 
Double stranded RNA from BTV also induced IFN in mice (Eksteen et al., 1972). 
However, the exact viral component involved in the induction is unknown. 
V.2 - IMMUNE RESPONSES AGAINST BTV 
Ruminants infected with BT virus develop a variety of protective antiviral responses 
including production of interferon as well as virus-specific humoral and cellular 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
33 
 
immune responses. Such capabilities are acquired during gestation so that ruminants 
are born immunologically competent to BT virus. Antiviral responses of infected 
ruminants clear the virus from infected animals and prevent reinfection with 
homologous serotypes of the virus. 
V.2.1 - INTERFERON PRODUCTION 
BT virus is a very efficient inducer of interferon in vitro, and interferon is present in 
serum soon after infection of both cattle and sheep. While interferon likely limits the 
dissemination of BT virus throughout the body it is unlikely that it influences virus 
clearance as viremia continues long after interferon no longer is detected in serum 
(MacLachlan et al., 1985a). 
V.2.2 - HUMORAL IMMUNITY AGAINST BTV 
BT virus infected cattle and sheep develop a prompt humoral immune response to a 
variety of different viral proteins (Jeggo et al., 1983; MacLachlan et al., 1987; 
Reddington et al., 1991; Richards et al., 1988). Neutralizing antibodies in serum 
prevent reinfection in a serotype specific manner and virus neutralization is 
dependent upon the presence of antibodies directed at the outer capsid protein VP2 
(Richards et al., 1988; DeMaula et al., 1993). Recent studies indicate that a least 
some neutralizing epitopes of BT viruses are conformationally dependent (DeMaula 
et al., 1993), and the significance of individual neutralizing epitopes may vary 
considerably amongst field strains of the same serotype of BT virus (MacLachlan et 
al., 1992; Rossitto et al., 1992). Thus the same epitope may function as a major or 
minor neutralization determinant on different strains of the virus. Furthermore, 
epitopes which are responsible for neutralization of one strain of BT virus may exist 
in a non-neutralizing conformation on other strains or serotypes. Neutralizing 
epitopes may be shared between viruses of different serotypes of BT virus, which is 
consistent with the fact that animals infected with 1 or more serotypes of BT virus 
may develop neutralizing antibodies to serotypes of the virus to which they were 
never exposed. Despite the considerable variation of VP2 amongst different strains 
and serotypes of BT virus, similar regions of the protein apparently are critical to the 
neutralization of genetically and antigenically distinct viruses (DeMaula et al., 1993). 
This suggests that these regions are evolutionarily conserved because of their critical 
roles in viral replication. Although neutralizing antibodes clearly prevent reinfection 
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of ruminants with a homologous virus (Jeggo et al., 1983), neutralizing antibodies do 
not immediately clear virus from the circulation (MacLachlan et al., 1991, 1987; 
Richards et al., 1988). Thus BT virus may co-circulate with specific neutralizing 
antibodies for several weeks after infection of both cattle and sheep (Richards et al., 
1988). The prolonged viremia which occurs in BT virus infected ruminants likely 
reflects association of virus with blood cells, especially erythrocytes. The 
erythrocyte-associated viremia appears to protect the virus from rapid clearance by 
neutralizing antibody (MacLachlan et al., 1991, 1990; Barratt-Boyes & MacLachlan, 
1994; Leudke et al., 1969; Brewer and MacLachlan, 1992).  
Ruminants also develop antibodies to a variety of other viral proteins (Jeggo et al., 
1983; Richards et al., 1988). These responses form the basis of diagnostic tests as 
core proteins such as VP7 and nonstructural proteins such and NSI have epitopes 
which apparently are common to all strains and serotypes of BT virus. Whether 
antibodies to proteins other than VP2 contribute to the protective antiviral response 
by mechanisms such as antibody-dependent cellular cytotoxicity currently is 
unknown. Recent studies indicate that the lymph node draining sites of virus 
inoculation develops a humoral immune response prior to the systemic response 
(Barratt-Boyes et al., 1992). Thus antibody can be detected in efferent lymph from a 
regional node several days prior to its detection in serum. Antibodies to BT virus 
usually are detected in the serum of BT virus infected ruminants by 7-28 days after 
inoculation, depending upon the type of assay and route of animal inoculation used. 
V.2.3 - CELLULAR IMMUNITY AGAINST BTV 
Cell mediated immunity likely limits viral spread during the initial stages of BT virus 
infection of ruminants, although such responses do not lead to rapid elimination of 
the virus. Increased numbers of CD8+ T cells are present in efferent lymph from 
lymph nodes draining the site of BTV inoculation in cattle at 6-8 days after infection 
(Barratt-Boyes et al., 1992), and peak numbers of CD8+ T cells were detected in 
blood at 14 days (Ellis et al., 1990). CD8+ T cells possess cytotoxic activity and 
could lyse BT virus-infected cells and so reduce virus production. In vitro studies 
suggest that some resistance to BT virus infection can be adoptively transferred with 
lymphocytes, and that such resistance is not serotype-specific (Jeggo et al., 1983). 
Attempts to quantitate cellular immunity by in vitro correlates such as the 
lymphocyte stimulation assay have produced variable results. This is hardly 
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surprising given that BTV frequently is present in the peripheral blood mononuclear 
cells from infected cattle, and that the virus is rapidly cytolytic to dividing 
lymphocytes (Barratt-Boyes et al., 1992). The induction of cytotoxic T lymphocytes 
in mice inoculated with BT virus has been documented (Jeggo et al., 1982a, 1982b, 
1982c), and similar cells presumably are induced in BT virus infected ruminants. 
Takamatsu and Jeggo (1989) propagated BTV-specific T lymphocyte cell lines from 
sheep previously inoculated with BT virus. The cultured cells proliferated after 
exposure to BT virus, with variable responses to heterologous serotypes (those to 
which the sheep were not exposed) and some lines exhibited cytotoxic activity, T cell 
lines which did not react with heterologous serotypes of BT virus were shown to 
specifically react with outer capsid protein VP2, the protein which also expresses the 
neutralization determinants of BT virus (Takamatsu et al., 1990). Uncloned lines also 
reacted with core proteins as well as VP5, the other component of the viral capsid. 
Although poorly characterized at present, it is likely that cellular immune responses 
limit virus replication in the initial stages of BT virus infection of ruminants but it is 
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VI. - DISEASE CHARACTERISTICS 
The disease is characterised by inflammation of the mucous membranes, congestion, 
swelling and haemorrhages. Sheep are generally the worst affected, while cattle and 
goats do not usually show any clinical signs of disease and can carry the virus for a 
certain period of time and transmit it to other ruminants (Maclachlan, 2004). Severity 
of illness is influenced by the BTV serotype involved, animal breed and 
environmental factors like the direct and prolonged exposure to sun light. In fact, 
photosensitization plays a crucial role in developing serious forms; sheep sheltered 
from direct sun light exposure show less severe signs of congestion. 
VI.1 - CLINICAL SIGNS 
The vast majority of infections with bluetongue are clinically inapparent. In a 
percentage of infected sheep and occasionally other ruminants, more severe disease 
can occur. 
In sheep, the clinical signs may include fever, excessive salivation, depression, 
dyspnea and panting. Initially, animals have a clear nasal discharge; later, the 
discharge becomes mucopurulent and dries to a crust around the nostrils (Fig. 10). 
The muzzle, lips and ears are hyperemic, and the lips and tongue may be very 
swollen. The tongue is occasionally cyanotic and protrudes from the mouth. The 
head and ears may also be edematous (Fig. 11). Erosions and ulcerations are often 
found in the mouth; these lesions may become extensive and the mucous membranes 
may become necrotic and slough. The coronary bands on the hooves are often 
hyperemic and the hooves painful (Fig. 12); lameness is common and animals may 
slough their hooves if they are driven. Pregnant ewes may abort their fetuses, or give 
birth to ―dummy‖ lambs. Additional clinical signs can include torticollis, vomiting, 
pneumonia or conjunctivitis (Erasmus, 1975; Pini, 1976; Gard, 1984; Mahrt & 
Osburn, 1986; MacLachlan, 1994). The death rate varies with the strain of virus. 
Three or four weeks after recovery, some surviving sheep can lose some or all of 
their wool.  
Infections in cattle are usually subclinical; often, the only signs of disease are 
changes in the leukocyte count and a fluctuation in rectal temperature. Rarely, cattle 
have mild hyperemia, vesicles or ulcers in the mouth; hyperemia around the coronary 
band; hyperesthesia; or a vesicular and ulcerative dermatitis. The skin may develop 
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thick folds, particularly in the cervical region. The external nares may contain 
erosions and a crusty exudate. Temporary sterility may be seen in bulls. Infected 
cows can give birth to calves with hydranencephaly or cerebral cysts. Cattle that 
have clinically apparent disease may develop severe breaks in the hooves several 
weeks after infection; such breaks are usually followed by foot rot. Infections in 
goats are usually subclinical, and similar to disease in cattle (Leudke et al., 1969; 
1970). Although many infections in wild ruminants are inapparent, severe disease 
can occur in some species. In pronghorn antelope and whitetail deer, the most 
common symptoms are hemorrhages and sudden death. 
VI.2 - POST MORTEM LESIONS 
In sheep, the face and ears are often edematous. A dry, crusty exudate may be seen 
on the nostrils. The coronary bands of the hooves are often hyperemic; petechial or 
ecchymotic hemorrhages may be present and extend down the horn. Petechiae, ulcers 
and erosions are common in the oral cavity (Fig. 13), particularly on the tongue and 
dental pad, and the oral mucous membranes may be necrotic or cyanotic (Mahrt & 
Osburn, 1986; Pini, 1976). The nasal mucosa and pharynx may be edematous or 
cyanotic, and the trachea hyperemic and congested. Froth is sometimes seen in the 
trachea, and fluid may be found in the thoracic cavity. Hyperemia and occasional 
erosions may be seen in the reticulum and omasum (Fig. 14). Petechiae, ecchymoses 
and necrotic foci may be found in the heart (Fig. 15). In some cases, hyperemia, 
hemorrhages and edema are found throughout the internal organs. Hemorrhage at the 
base of the pulmonary artery is particularly characteristic of this disease (De Maula 
et al., 2001). In addition, the skeletal muscles may have focal hemorrhages or 
necrosis, and the intermuscular fascial planes may be expanded by edema fluid. 
In deer, the most prominent lesions are widespread petechial to ecchymotic 
hemorrhages. More chronically infected deer may have ulcers and necrotic debris in 
the oral cavity. They may also have lesions on the hooves, including severe fissures 
or sloughing. 
VI.3 - MORBIDITY AND MORTALITY 
In sheep, the severity of disease varies with the breed of sheep, virus strain and 
environmental stresses. The morbidity rate can be as high as 100% in this species. 
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The mortality rate is usually 0-30%, but can be up to 70% in highly susceptible 
sheep. Similar morbidity and mortality rates are seen in bighorn sheep. Bluetongue is 
usually severe in whitetail deer and pronghorn antelope, with a morbidity rate as high 
as 100% and a mortality rate of 80-90%. 
Most infections in cattle, goats and North American elk are asymptomatic. In cattle, 
up to 5% of the animals may become ill, but deaths are rare. In some animals, 
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VII. - DIAGNOSIS 
Bluetongue should be suspected when typical clinical signs are seen during seasons 
when insects are active. A recent history of wasting and foot rot in the herd supports 
the diagnosis. 
VII.1 - DIFFERENTIAL DIAGNOSIS  
The differential diagnosis includes foot-and-mouth disease, vesicular stomatitis, 
peste des petits ruminants, plant photosensitization, malignant catarrhal fever, bovine 
virus diarrhea, infectious bovine rhinotracheitis, parainfluenza-3 infection, 
coenurosis, contagious ecthyma (contagious pustular dermatitis), sheep pox, foot rot 
and Oestrus ovis infestation. In cattle and deer, EHD can also result in similar 
symptoms. 
VII.2 - LABORATORY TESTS 
Bluetongue can be diagnosed by isolating the virus in embryonated chicken eggs or 
cell cultures. Appropriate cell cultures include mouse L, baby hamster kidney 
(BHK)-21, African green monkey kidney (Vero), and Aedes Albopictus (AA) cells. 
Isolation in embryonated eggs is more sensitive than isolation in cell culture. 
Bluetongue virus can also be isolated by inoculation into sheep, and sometimes 
suckling mice or hamsters. Animal inoculation is more sensitive than virus isolation 
in cell culture, and may be particularly valuable when the virus titer is very low. 
Bluetongue viruses can be identified to the serogroup level by immunofluorescence, 
antigen-capture enzyme-linked immunosorbent assay (ELISA) or the Immunospot 
test, as well as other techniques. These viruses can be serotyped with virus 
neutralization tests. 
Polymerase chain reaction (PCR) techniques are widely used to identify the 
bluetongue virus in clinical samples. These techniques allow for rapid diagnosis and 
can identify the serogroup and serotype. 
Serology is sometimes used for diagnosis. Antibodies appear 7 to 14 days after 
infection and are usually persistent. Available serologic tests include agar gel 
immunodiffusion (AGID), competitive ELISA, and virus neutralization. The AGID 
and indirect ELISA tests can identify serogroup-specific antibodies. A newer 
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monoclonal antibody-based competitive ELISA can also distinguish antibodies to 
viruses in the bluetongue serogroup from antibodies to the EHD serogroup. Virus 
neutralization tests can determine the serotype specificity of antibodies, but are 
cumbersome. Complement fixation has largely been replaced by other tests, but is 
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VIII. - BLUETONGUE CONTROL STRATEGY 
Bluetongue is an OIE-listed disease that has the potential for rapid spread with 
significant production losses and is of major importance to the international trade in 
ruminant livestock (including sheep, goats, cattle and deer). 
The policy with regard to an outbreak of bluetongue is to minimise the economic 
impact and to eliminate clinical disease if circumstances permit. This may be feasible 
if the disease is detected early in isolated animals and infected vectors are absent, if 
the disease occurs in a vector-free area, or if frosts are imminent in vector areas. If 
the disease occurs in areas with competent vectors early in the vector season, control 
will be difficult. 
VIII.1 - EUROPEAN UNION LEGISLATION 
To begin on 1999, BTV infection spread progressively across most of Europa and the 
Mediterranean Basin. At the time, control of BT was covered by European Union 
(EU) Directive 92/119/EEC (European Council, 1992a), together with some other 
Office International des Épizooties (OIE) List A diseases (such as foot and mouth 
disease, rinderpest, sheep pox, swine vesicular disease etc.), and EU Directive 
92/35/EEC (European Council, 1992b) had already defined specific measures against 
African horse sickness. 
Directive 92/119/EEC outlined direct control measures and the demarcation of a 3 
km radius protection zone and a 10 km radius surveillance zone, around infected 
farms. Direct control measures included the slaughter of all susceptible animals on 
farms and the possible extension of such measures to neighbouring farms suspected 
of being exposed. In November 2000, the EU, after reviewing the provisions of 
Directive 92/35/EEC (European Council, 1992b), issued EU Directive 2000/75/EC 
(European Council, 2000) defining specific rules for the control and eradication of 
BT.  
Directive 2000/75/EC establish a combination of strategies to use to limit or control 
the BT, which included: 
1. Quarantine and movement controls; 
2. Slaughter of infected / suspected animals; 
3. Surveillance and monitoring; 
4. Husbandry modification; 
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5. Vector control; 
6. Vaccination. 
The application of Directive 2000/75/EC, through the adoption of Decision 
2001/138/EC (European Commission, 2001), has disrupted animal trade in at least a 
third of Italy. All existing EU legislation regarding the compensation of farmers was 
developed in relation to contagious diseases of OIE List A, mainly foot and mouth 
disease and hog cholera (classical swine fever). The control strategy used in Europe 
for outbreaks of these diseases resorts to stamping-out of infected and in-contact 
animals and, since 1990, vaccination is only an ancillary measure. In this context, the 
principal economic losses are direct, due to the slaughter of infected and in-contact 
animals. According to European legislation, any compensation for indirect losses 
would perturb the market. Moreover, losses suffered by farmers whose livestock is 
subjected to movement restrictions also affect the earnings of farmers living in free 
areas. This has been recognised only recently (July 2003) by the European 
Commission that enacted the Decision C(2003)2519fin (European Commission, 
2003), authorising the region of Sardinia to compensate cattle farmers for indirect 
losses due to movement restrictions imposed from 6 September 2000 to 31 
December 2001. 
VIII.1.1 - QUARANTINE AND MOVEMENT CONTROLS 
When a clinical outbreak of bluetongue occurs, the initial strategy is a quarantine of 
domestic ruminants on affected properties, while an epidemiological investigation is 
carried out. All environmental factors, including ruminant stocking densities, recent 
movements of ruminants onto and off the property, and recent rain and wind patterns, 
are recorded. The premises, on which the infected animals are detected, are subjected 
to quarantine and movement controls and are officially declared as Infected Premises 
(IP). After confirmation that BTV is circulating, a Restricted Zone (RZ) will then be 
imposed, consisting of an inner Protection Zone (PZ) - at least 100 km around an IP, 
and an outer Surveillance Zone (SZ) - at least 50 km in radius beyond that (A. 
Giovannini et al., 2004a). The area outside of the Bluetongue Restricted Zone is 
referred to as Bluetongue-free. The movement of cattle or sheep are controlled within 
and from the control zones and exports of live animals may be subject to restrictions. 
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VIII.1.2 - SLAUGHTER OF INFECTED / SUSPECTED ANIMALS 
Slaughter of susceptible animals infected with bluetongue might, in some 
circumstances, be considered as a control measure, for example, in the context of 
single infected imported animal where no further disease is detected (as a 
precautionary measure to try to stop disease establishing). In some cases, it may be 
necessary to slaughter infected animals for animal welfare reasons or for trade 
purposes. 
VIII.1.3 - SURVEILLANCE AND MONITORING 
A surveillance and monitoring program for virus and competent vectors in affected 
or threatened areas start immediately when disease is detected. The survey will 
attempt to determine the extent of the virus and vectors, the serotype involved and its 
virulence. The survey will also help to define the limits of the bluetongue-free area. 
If vaccination is used, it will be necessary to distinguish between natural infections 
and vaccination responses. The epidemiological investigation should include: 
• examination of the time and location of the outbreak and the location of the 
susceptible population; 
• recording of recent movements of ruminants onto and off IP; 
• identification of the species of vectors and virus serotypes present; 
• collection of meteorological data;  
• a serum survey of affected animals and contacts. 
The size of the area may be very large (100 km radius), depending on meteorological 
and other factors assessed by epidemiologists. 
VIII.1.4 - HUSBANDRY MODIFICATION 
This measure is aimed at denying or reducing vector access to susceptible animals. 
Most vector species of Culicoides including C. Imicola are strongly exophilic 
(Meiswinkel et al., 2000), therefore, housing susceptible stock during times of 
maximum vector activity (i.e. the crepuscular periods and during the night) will 
significantly reduce biting rates and hence the likelihood of infection. In addition, if 
obvious ports of access to such housing such as windows and doors are screened 
with material of fine mesh (e.g. sand-fly netting) or with coarser material 
impregnated with insecticide (e.g. a synthetic pyrethroid) this will reduce biting even 
further (Braverman, 1989). As BTV vector species of Culicoides seem to be more 
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attracted to cattle than to sheep some authorities have advocated running the two 
ruminant species together in order to divert vector-attention from the disease-
susceptible sheep (Nevill, 1978). 
However, this measure will not break the virus transmission cycle which will 
continue, covertly, through the cattle population and so is not recommended if virus 
eradication is the overall objective (Mellor, 1994). 
VIII.1.5 - VECTOR CONTROL 
It is rarely possible to completely eliminate populations of vector Culicoides. The 
main aim, therefore, is to reduce the number of potentially infecting bites that 
animals of the target species receive, to levels where maintenance of an epizootic 
becomes unsustainable (Anderson & May, 1991). Vector control can be tackled in a 
number of ways but it is important to remember that a combination of approaches is 
likely to yield the best results. 
VIII.1.5.1 - HABITAT ALTERATION 
This control method is dependent upon an ability to be able to recognize and then 
destroy the breeding sites of the vector species of Culicoides. Culicoides Imicola 
usually breeds in organically enriched (mainly animal dung), moist but not 
waterlogged soils. Such areas may be bare or covered with short grass (e.g. irrigated 
pastures) and need to remain moist for sufficient time to complete the developmental 
part of the vector's life cycle (i.e. at least 7-10 days). Consequently, slow draining or 
clay soils are better for C. Imicola than free-draining, nutrient-poor, sandy soils. 
High populations of C. Imicola usually occur only on livestock farms and seem to be 
a phenomenon of this type of activity. In such locations humans inadvertently 
`manufacture' an ideal Imicola habitat by providing ample water, soil contaminated 
with animal dung and a sedentary `blood bank' of domestic animals. Culicoides 
Imicola breeding sites can vary in size from a few metres in diameter (irrigation pipe 
leaks, cattle trough overflows, leaking taps) to whole pastures. Breeding site 
destruction may be easily achieved through habitat modification, when the sites are 
few in number and are small (e.g. by turning off taps,mending leaks and filling in or 
draining damp areas) but may be impossible or not economically feasible in other 
situations (Braverman, 1989). 
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VIII.1.5.2 - ADULTICIDING 
Older recommendations for broadscale, aerial application of insecticides with all of 
the attendant risks to non-target organisms are not likely to find favour in these more 
environmentally conscious times. However, targeted application of insecticides of 
known low mammalian toxicity (e.g. the synthetic pyrethroids) in and around animal 
housing and directly to the target animals themselves can be efficacious against 
Culicoides species and may be environmentally acceptable (Braverman, 1989; 
Braverman et al., 1995). Intradermal or subcutaneous inoculation of systemic 
insecticides such as Ivermectin may also be effective at killing biting Culicoides 
(Standfast et al., 1985). An additional advantage with this system and with such 
insecticidal food additives as tetrachlorvinphos, is that these drugs are eliminated in 
the faeces which, should they be deposited on breeding sites, are toxic to the 
immature stages of Culicoides (Jackson, 1989; Standfast et al., 1985). 
VIII.1.5.3 - LARVICIDING 
Application of a larvicide such as ―Abate‖ (American Cyanamid) (5% temephos 
granulated with gypsum) to Culicoides breeding sites, provides a slow but sustained 
release of the insecticide and may be effective for periods as long as 30 days 
(Holbrook, 1985). Such preparations are effective even when used on breeding sites 
that are rich in organic matter which makes them particularly suitable in Culicoides 
control (Braverman, 1989). Biological control of larval Culicoides by agents such as 
Bacillus thuringensis has apparently not proved successful (Lacey & Kline, 1983). 
VIII.1.5.4 - REPELLENTS 
There are several candidate and established repellents that have been tested at 
deterring Culicoides attack. However, none is completely effective and the deterrent 
effect, even of the best, rarely persists for more than a few hours (Schreck et al., 
1979; Braverman & Chizov-Ginzburg, 1997). Di-ethyl toluamide (DEET) seems to 
be the only commercially available repellent that has been shown to have a 
significant deterrent effect against Culicoides for periods of up to 4 h (Braverman & 
Chizov-Ginzburg, 1997). Since C. Imicola attacks apparently peak during the first 4 
h of the night, if applied nightly to target animals, DEET may have a significant but 
temporary effect in reducing the biting rate of this species. 
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IX. - VACCINES AGAINST BLUETONGUE IN EUROPE 
The incursion of BTV into Mediterranean Europe is having a considerable negative 
economic impact, partly due to direct losses from mortality and reduced production 
in affected livestock but, more importantly, because of the total ban of ruminant trade 
between BTV-infected and non-infected areas (Calistri et al., 2004). To limit direct 
losses and in an effort to minimize the circulation of BTV, as well as to allow the 
safe movement of animals, the Italian, French, Portuguese and Spanish authorities all 
undertook vaccination of livestock according to their individual national policies, the 
geographic distribution of the incurring BTV serotype(s), and the availability of 
appropriate vaccines. In France, only sheep were vaccinated whereas in Italy, all 
susceptible domestic ruminant species were vaccinated, i.e. sheep, goats, cattle and 
water buffalos (Patta et al., 2004). In Spain, initially only sheep were vaccinated 
(2001/2003 in Balearic Islands) but in later outbreaks (southwest Spain) both cattle 
and sheep were subjected to vaccination (MAPA 2006). The Italian vaccination 
campaign was based on a risk assessment that demonstrated that such a vaccination 
strategy would prevent direct economic losses, significantly reduce virus circulation 
(Giovannini et al., 2003) and minimize risks linked to the movement of animals from 
infected to free areas. 
Different vaccines against BT have been used and these include inactivated whole 
[killed] virus preparations, virus-like particles (VLPs) produced from recombinant 
baculoviruses, live attenuated vaccines (modified live viruses, MLVs) and live 
recombinant vaccinia or canarypox virus-vectored vaccines (Murray et al., 1996; 
Boone et al., 2007). All have inherent potential advantages and disadvantages, but 
only MLVs and some inactivated vaccines are currently available under European 
Community approved national disease control programs. VLPs are also safe and 
have been shown to be efficacious in laboratory trials (Roy et al., 1990, 1992, 1994; 
Roy, 2004), but their efficacy in the field is still under evaluation. 
IX.1 - INACTIVATED VACCINES 
The first inactivated vaccine that was developed and used in the field after the 
emergence of BT in Europe was the vaccine against BTV-2. Subsequently, a 
monovalent BTV-4 and a bivalent BTV-2 and -4 vaccines have been developed and 
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used in Corsica, Spain, Portugal and Italy. Other inactivated vaccines have recently 
been developed or are under development. 
Inactivated whole virus vaccines are very safe if properly produced. They can be 
highly efficacious (Stott et al., 1985; Di Emidio et al., 2004) and although not yet 
available, strategies for differentiating infected from vaccinated animals (DIVA) are 
theoretically possible with these type of vaccines. Their inherent potential 
disadvantages include their high costs of production, as vaccination requires large 
amounts of antigen; and the need for booster immunizations, as inactivated vaccines 
generally induce a relatively transient immunity. 
IX.1.1 - QUALITY CONTROL 
For quality control testing, no data were given regarding the control tests performed 
during the different stages of production of the inactivated vaccine; however, all 
companies must follow the current guidelines described in the EU legislation 
concerning the manufacture of veterinary vaccines. 
IX.1.2 - SAFETY 
Several studies have been conducted on sheep to evaluate the safety of the 
subcutaneous injection of inactivated prototype vaccines against BTV-2, BTV-4 and 
BTV-2&4 in either simple, repeated or overdose trials. In all conditions, the 
inactivated BTV prototype vaccines were very well tolerated as demonstrated by the 
absence of systemic reaction (fever, weight loss, reproductive dysfunction, etc.) 
related to vaccination. Some vaccines induced transient local reactions of variable 
severity (mild to moderate) with different frequency (unusual to common). These 
usually disappeared within 3 days but, in a single case, a moderate local reaction 
persisted for 2 weeks (Hamers et al., 2006a). Anaphylactic shock was also reported 
in 0.02% sheep following vaccination with a BTV-4 inactivated vaccine. This event 
was observed only in areas where BTV-4 MLV had previously been used. 
BTV-4 and BTV-2&4 inactivated vaccines have also been tested for safety in cattle 
(MAPA, 2006; Savini et al., 2006a, 2006b). The vaccines were very well tolerated, 
and no side effects or local reactions were observed even when five doses of the 
BTV-4 inactivated vaccine were administered to the same animal (MAPA, 2006). 
No data documenting systemic or local reactions in vaccinated animals are available 
from the field use of these vaccines, as no complaints were reported from farmers. In 
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addition, as no significant antigenic variation was yet documented amongst the BTV-
2 and -4 strains currently circulating in Europe, the strains used to produce the 
inactivated vaccine are still suitable for the production of effective vaccines against 
these serotypes. 
IX.1.3 - EFFICACY 
Most companies producing BTV inactivated vaccines follow the guidelines of the 
European Pharmacopea and Committee for Veterinary Medicines Products for 
quality and safety control and efficacy. Assessment of efficacy is based on clinical 
and virological data as well as on immunogenicity. Immunogenicity is assessed by 
the analysis of the antibody response induced by each immunization, as measured by 
ELISA and by titration in a VNT against the same serotype (BTV-2 or BTV-4). The 
efficacy of the vaccine is evaluated in vaccinated animals by inoculation of an 
infective dose of live virulent BTV. The level of viremia after virus challenge is 
considered the most objective way to assess the efficacy of the vaccine-induced 
immunity. The level of viremia is analyzed by either a BTV-specific quantitative 
real-time RT-PCR assay (Jiménez-Clavero et al., 2006) or by virus isolation. In 
addition, clinical signs (fever, general congestion of the skin, edema and lameness) 
are evaluated after challenge. 
The inactivated prototype BTV vaccines induced significant titer of neutralizing 
antibodies after either one or two injections in sheep. A booster effect was observed 
after the second immunization (Hamers et al., 2006a, 2006b). In cattle, one dose of 
BTV-4 or BTV-2&4 inactivated vaccines induced a weak humoral response which 
rapidly declined to be undetectable 21 days following vaccination. However, the 
second dose of vaccine elicited high and stable titers of neutralizing antibodies 
(MAPA, 2006; Savini et al., 2006a). 
The number, age and breed of animals, as well as the challenge dose and virus strain 
vary for the different vaccines. A preliminary study was carried out to establish and 
standardize the optimal conditions for BTV vaccine trials on sheep and cattle. The 
effect of factors like the number of cell culture passages of the virus inoculum, the 
virus dose, type of inoculum and route of inoculation have all been evaluated. The 
infectivity of the field isolate was confirmed after four passages in cell culture, and 
the route of inoculation (subcutaneous or intravenous) did not affect either the 
occurrence of clinical signs or the duration and titer of viremia. Appropriate titers of 
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viremia were also obtained with different inocula (infected blood or cell culture-




 TCID50 (50% tissue culture 
infective dose)/dose or threshold cycle (TC): 25–27 and TC: 30–33].  The 
inoculation of cell culture-propagated virus-induced detectable viremia 3 days earlier 
(day 4) than that of blood from highly viremic sheep. 
One or two doses of inactivated BTV-2, BTV-4 and BTV-2&4 vaccine at 3–4 week 
intervals gave full and significant protection against clinical signs and viremia in 
sheep that were intradermally challenged with virulent BTV-2 and/or BTV-4 a week 
or a month after last vaccination. For BTV-2, it was also shown that a single dose 
protected sheep against both clinical signs and viremia for at least 6 months (Hamers 
et al., 2006a, 2006b). For BTV-2&4, two doses fully protect sheep for up to 12 
months. 
In cattle, efficacy studies have been performed on BTV-4 and BTV-2&4 vaccines. 
Two doses of the inactivated BTV-4 vaccine administered at a 24-day interval 
prevented viremia in vaccinated animals challenged with the homologous virulent 
serotype. Similarly, none of the animals vaccinated with two doses of BTV-2&4 
inactivated vaccine developed detectable viremia following challenge with virulent 
field strains of BTV-2 and/or BTV-4 that were performed up to 1 month after the 
second vaccination (Savini et al., 2006a). However, although a single dose of BTV-4 
inactivated vaccine prevented viremia in vaccinated animals challenged 2 weeks 
after vaccination, a single vaccination did not fully prevent viremia in animals 
challenged 7 months after vaccination (MAPA, 2006). 
The efficacy of the inactivated BTV vaccine was indirectly confirmed in the field 
when all but 2 of more than 40.000 seasonally migrating vaccinated Spanish cattle 
remained negative for BTV by RT-PCR after staying in a restricted area in the 
presence of BTV circulation (Jiménez-Clavero et al., 2006). 
IX.2 - MODIFIED LIVE VIRUS (MLV) VACCINES 
Outside of the EU, including the USA, Turkey, Republic of South Africa and India, 
BTV MLVs are available for many BTV serotypes. MLVs are produced by adapting 
BTV field isolates to growth in vitro through serial passages in tissue culture or in 
embryonated chicken eggs. Stimulation of a strong antibody response by these 
vaccines directly is correlated with their ability to replicate in the vaccinated host. 
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MLVs are cheap to produce in large quantities, they generate protective immunity 
after a single inoculation and have proven effective in preventing clinical BT disease 
in the areas where they are used (Patta et al., 2004; Caporale et al., 2004; Dungu et 
al., 2004). However, BTV MLVs suffer from a variety of documented or potential 
drawbacks including under-attenuation, whose impact may vary with sheep of 
different breeds. Potential adverse consequences are depressed milk production in 
lactating sheep, and abortion/embryonic death and teratogenesis in offspring when 
used on pregnant females (MacLachlan et al., 1985b; Venter et al., 2004; Savini, et 
al., 2004a; Monaco et al., 2004a; Monaco et al., 2004b; Ferrari, et al. 2005; Gerbier 
et al., 2003). Another risk associated with the use of MLVs is that of their potential 
for spread by vectors, with eventual reversion to virulence and/or reassortment of 
MLV genes with those of wild-type virus strains. The frequency and significance of 
these events remain poorly defined but natural and local dissemination of BTV-2 and 
-16 MLV vaccine strains has already been documented in Europe. Natural 
dissemination of MLV strains of BTV likely also is responsible for the sporadic 
incidence of teratogenic defects in unvaccinated cattle in South Africa and North 
America. Finally, the intrinsic inability to serologically distinguish naturally infected 
from MLV vaccinated animals precludes the possibility of developing a DIVA 
strategy with the MLV vaccines. 
After the incursion of BTV into Mediterranean Europe, the Spanish, French, Italian 
and Portuguese authorities have all carried out compulsory vaccination campaigns 
since 2000 using MLVs produced by Onderstepoort Biological Products in an 
attempt to reduce direct losses due to disease and indirect losses due to trade 
embargoes caused by the presence of BTV. At that time, these were the only 
commercially available BTV vaccines. Based on the serotype(s) present in a given 
country/area, various MLV monovalent serotype formulations have been used. 
IX.2.1 - QUALITY CONTROL 
Four monovalent MLV vaccines have been imported from South Africa and used in 
the EU (Table V). Before use, these vaccines were confirmed by the various EU 
National Laboratories to be free of bacterial, fungal and viral contaminants. Titer and 
serotype of the MLV batches also have been verified with no major discrepancies 
with information provided by the manufacturer. For the BTV-2 MLV, it was 
observed that the titer strongly decreased at temperatures above 35 °C (Hammoumi, 
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et al., 2003), but that it was retained for at least 36–48 h if sterility conditions were 
ensured during rehydration and the reconstituted vaccine was stored at a temperature 
below 19 °C (Ronchi et al., 2003). 
 
Table V. Characteristics of the bluetongue virus vaccine strains (Savini et al., 2007). 
 
 
IX.2.2 - SAFETY 
Modified live viruses have different potential adverse impacts according to the 
specific formulation used, the specific serotypes and the number of serotypes 
included in the vaccine. 
IX.2.2.1 - FEVER AND SICKNESS 
Apart from a study performed by the Institute of Animal Health at Pirbright using 
either BTV-2 or BTV-9 and Polled Dorset sheep, in which moderate to severe 
clinical signs of BT, albeit short lived, were observed following vaccination 
(Veronesi et al. 2005), only mild symptoms were observed in most experimental 
MLV vaccination studies. These were characterized by transient fever starting from 
the fifth day after vaccination (p.v.) and mild hyperemia of the oral cavity during the 
second week. 
Reports of adverse events in the field greatly vary with the strain of BT MLV used 
for vaccination of the animals. The monovalent BTV-2 MLV vaccine was used in 
Corsica (from 2001 to 2004) and Italy (from 2002) on approximately 130.000 and 
4.000.000 sheep and goats, respectively. In both locations, there were no or 
negligible adverse reactions reported after vaccination (Bréard et al., 2004; Gerbier 
et al., 2003; IZSAM, 2001; IZSAM, 2004). However, when the same vaccine was 
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used in 2000/01 in Menorca and Mallorca on 320.000 sheep, adverse events were 
observed in 0.13% and abortion in 0.16% of the vaccinated animals (MAPA, 2006). 
The BTV-2 MLV vaccine was also used on more than 400.000 cattle during the 2002 
Italian vaccination campaign with no adverse reactions reported. 
The monovalent BTV-4 MLV vaccine has been only used in sheep in Corsica in 
2004. No adverse reactions were reported (Bréard et al., 2004). In 2003 a new 
outbreak of BT occurred in Menorca that was due to BTV-4. A combined BTV-2 and 
-4 MLV vaccine was used to vaccinate sheep and goats, and no side effects were 
observed. The same vaccine combination was used in 2004 in Tuscany, and the 
following year in Tuscany and Sardinia, involving some 4.000.000 sheep and goats. 
Again, no or negligible adverse reactions were reported. Similarly, no adverse side 
effects were recorded among approximately 400.000 cattle vaccinated with the 
combined BTV-2 and -4 MLVs in 2004 and among a similar number of animals in 
2005. 
A bivalent BTV-2 and -9 MLV vaccine was used to vaccinate sheep and goats in 
some regions of Italy since 2002. Of the more than 1.700.000 animals vaccinated, 
only a very small percentage (<0.1%) developed fever and facial edema at 7–14 days 
p.v. (IZSAM, 2004). In the same vaccination campaign, BTV-2/BTV-9 MLVs were 
also administered to more than 600.000 cattle and no adverse reactions were 
reported. Similarly, a trivalent MLV vaccine containing BTV serotypes 2, 4 and 9 
was used since 2005 on more than 1.000.000 sheep, goat and cattle, and no or 
negligible adverse reaction were reported. 
In 2004, BTV-16 was isolated in Corsica by the AFSSA Maisons-Alfort laboratory 
(Zientara et al., 2006). Vaccination of sheep with BTV-16 MLV was performed in 
the southern part of the island. Typical signs of BT were reported in vaccinated sheep 
several days after vaccination. The vaccination program was therefore immediately 
terminated. The nucleotide sequence of segments 2, 7, 8, 9 and 10 from the virus 
isolated from ill animals was determined and found to be exactly identical to that of 
the vaccine MLV strain (Zientara, unpublished). 
Also in 2004, a trivalent MLV vaccine containing serotypes 2, 4 and 16 was used in 
Sardinia. However, a few weeks after vaccination, many vaccinated and 
unvaccinated sheep and goats became ill because of infection with the BTV-16 
vaccine strain (Monaco et al., 2006). These incidents were attributed to inadequate 
attenuation of the BTV-16 MLV that was in the vaccine, and for this reason the use 
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of monovalent BTV-16 MLV vaccine was discontinued (Italian Ministry of Health, 
2005). In contrast to what occurred in sheep and goats; however, the BTV-2, -4 and -
16 MLV combination did not cause significant adverse reactions in cattle 
(approximately 600.000 vaccinated animals). 
A polyvalent MLV containing BTV serotypes 2, 4, 9 and 16 was used in southern 
regions of Italy in 2004, and approximately 1.700.000 sheep and goats were 
vaccinated. No adverse reactions were reported. The same BTV-2, -4, -9 and -16 
MLV combination did not cause adverse reactions in cattle (approximately 600.000 
vaccinated animals). 
Finally, the safety of a pentavalent BTV serotypes 1, 2, 4, 9 and 16 MLV vaccine 
was evaluated in sheep maintained in isolation facilities at the Afssa Sophia 
Antipolis laboratory. Significant fever (41-42 °C) was reported in many animals 
(unpublished data). Based on these observations, it was decided that this vaccine 
should not be used in the field. 
IX.2.2.2 - EFFECT ON PREGNANCY 
Experimental infection studies using MLV strains of BTV-2 or BTV-2 and -9 were 
conducted on cattle to evaluate potentially deleterious effects on reproduction. In 
none of these studies was any adverse effect on pregnancy observed (Monaco et al., 
2004b, 2004c; Lucifora et al., 2004). 
Abortions and/or stillbirth have however been reported in the various vaccination 
campaigns that used BTV MLVs. During the 2000/01 Balearic BTV-2 campaign, 
approximately 0.16% of the 320.000 vaccinated sheep aborted. Similarly, during the 
Italian BTV-2 vaccination campaign, abortion was reported on 0.42% and 0.18% of 
vaccinated sheep and cattle, respectively. However the virus was detected in only 
0.06% and 0.01% of their respective aborted fetuses. In 2002, the combined BTV-2 
and -9 MLV resulted in abortion of 0.53% and 0.14% of vaccinated sheep and cattle, 
respectively, although BTV was detected only in a small percentage of abortions 
(0.09% and 0.01% of the sheep and cattle fetuses, respectively) (Monaco et al., 
2004c). 
IX.2.2.3 - EFFECT ON SEMEN 
The effects of the BTV-2 MLV on the quality of semen were investigated (Bréard et 
al., 2007) in 23 rams vaccinated at a 47-day interval. Although BTV was not 
detected in any of the semen samples, a decrease of the semen quality (volume, 
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sperm concentration, motility, abnormal and dead spermatozoa) was demonstrated 
after the first vaccination. A decrease in semen quality was also observed after the 
second vaccination; however, at day 69, the semen quality of the vaccinated animals 
was not significantly different from those of the 23 controls. 
IX.2.2.4 - MILK PRODUCTION 
Given the economic importance of milk production, numerous studies have been 
conducted to determine the effects of several MLV combinations on milk production 
in both sheep and cattle. 
Vaccination of sheep with either BTV-2 or BTV-2 &4 MLVs did not affect the 
quantity and quality of milk produced by the vaccinated animals (Zientara, 
unpublished; and (Caporale et al., 2003; Cannas et al., 2005; Giovannini et al., 
2004b). 
Quite different were the observations made with BTV-2 and -9, BTV-2 and -16, 
BTV-2, -4 and -9 or BTV-2, -4, -9 and -16 MLVs. Vaccination with each of these 
combinations had a marked negative impact on total milk production with production 
decreases of 20–30% as compared to normal production levels. The decrease, evident 
in the second week following vaccination, was transient and not accompanied by 
significant changes in milk quality (cell count, pH, fat, protein and lactose) (Savini et 
al., 2004a; Cannas et al., 2005). It was suggested that the effects of vaccination on 
milk production were primarily due to the transient perturbation of health induced by 
the vaccine and not to a direct virus effect on the mammary tissue (Savini et al., 
2004a). 
In contrast, vaccination of 30 cows with combined BTV-2 and -9 MLV vaccines had 
no effect on the production and quality (somatic cell count, pH, milk fat, protein and 
lactose content) of their milk (Monaco et al., 2004b). 
IX.2.2.5 - DURATION AND TITER OF VIREMIA 
After immunization with MLVs, the attenuated virus circulates in the blood stream 
and so potentially can infect competent vectors and be transmitted to other 
susceptible hosts. Therefore, MLV vaccination should be performed in the cooler 
months when the Culicoides population and its activity typically are at the lowest 
level. This will limit the possibility of transmission of the vaccine strains by biting 
midges while immunizing susceptible animal populations before the next epidemic 
season. 
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Transmission of MLV strains of BTV to insects most likely would occur from 
viremic animals that are introduced into infection-free areas where competent 
Culicoides species are present and highly active. In this scenario, the magnitude and 
duration of viremia in vaccinated animals would be clearly important in determining 
whether or not MLV strains of BTV could be acquired and transmitted by local 
vectors. Although virus titers in blood less than 10
3
 TCID50/ml have traditionally 
been considered a ‗‗safe‘‘ threshold, authentic instances of insects acquiring BTV 




/ml have been reported. Given 
the complex interaction of BTV, Culicoides vectors and animal hosts in the life cycle 
of infection, virus titers induced by MLV should be kept to an absolute minimum 
specially if field transmission of MLV strains is a concern. 
Studies on the duration and titers of viremia have been performed on sheep and cattle 
following vaccination with different MLV combinations. Viremia following 
vaccination with BTV-2, -4, -9 and -16 MLV strains (including multivalent 
combinations) was found to persist for up to 24 days in sheep and 78 days in cattle 
(Monaco et al., 2004a, 2004b, 2006; Savini et al., 2004b, 2004c, 2004d, 2005). 
Information pertaining to the MLV strains used in Europe is however limited; 
available data suggests that cattle vaccinated with BTV-2 and BTV-9 MLVs can be 
moved safely 32 days after vaccination (Monaco et al., 2004a), whereas sheep 
vaccinated with the same strains can be moved 28 days following immunization 
(Savini et al., 2004a). From the viremia data obtained in cattle following BTV-2, -4, 
-9 and -16 MLV vaccination, it was determined that cattle could be moved safely 
(risk of infection <0.01%) at 60 days after vaccination (Savini et al., 2006b). The 
latter result, however, is most likely related to the inadequate attenuation of the BTV-
16 MLV strain and cannot be extrapolated to MLV vaccines that do not include this 
serotype. 
Apart from some BTV-2 MLV vaccination studies on sheep and cows where virus 
titers were never found to be higher than 10
3
 TCID50/ml (Hammoumi et al., 2003; 
Monaco et al., 2004c), all other MLV combinations which have been studied in 
sheep (BTV-2, BTV-9, BTV-16, BTV-2 and -9, BTV-2 and -4, BTV-2, -4 and -16, 
BTV-2, -4, -9 and -16) and cattle (BTV-2 and -9, BTV-2, -4, -9 and -16) gave rise, 
for a brief period of 2–4 days, to viremic titers above the infecting threshold at least 
in some of the vaccinated animals (Savini et al., 2006a, 2006b, 2005a, 2004a; 
Monaco et al., 2004a, 2006; Veronesi et al., 2005; ). 
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No data have been reported, however, on the duration and titers of viremia in animals 
vaccinated with these MLV in the field, but local transmission of BTV-2 and BTV-
16 vaccine strains in the field has been demonstrated (Ferrari et al., 2005; Monaco et 
al., 2006). 
IX.2.3 - EFFICACY 
An important factor in confirming the efficacy of MLV vaccines is their ability to 
elicit neutralizing antibodies in vaccinated animals. Neutralizing antibodies play a 
key role in protecting animals from disease and viremia following infection with the 
homologous wild-type BTV. Knowing the duration of the immune status derived 
from vaccination is of paramount importance for both planning the frequency of 
vaccine booster immunizations to adequately protect the animals against disease, and 
to facilitate the safe movement of vaccinated animals (OIE, 2005). 
Experimental challenge studies have demonstrated that vaccination with the BTV-2 
MLV strain prevented viremia in at least 90.5% of vaccinated cattle that were 
challenged at 7 months after vaccination with a dose of 2x10
5.8 
TCID50 of virulent 
homologous field isolate (Savini et al., 2004b). Serological studies performed on 
cattle and sheep that were vaccinated with several MLV combinations have shown 
that more than 80% of the vaccinated animals had specific BTV antibodies 
(Hammoumi et al., 2003; Gerbier et al., 2003; Savini et al., 2004c, 2004e). Colostral 
antibodies were found in calves born from vaccinated dams until 39 days of age 
(Savini et al., 2004c). 
The efficacy of MLV vaccination has widely been demonstrated in the field. 
Following the 2000/01 and 2003 BT vaccination campaigns in the Balearic Islands, 
no outbreaks have been detected since December 2003 in the area. 
With regard to the vaccination strategy in Italy, several points warrant attention. 
First, on the basis of a risk assessment (Giovannini et al., 2003) and considering the 
encouraging results of preliminary studies, the Italian Authorities decided to 
vaccinate all susceptible domestic ruminant species (i.e. sheep, goats, cattle and 
water buffalo) in the infected and at risk areas, with the aim of limiting direct losses 
and reducing virus BTV circulation (Patta et al., 2004). Mass vaccination of 
susceptible populations started in January 2002, although the starting dates and the 
percentages of vaccinated population achieved varied greatly among regions (Patta et 
al., 2004). In those areas where more than 80% of the target population was properly 
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vaccinated before the new epidemic peak, clinical disease in sheep disappeared 
almost completely and virus circulation was significantly reduced (Patta et al., 2004), 
with substantial benefit to internal animal trade/movement. The results obtained in 
some Italian regions with mass vaccination of all susceptible domestic ruminants and 
the experience gained during the vaccination campaigns contributed to the 
modifications of BT international standards. Specifically, risk analysis can be used as 
an alternative to individual testing to assess immunity level in the population of 
origin and determine the risk of spreading infection to free areas by movement of 
vaccinated animals from infected territories (Giovannini et al., 2003). In particular, 
the analysis performed by Giovannini (Giovannini et al., 2003) indicates that when 
more than 80% of the susceptible population in the territory of origin was vaccinated, 
the risk associated with the movement of vaccinated animals to free areas appeared 
acceptable and could further be mitigated by ancillary control measures. 
In the absence of effective inactivated vaccines and in an emergency, MLVs still 
represent a valid option for vaccination, provided that the quality, safety and efficacy 
of the MLV strains match EU standards. These vaccines can be an alternative also in 
a non-emergency situation when local conditions (e.g. in case a large amount of 
animal must be immunized in a very short period of time) indicate their use. 
IX.3 - RECOMBINANT VACCINES 
Several experimental recombinant vaccines have been described and they clearly 
have numerous inherent potential benefits, including rapid onset of immunity, lack of 
transmissibility and even a polyvalent strategy. 
A recombinant vaccinia virus that expressed both VP2 and VP5 of Australian BTV 
serotype 1 induced variable titers of neutralizing antibody in sheep and afforded 
protection against homologous challenge (Lobato et al., 1997), but this approach has 
not been pursued further. 
A recombinant capripoxvirus expressing VP7 was shown to provide partial 
protection against heterologous BTV challenge (Wade-Evans et al., 1996), but like 
the recombinant vaccinia BTV vaccine, its development was not continued. 
Finally, a recombinant canarypox virus-VP2/VP5 vaccine was recently described 
that induced highly effective protective immunity in sheep (Boone et al., 2007). This 
vaccine has a major inherent advantage in that the existing VP7 competitive ELISA 
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assay would distinguish vaccinated from naturally infected animals (DIVA), and it 
utilizes an expression vector that is incorporated in several vaccines already in use in 
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X. - FLOW CYTOMETRY 
Flow cytometry is a technique for counting, examining, and sorting microscopic 
particles suspended in a stream of fluid. It allows simultaneous multiparametric 
analysis of the physical and/or chemical characteristics of single cells flowing 
through an optical and/or electronic detection apparatus. 
The first practical applications of flow cytometry, beginning in the 1940‘s, were to 
counting blood cells in liquid suspension, on the one hand, and bacteria and other 
small particles in aerosol, on the other, based on measurements of light scattering; 
these signals were also used to provide estimates of cell size. In the early 1960‘s, 
light absorption measurements were used for quantitative flow cytometric analyses 
of cellular nucleic acid and protein. Flow cytometers in modern clinical haematology 
laboratories perform counts of red cells, white cells, and platelets in blood, as well as 
differential leukocyte counts, using combinations of electrical impedance, light 
scattering and light absorption measurements (Shapiro, 1995). As regards the 
veterinary sector the flow cytometry is lately obtaining greater consensus thanks to 
greater demand for specialist examinations in clinical diagnostic process of small 
animals. 
X.1 - PRINCIPLES 
One of the fundamentals of flow cytometry is the ability to measure the properties of 
individual particles. When a sample in solution is injected into a flow cytometer, the 
particles are randomly distributed in three-dimensional space. The sample must 
therefore be ordered into a stream of single 
particles that can be interrogated by the 
machine‘s detection system. This process is 
managed by the fluidics system. Essentially, 
the fluidics system consists of a central 
channel/core through which the sample is 
injected, enclosed by an outer sheath that 
contains faster flowing fluid. As the sheath 
fluid moves, it creates a massive drag effect 
on the narrowing central chamber. This alters 
 
 
Fig. 14. Hydrodynamic focusing produces  
a single stream of particles 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
61 
 
the velocity of the central fluid whose flow front becomes parabolic with greatest 
velocity at its center and zero velocity at the wall (Fig. 14).  
The effect creates a single file of particles and is called hydrodynamic focusing. 
Under optimal conditions (laminar flow) the fluid in the central chamber will not mix 
with the sheath fluid. Without hydrodynamic focusing the nozzle of the instrument 
(typically 70 μM) would become blocked, and it would not be possible to analyze 
one cell at a time. 
After hydrodynamic focusing, each particle passes through one or more beams of 
light. Light scattering or fluorescence emission (if the particle is labeled with a 
fluorochrome) provides information about the particle‘s properties. The laser and the 
arc lamp are the most commonly used light sources in modern flow cytometry. 
Lasers produce a single wavelength of light (a laser line) at one or more discreet 
frequencies (coherent light). Arc lamps tend to be less expensive than lasers and 
exploit the color emissions of an ignited gas within a sealed tube. However, this 
produces unstable incoherent light of a mixture of wavelengths, which needs 
subsequent optical filtering. 
Light that is scattered in the forward direction, typically up to 20° offset from the 
laser beam‘s axis, is collected by a lens known as the forward scatter channel (FSC). 
The FSC intensity roughly equates to the particle‘s size and can also be used to 
distinguish between cellular debris and living cells. 
Light measured approximately at a 90° angle to the excitation line is called side 
scatter. The side scatter channel (SSC) provides information about the granular 
content within a particle. Both FSC and SSC are unique for every particle, and a 
combination of the two may be used to differentiate different cell types in a 
heterogeneous sample. 
Fluorescence measurements taken at different wavelengths can provide quantitative 
and qualitative data about fluorochrome-labeled cell surface receptors or intracellular 
molecules such as DNA and cytokines. 
Flow cytometers use separate fluorescence (FL-) channels to detect light emitted. 
The number of detectors will vary according to the machine and its manufacturer. 
Detectors are either silicon photodiodes or photomultiplier tubes (PMTs). Silicon 
photodiodes are usually used to measure forward scatter when the signal is strong. 
PMTs are more sensitive instruments and are ideal for scatter and fluorescence 
readings. 
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The specificity of detection is controlled by optical filters, which block certain 
wavelengths while transmitting (passing) others. There are three major filter types. 
‗Long pass‘ filters allow through light above a cut-off wavelength, ‗short pass‘ 
permit light below a cut-off wavelength and ‗band pass‘ transmit light within a 
specified narrow range of wavelengths (termed a band width). All these filters block 
light by absorption (Fig. 15). 
When a filter is placed at a 45° angle to the oncoming light it becomes a dichroic 
filter/mirror. As the name suggests, this type of filter performs two functions, first, to 
pass specified wavelengths in the forward direction and, second, to deflect blocked 













When light hits a photodetector a small current (a few microamperes) is generated. 
Its associated voltage has an amplitude proportional to the total number of light 
photons received by the detector. This voltage is then amplified by a series of linear 
or logarithmic amplifiers, and by analog to digital convertors (ADCs), into electrical 
signals large enough (5–10 volts) to be plotted graphically. 
Log amplification is normally used for fluorescence studies because it expands weak 
signals and compresses strong signals, resulting in a distribution that is easy to 
display on a histogram. Linear scaling is preferable where there is not such a broad 
range of signals e.g. in DNA analysis. 
The measurement from each detector is referred to as a ‗parameter‘ e.g. forward 




Fig. 16: Schematic overview of a typical  
flow cytometer setup. 
Fig. 15. Different types of optical filters. 
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as the ‗events‘ and refer to the number of cells displaying the physical feature or 
marker of interest. 
X.2 - IMMUNOPHENOTYPING                                                            
Immunophenotyping is a technique used to study the protein expressed by cells. This 
technique is commonly used in basic science research and laboratory diagnostic 
purpose. This can be done on cell suspension, tissue section (fresh or fixed tissue), 
etc. It involves the labelling of white blood cells with antibodies directed against 
surface proteins on their membrane. By choosing appropriate antibodies, the 
differentiation of subpopulations of normal o abnormal lymphocytes cells can be 
accurately determined. The labelled cells are processed in a flow cytometer, a laser-
based instrument capable of analyzing thousands of cells per second. The whole 
procedure can be performed on cells from the blood, bone marrow or spinal fluid in a 





























Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 








































- SECOND PART –  
Monovalent modified-live vaccine against Bluetongue 
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XI. - AIM 
The aim of this study was to determine the safety of a newly produced BTV serotype 
1 modified-live virus (MLV) vaccine and its efficacy in protecting sheep against 
bluetongue infection. For this purpose the protocol reported on the ―Manual of 
diagnostic tests and vaccines for terrestrial animals‖ of the ―Office International des 
Épizooties‖ (OIE, 2004f) was used, except for some additional laboratory tests useful 
to evaluate health status. In this way it was possible to establish the real vaccine‘s 
ability to prevent clinical insurgence of BT disease. Furthermore, in the challenge 
trial of efficacy test, white blood cell subsets of immunised and non immunised 
sheep following BTV-1 experimental infection were identified by flow cytometry. 
Finally a group of sheep were challenged with virulent strain of BTV2 in order to 
verify the protection of animals vaccinated with BTV1 vaccine against serotype 2, 
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XII.  - MATERIALS AND METHODS 
Our experimental trial consists of different tests to ensure innocuity (safety tests) and 
efficacy (efficacy tests) of BTV-1 modified-live virus vaccine as described in the 
―Manual of diagnostic tests and vaccines for terrestrial animals‖ by OIE (OIE, 
2004f). The MLV vaccine against BT serotype 1 used was manufactured and 
supplied by ―Centro Studi Malattie Esotiche‖ (CESME) of ―Istituto Zooprofilattico 
dell‘Abruzzo e Molise - G. Caporale‖ in Teramo. 
XII.1 - SAFETY TESTS 
This test is conducted on sheep to evaluate the safety of inactivated vaccines in either 
simple or overdose trials as demonstrated by the absence of systemic (fever, 
reproductive dysfunction) or local reaction related to vaccination. Safety test is 
important also in determining whether or not attenuated virus strains of BTV could 
be acquired and transmitted by local vectors and could possibly lose some of its 
characteristic of attenuation to acquire other more pathogenic. 
XII.1.1 - ANIMALS 
Thirty-one Sarda sheep (Table VI) of various ages, healthy and BTV seronegative 
were selected for this trial. Animals were kept at the ―Istituto Zooprofilattico 
Sperimentale della Sardegna‖ facilities in a Culicoides - free area. Animals were 
treated in accordance with national and European Union animal welfare regulations.  
Clinical examination and laboratory analysis were executed in order to ensure sheep 
health condition. Blood samples were collected to verify eventual seropositivity 
against common ruminant infectious diseases (visna-maedi, pestivirus, 
paratubercolosis) and to determine haematological and biochemical parameters. 
Furthermore,  echography examinations to diagnose pregnancy and identify its stage 
were performed. 
XII.1.2 - VACCINE INOCULATION 
A group of 19 sheep were vaccinated subcutaneously with 1 ml of 10
3 
TCID50 of 
BTV-1 modified-live virus vaccine; 7 sheep were vaccinated with 1 ml of decuple 
dose (10
4
 TCID50); the remaining 5 sheep were inoculated with 1 ml of sterile saline 
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solution and were used as mock-vaccinated control animals to detect possible local 
circulation of wild BTV in the experimental group.  







Age Sex Birth Date 
1 N19 103 TCID50 2 years Female January 
2 903 103 TCID50 1 year Female End of February-March 
3 907 103 TCID50 1 year Female End of February-March 
4 915 103 TCID50 1 year Female End of February-March 
5 912 103 TCID50 1 year Female End of February-March 
6 N06 103 TCID50 2 year Female End of February-March 
7 897 103 TCID50 -------- Female End of February-March 
8 909 103 TCID50 1 year Female End of February-March 
9 917 103 TCID50 1 year Female End of February-March 
10 905 103 TCID50 1 year Female End of February-March 
11 908 103 TCID50 1 year Female End of February-March 
12 N08 103 TCID50 2 years Female January 
13 F3 103 TCID50 4 years Female January 
14 F4 103 TCID50 4 years Female January 
15 N14 103 TCID50 2 years Female not pregnant 
16 921 103 TCID50 1 year Female not pregnant 
17 895 103 TCID50 7 years Female not pregnant 
18 911 103 TCID50 1 year Female not pregnant 
19 899 103 TCID50 7 years Female not pregnant 
20 910 Placebo 1 year Female January 
21 898 Placebo 7 years Female not pregnant 
22 N16 Placebo 2 years Female January 
23 F5 Placebo 4 years Female January 
24 N09 Placebo 2 years Female January 
25 916 104 TCID50 1 year Male ------------- 
26 914 104 TCID50 1 year Male ------------- 
27 919 104 TCID50 1 year Female not pregnant 
28 902 104 TCID50 1 year Female not pregnant 
29 918 104 TCID50 1 year Female not pregnant 
30 913 104 TCID50 1 year Female not pregnant 
31 900 104 TCID50 1 year Female not pregnant 
 
 
XII.1.3 - FOLLOW UP: HEALTH STATUS AND VIRAEMIA 
After inoculation animals were followed to check their health status (clinical 
examination and laboratory analysis) and viraemia (isolation and titres). 
XII.1.3.1 - CLINICAL EXAMINATION AND RECTAL TEMPERATURES 
Recording of rectal temperatures and clinical examination were conducted daily for 
36 days following inoculation to reveal any clinical signs. Sheep were monitored for 
possible teratogenic effect. 
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XII.1.3.2 - BIOCHEMICAL ANALYSIS AND COMPLETE BLOOD COUNT 
(CBC) 
Blood samples were collected from the jugular vein before the vaccination (day 1) 
and weekly for the following 21 weeks to follow temporal modification occurred in 
biochemical analysis. The parameters measured by an automatic clinical chemistry 
analyzer with spectrophotometric method (Dimension RXL, Dade Behring) were: 
albumin (ALB),  azotemia (Urea), Gamma glutamyl transferase (GGT), creatinine 
(Crea), Glucose (GLU), total bilirubin (TB), total serum protein (TP), alkaline 
phosphatase (ALP), Aspartate aminotransferase (AST), Alanine aminotransferase 
(ALT), Creatine kinase (CK). 
CBC was conducted on blood supplemented with ethylenediamine tetra-acetic acid 
(EDTA) with the following determinations: white blood cells (WBC), red blood cells 
(RBC), haemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), 
mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin 
concentration (MCHC), platelets (PLT), lymphocytes (Li), monocytes (Mo), 
neutrophils (Gran). CBC were performed by an automatic blood cell counter 
(ADVIA 2120, Siemens) 
XII.1.3.3 - VIRUS ISOLATION AND TITRES  
On all animals EDTA blood samples were collected three times per week for 30 days 
beginning from the day of vaccination. In order to determine the presence of the 
virus and to define the titres, samples have been tested by CESME. Blood samples 
collected from animals were washed three times with sterile phosphate-buffered 
saline (PBS) containing antibiotics. The washed blood cells were re-suspended in 
lactose peptone buffer and sonicated to disrupt the red cells. After sonication, 0.1 ml 
of the sonication product was inoculated intravenously into 12 days old embryonated 
chickens eggs, which were incubated in a humidity chamber at 34°C and candled 
daily. Any embryo deaths within the first 24 hours were regarded as non-specific. 
Embryos that died after between two and seven days were kept at 4°C and embryos 
that were still alive after seven days were euthanased. The infected embryos were 
dissected and the brains, lungs, hearts, livers and kidneys were collected and 
homogenised with sterile quarts powder. The tissue debris was removed by 
centrifugation, and the supernatant was inoculated into flasks containing confluent 
monolayers into Vero cells maintained in an antibiotic medium and  incubated at 
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37°C in a humid atmosphere containing 5% carbon dioxide (CO2). The flasks were 
monitored daily for seven days for signs of cytopathic effects (cpe). If no cpe 
appeared, a second passage was made in cell culture, and incubated and monitored as 
before. The presence and identity of BTV in the culture medium of the cells showing 
cpe, and in those at the end of the second passage, were determined by 
immunofluorescence, using monoclonal antibody to BTV core protein VP7 (VMRD) 
and fluorescein isothiocyanate-labelled anti-mouse immunoglobulin G. Virus 
characterised as BTV was typed by virus microneutralisation assays, using type-
specific antibodies.     
Virus titres were determined in the blood of viraemic animals as follows: the blood 
cells were washed three times in phosphate-buffered saline (PBS) containing 
antibiotics. After the last washing, the sample was resuspended in MEM with 
antibiotics (1/10 v/v) and sonicated. Four tenfold dilutions of each sample suspension 
(from 1:10 to 1:10000) were inoculated into 96 flat-bottomed microtitre plate wells, 
following the method described in the OIE Manual of standards for diagnostic tests 
and vaccines (2004). Four replicates were made for each dilution. Approximately 10
4
 
cells, in a volume of 100 μl of MEM plus antibiotics and 3% FCS, were added per 
well and the plates incubated at 37°C under 5% CO2. The plates were examined after 
six days and the TCID50 calculated. 
XII.1.4 - REVERSION TO VIRULENCE 
This test was executed to confirm that attenuated viruses do not revert to virulence in 
vaccinated sheep and it was conceived in three steps. 
1° STEP 
Blood samples were collected in EDTA by vaccinated animals belonging to the 
safety test group (19 sheep inoculate with a single dose vaccine) in correspondence 
with hyperthermia (7° - 10° days after vaccination). Samples were used to form two 
different pools that were titrated by CESME following the protocol previously 
described. The blood pool with higher virus titre was chosen to inoculate three 
seronegative sheep (40 ml/each). After inoculation animals were followed as 
previously described to evaluate their health status and viraemia for almost 3 weeks. 
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After two weeks three seronegative  sheep were inoculated (40 ml/each) with a blood 
pool collected from the first group during the hyperthermia phase. Health status and 
viraemia were valued as the previous point. 
3°STEP 
After other two weeks, three seronegative  sheep were inoculated (40 ml/each) with a 
blood pool collected from the second group during the hyperthermia phase. Health 
status and viraemia were valued as the previous point. 
XII.2 - EFFICACY TESTS 
Assessment of efficacy is based on clinical and virological data as well as on 
immunogenity. Immunogenity is determined by the analysis of the antibody response 
induced by each immunization, as measured by ELISA and by titration in a serum 
neutralisation test (SN) against the same serotype. Vaccine efficacy is evaluated in 
vaccinated animals by inoculation of an infective dose of live virulent BTV. The 
level of viraemia, analyzed by virus isolation, and clinical signs together with 
laboratory analysis are evaluated after challenge. 
XII.2.1 - IMMUNOGENITY  
This test was executed to confirm the efficacy of BTV-1 modified-live virus vaccine 
by evaluating its ability to elicit neutralizing antibodies in vaccinated animals. 
Serum samples have been examined for BTV antibodies using a commercially 
available competitive Enzyme-Linked Immunosorbent  Assay (c-ELISA) (Lelli et al. 
2003) and serum neutralisation test (SN) (Savini et al. 2004b). 
Vaccinated and control animals were bled once a week for 15 weeks form the day of 
vaccination. The c-ELISA was conducted using a kit developed by CESME (Lelli et 
al. 2003). The purified antigen was diluted in pH 9.6 carbonate/bicarbonate buffer 
solution and dispensed into microplate wells where it was left to adsorb overnight at 
4°C. After washing, the sera and monoclonal antibodies, labelled with peroxidase, 
were added. The antigen-antibody reaction was revealed by the addition of a 
substrate. Samples presenting an optical density less than 35% of that found in the 
control wells were considered as positive. 
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The SN revealed the serotype and antibody titre; 50 µl of diluted serum from 1:10 to 
1:280 were added to each test well of flat-bottomed microtitre plates and mixes with 
100 TCID50 of previously titrated BTV serotypes 1. They were incubated at 37°C in 
5% CO2, and after one hour approximately 10
4
 Vero (African green monkey kidney) 
cells were added to each well in 100 µl of minimum essential medium (MEM) 
(Eurobio, France) containing antibiotics: penicillin 100 IU/ml (Sigma, Germany), 
streptomycin 100 µg/ml (Sigma), gentamicin 5 µg/ml (Sigma), nystatin 50 IU/ml 
(Sigma) and 10% foetal calf serum (FCS) (Sigma), were added to each well. After 3 
days, the cytopathic effect (CPE) in the wells was evaluated and the antibody titre 
was defined as the highest serum dilution able to inhibit at least 50% of the virus 
CPE. The positive and negative reference sera, cell and virus control were included 
in each plate. Positive and negative control sera were kindly supplied by the OIE 
reference laboratory of the Onderstepoort Veterinary Institute (OVI) in South Africa. 
XII.2.2 - CHALLENGE 
The challenge study was performed about 7- 8 months after the inoculation of BTV1 
modified-live virus vaccine. The sheep previously vaccinated were divided into two 
groups: the first group was inoculated with virulent strain of BTV1, to test the 
efficacy of the vaccine, the second group with BTV-2, in order to verify the 
protection of animals vaccinated with BTV-1 vaccine against serotype 2. Viraemia 
level, clinical examination, serological analysis and leukocytes subsets were carried 
out on challenged animals. 
XII.2.2.1 - CHALLENGE WITH VIRULENT STRAIN BTV-1 
XII.2.2.1.1 - ANIMALS 
Twenty-four healthy Sarda sheep of various ages were used for this trial. Animals 
were kept at the ―Istituto Zooprofilattico Sperimentale della Sardegna‖ facilities in a 
Culicoides - free area. Animals were treated in accordance with national and 
European Union animal welfare regulations. Seven months before the challenge 
started 12 sheep were vaccinated with 10
3
 TCID50/ml of BTV-1 modified-live virus 
vaccine and the remaining twelve were left unvaccinated. 
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XII.2.2.1.2 - BTV STRAIN PREPARATION  
A wild BTV strain isolated from the spleen of a sheep which died due to BTV-1 
infection during 2006 epidemic in Sardinia was used for the challenge test. 
The inoculum was prepared according to the method described by Savini et al. 
(2005b): the spleen was fragmented using sterile quartz powder, suspended in a 
lactose peptone buffer containing antibiotics, sonicated and centrifuged. After 
centrifugation, 100 µl of the suspension was inoculated intravenously into 
embryonated chicken eggs and then passaged on a confluent monolayer of Vero 
cells. At maximum cpe, the material was collected, divided into aliquots and stored 
at 80°C. The strain was then titrated and typed by the virus neutralisation test. 
Virus titre 




) were tested for each positive sample. Six 
replicates for each dilution were dispensed into 96 flat bottomed microtitre plate 
wells; Vero cells at a concentration of approximately 10
4
 cells/ml in MEM with 
antibiotics and 10% FCS were added to each well as the detection system. The test 
was read after six days‘ incubation at 37°C with 5% CO2. The content, calculated 
using the Reed and Muench formula, is defined as the highest virus dilution 
producing a cpe in 50% of the inoculated Vero cells (TCID50). 
Serological Typing 
Starting from 1:10, four ten-fold viral dilutions were placed in contact with each of 
24 serum-specific antisera diluted 1:20, as described by OIE. The viral serotype was 
identified on the basis of the specific antiserum able to neutralise viral growth on a 
cell monolayer, detectable through 50% inhibition of the CPE.   
XII.2.2.1.3 - ANIMAL INOCULATION 
Nineteen sheep, 12 vaccinated and 7 unvaccinated, were intramuscularly injected 
with 1 ml containing 10
6
 TCID50/ml of wild strain BTV1. Five seronegative sheep 
were not infected and used as negative control to possibly evidence wild BT virus 
circulation. 
XII.2.2.1.4 - CLINICAL EXAMINATION AND RECTAL TEMPERATURES 
Recording of rectal temperatures and clinical examination were conducted daily for 4 
weeks following inoculation to reveal any clinical signs. 
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XII.2.2.1.5 - BIOCHEMICAL ANALYSIS AND CBC 
Blood samples, with and without EDTA, were collected weekly for 6 weeks post 
infection (p.i.) for biochemical analysis and complete blood count (CBC). Laboratory 
analysis were executed from the Clinical Diagnostic Laboratory of the ―Istituto 
Zooprofilattico Sperimentale della Sardegna‖ as previously described. 
XII.2.2.1.6 - VIRUS ISOLATION AND TITRE 
In order to determine the presence of BTV1 and eventually to define its titre, EDTA 
blood samples, collected thrice a week for 4 weeks p.i., have been analysed by 
CESME, using the methods described above. 
XII.2.2.1.7 - SEROLOGICAL TESTS 
To evidence eventual seroconversions due to the inoculated virus or others viral 
serotypes, serum samples were collected once a week for 7 weeks p.i. and examined 
for antibodies presence of varied serotypes 1, 2, 4, 8, 9 and 16 of the virus of the 
bluetongue using the competitive enzyme-linked immunosorbent  assay (c-ELISA) 
and serum neutralisation test (SN), as previously described. 
XII.2.2.1.8 LEUKOCYTES SUBSETS 
Blood samples were collected at 0, +5, +7, +10, +14, +17, +21, +26, +33 to study 
leukocyte subset alterations following experimental infection. 
Cells were directly stained with monoclonal antibodies (Table VII) conjugated with 
different fluorochromes in a three-colour ―Lyse & Wash‖ staining procedure 
described below. 
 
Table VII. the panel of monoclonal antibodies used in the study 
 
Antigen Clone Label Specificity Supplier 
CD4 44.38 FITC sheep Serotec 
CD8 38.65 PE sheep Serotec 
CD14 TUK4 Alexa 647 human Serotec 
 
 
An aliquot of 50 µl of EDTA blood samples were transferred into 12x75 mm tubes 
(BD Falcon, Franklin Lakes, NJ, USA), added with 5 µl of each monoclonal 
antibody (0.05 µg/µl) and gently vortexed before ice-incubation for 20 min in dark. 
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Then, 450 μL of FACS Lysing Solution (BD Biosciences, San Jose, CA, USA) were 
added to each tube and  samples were incubated for 10 min at room temperature in 
dark. FACS Lysing Solution essentially lyses the red blood cells, maintaining 
cellular integrity without distortion, minimizing debris or platelet adhesion to 
leucocytes preparation. Following red blood cell lysis, samples were washed twice 
(200 x g for 5 min at 4°C) and after  resuspending in sheet fluid (Facs Flow, BD 
Falcon, Franklin Lakes, NJ, USA) they were acquired in a FacsCalibur flow 
cytometer (BD, Franklin Lakes, NJ, USA). Data analysis were performed using 
CellQuest™ software (BD, Franklin Lakes, NJ, USA). 
XII.2.2.2 - CHALLENGE WITH VIRULENT STRAIN BTV-2 
XII.2.2.2.1 - ANIMALS 
Eleven Sarda sheep of various ages were used for this trial. Animals were kept at the 
―Istituto Zooprofilattico Sperimentale della Sardegna‖ facilities in a Culicoides - free 
area. Animals were treated in accordance with national and European Union animal 
welfare regulations. Eight months before the challenge started 6 sheep were 
vaccinated with 10
3
 TCID50/ml of BTV-1 modified-live virus vaccine and the 
remaining 5 were left unvaccinated. Animal health status was tested as previously  
described before the challenge started.  
XII.2.2.2.2 - BTV STRAIN PREPARATION  
A wild BTV strain isolated from the spleen of a sheep which died due to BTV-2 
infection during 2000 epidemic in Sardinia was used for the challenge test. The virus 
was isolated and titrated in the same way of the BTV-1. Sheep were infected with 1 
ml containing 10
6
 TCID50/ml of wild strain BTV-2.  
XII.2.2.2.3 - ANIMAL INOCULATION 
Eight months after vaccination, 6 vaccinated and 5 unvaccinated Sarda sheep, were 
infected with the wild strain of BTV-2. 
XII.2.2.2.4 - CLINICAL EXAMINATION AND RECTAL TEMPERATURES 
Recording of rectal temperatures and clinical examination were conducted daily for 3 
weeks following inoculation to reveal any clinical signs. 
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XII.2.2.2.5 - BIOCHEMICAL ANALYSIS AND CBC 
Blood samples, with and without EDTA, were collected weekly for 7 weeks post 
infection (p.i.) for biochemical analysis and CBC. Laboratory analysis were executed 
from the Clinical Diagnostic Laboratory of the ―Istituto Zooprofilattico Sperimentale 
della Sardegna‖ as previously described. 
XII.2.2.2.6 - VIRUS ISOLATION AND TITRE 
In order to determine the presence of BTV-2 and eventually to define its titre, EDTA 
blood samples, collected thrice a week for 4 weeks p.i., have been analysed by 
CESME, using the methods described above. 
XII.2.2.2.7 - SEROLOGICAL TEST 
To evidence eventual seroconversions due to the inoculated virus, serum samples 
were collected once a week for 5 weeks p.i. and examined for antibodies presence  
serotypes 2 and 1 of the virus of the bluetongue using the competitive enzyme-linked 
immunosorbent  assay (c-ELISA) and serum neutralisation test (SN), as previously 
described. 
XII.3 - STATISTICAL ANALYSIS 
Differences between the viraemic titres and antibody titres of the vaccinated and 
unvaccinated groups of sheep before and after challenge were analysed using the 
non-parametric Mann–Whitney test for independent. Statistical significance of the 
tests was based on P values equal or lower than 0.05. 
Statistical analysis of laboratory data (biochemical analysis and CBC) was performed 
with analysis of variance (ANOVA) between groups and within groups (single dose, 
decuple dose and control); Tukey‘s Test was used to perform pairwise comparisons 
between different sampling times. 
Statistical analysis of WBC subsets were performed by ANOVA. P values ≤ 0.05 
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XIII. - RESULTS 
XIII.1 - SAFETY TESTS 
XIII.1.1 - FOLLOW UP: HEALTH STATUS AND VIRAEMIA 
XIII.1.1.1 - CLINICAL EXAMINATION AND RECTAL TEMPERATURES 
Vaccinated animals did not developed any clinical signs suggestive of bluetongue as 
well as local reactions at the injection site. Inoculation of the vaccine appeared not to 
cause reproductive failures including abortion, stillbirth, newborn mortality or 
congenital anomalies. Control animals did not show any signs of clinical disease. 
Two vaccinated ewes, one with single dose and the other with decuple dose, showed 
fever (>40° C) from day 6 to day 11 p.v. It could be evidenced short-term 
hyperthermia in sheep belonging to the three groups (single dose, decuple dose and 
control) during the whole trial period (Fig. 17). 
It has to be recorded the death of a sheep (F4) that was vaccinated with single dose. 
To identify the cause of death, autopsy, bacteriological and virological examination 
were conducted. Autopsy established injury attributable to enterotoxemia. 
Virological examination showed the presence of BTV-1 in the spleen. In a blood 
sample taken by the animal four days before death were observed changes in some 
liver parameters in presence of normal CBC. 
XIII.1.1.2 - BIOCHEMICAL ANALYSIS AND CBC 
Statistical analysis performed for biochemical and CBC parameters showed 
significant differences between groups (single dose, decuple dose, control) in some 
sampling times. Data were all included in normal reference intervals typical of ovine 
specie except for AST, GGT and monocytes (see Appendix 1). 
XIII.1.1.3 - VIRUS ISOLATION AND TITRES  
Vaccinated animals (single and decuple dose) have shown virus titres for 14 days, 
starting from day 5 p.v. (Fig. 18). No significant differences were found between 
viraemia levels of the two groups.  Eight animals (42.1%) of the group vaccinated 
with 10
3
 TCID50 and 4 (57.1%) of the group with 10
4
 TCID50 showed viraemia. In 
both groups the viraemia peak was found 7 days p.v. (Fig. 19). Three (15.8%) sheep 
of the group vaccinated with single dose and 2 (28.6%) of the group vaccinated with 
decuple dose showed, between the 5
th
 and the 7
th
 day p.v. levels of viraemia higher 
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than those necessary to infect the vectors (10
3
 TCID50). It was not possible to isolate 




Fig. 17. Average evolution of rectal temperatures recorded in sheep vaccinated with single and 



























Fig. 18. Virus titres (mean ± SD) in sheep vaccinated with single (10
3
 TCID50/ml) and decuple dose 
(10
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Fig. 19. Percentages of viraemic animals vaccinated with single and decuple dose of BTV-1 modified-
live virus vaccine and unvaccinated sheep.  
 
 
XIII.1.2 - REVERSION TO VIRULENCE 
As reported in Table VIII, IX and X the blood pools collected seven days after each 
inoculation (Step 1, 2 and 3) showed higher virus titres than those collected ten days 
after inoculation. The virus titre of blood pool used for subsequent inoculation was 
10
3,63
 TCID50/ml in the first step, 10
2,53
 TCID50/ml in the second step and 10
4,3 
TCID50/ml in the third step. 
 
Table VIII. Virus titres recorded in the pools of blood taken from vaccinated animals 
 
Sample date 16/01/2007 18/01/2007 
Days after vaccination 7 9 








Table IX. Virus titres recorded in the pools of blood taken from animals after the first step. 
 
Sample date 02/02/2007 05/02/2007 
Days after infection 7 10 


























Dose 10^3 TCID50/ml Dose 10^4 TCID50/ml Placebo
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Table X. Virus titres recorded in the pools of blood taken from animals after the second step. 
 
Sample date 16/02/2007 19/02/2007 
Days after infection 7 10 







Animals showed no clinical signs suggestive of BT disease during this trial. Fever 
(>40°C) was recorded in sheep of the second and third step (Fig. 20), which 
respectively showed hyperthermia between the 4th and the 9th day p.i. and between 
8th and the 10
th
 p.i. 
Statistical analysys performed for CBC showed significant differences for 
limphocytes and neutrophils in the three groups even if data were all included in 
normal reference intervals typical of ovine specie. Biochemical analysis showed 
significant differences for ALT in the second step and Crea in the third step. Urea 
differed significantly in the first and second step, TB in the second step and CK in 
the first step, being these data all included in normal reference intervals typical of 
ovine specie (see Appendix 2).  
No significant differences were found between viraemia levels of the three steps 
groups respect to the vaccinated aniamals.  Higher virus titre occurred in animals 
belonging to the second step group (Fig. 21) while in the third  step group more 
lasting levels of viraemia were found (14 days). All animals in the second and third 
step showed viraemia, while in the group of the first step BTV was found only in one 
blood sample. Levels of viraemia necessary to infect the vectors (10
3
 TCID50) were 
found in: 
 1 sheep of the first step, between the 5° and 10° day p.i.; 
 2 sheep of the second step, between the 5° and 10° day p.i.; 
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Fig. 21. Virus titres (mean ± SD) in sheep of the three steps and vaccinated with single dose of BTV-1 
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XIII.2 - EFFICACY TESTS 
XIII.2.1 - IMMUNOGENITY  
From day 14 p.v. an antibody titres increase was observed both in fourteen  animals 
(77.8%) of single dose vaccinated group and in 6 (85.7%) of decuple dose vaccinated 
group (Fig. 22). All animals, except one, seroconverted at 21 days p.v. with 
neutralising antibody titres peaking on day 35 p.v. There were no antibody titres for 
BTV-2, BTV-4, BTV-8, BTV-9, BTV-16, so as no BTV antibody titres have been 
found in control group. ). No significant differences were found between neutralising 
antibody titres levels of the single and decuple dose groups.  On the contrary the two 





















Fig. 22. Neutralising antibody titres in sheep after vaccination with BTV-1 modified-live virus 
vaccine.  
 
XIII.2.2 - CHALLENGE 
XIII.2.2.1 - CHALLENGE WITH VIRULENT STRAIN BTV-1 
XIII.2.2.1.1 - CLINICAL EXAMINATION AND RECTAL TEMPERATURES 
Control group animals developed hyperthermia from day 5 p.i. to day 9 p.i. peaking 
at day 7 p.i. (41.9°C) within the first 2 weeks of challenge. Only a sheep of 
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starting from day 4 p.i and lasting the following 4 days. Challenged vaccinated 
animals did not show any clinical signs and hyperthermia (Fig. 23). 
XIII.2.2.1.2 - BIOCHEMICAL ANALYSIS AND CBC 
Statistical analysis performed for biochemical and CBC parameters showed 
significant differences between and in the groups (vaccinated animals and control) in 
some sampling times. Data were all included in normal reference intervals typical of 
ovine specie except for ALT, CK, GGT, RBC and PLT in the control group and 
AST, MCH, MCHC and Mo in both groups (see Appendix 3). 
XIII.2.2.1.3 - VIRUS ISOLATION AND TITRE 
BTV-1 virus was isolated in the blood of all unvaccinated control animals from days 
3 to 13 p.i., with peak titres observed on day 5 p.i. Control animals virus titres 
differed significantly (P≤ 0,05) from those of vaccinated animals on day 3, 5, 7 and 
10 p.i. In vaccinated group virus isolation was not evidenced, except for one sheep 
which did not shown seroconvertion after vaccination performed seven months 
before (Fig. 24).  
XIII.2.2.1.4 - SEROLOGICAL TESTS  
In vaccinated animals an increase of antibody titres against BTV-1 was evidenced  
starting from 5 days p.i. and peaking after 19 days when it appeared 4 logarithms-
fold higher than day 0. Control group animals showed antibody titres against BTV-1 
from day 12 (Fig. 25). Statistical analisys performed between the two groups showed 
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Fig. 23. Average evolution of rectal temperatures of sheep vaccinated (VAX), unvaccinated (CTR) 






















Fig. 24. Virus titres (± SD) in sheep vaccinated with BTV-1 modified-live virus vaccine and 
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Fig. 25. Neutralising antibody titres in sheep vaccinated with BTV-1 modified-live virus vaccine after 
challenge with homologous strain. 
 
 
XIII.2.2.1.5 - LEUKOCYTES SUBSETS 
In ewes of the unvaccinated group the percentage of granulocytes markedly (P≤0.05) 
increased while the lymphocyte number significantly (P≤0.05) decreased compared 
to the values observed in the vaccinated animals. The latter change was the 
consequence of a CD4+ T-cells depletion. On day 5 and from day 10 till day 17 the 
unvaccinated group exhibited CD+4 T-cell lower percentage respect to vaccinated 
ewes (P≤0.05). As a consequence, the CD4/CD8 ratio also resulted significantly 
lower (P≤0.05) in the unvaccinated animals compared to the value observed in the 
vaccinated group on day 10 and 22. No significant differences were found in CD8 
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Fig. 26. Leukocytes subsets in vaccinated (VAX) and unvaccinated sheep (CTR). CD4 (a), CD8 (b), 
CD4/CD8 ratio (c), CD14 (d). CD4+ cells= lymphocytes T-helper; CD8+ cells= lymphocytes T cell 
suppressor/cytotoxic; CD14+ cells= monocytes. Day 0= BTV1 inoculation. 
 
 
XIII.2.2.2 - CHALLENGE WITH VIRULENT STRAIN BTV-2 
XIII.2.2.2.1 - CLINICAL EXAMINATION AND RECTAL TEMPERATURES 
After challenge with virulent strain BTV-2, both groups of animals, vaccinated and 
not, have shown hyperthermia during the first week (Fig. 27). 
XIII.2.2.2.2 - BIOCHEMICAL ANALYSIS AND CBC 
Statistical analysis performed for biochemical and CBC parameters showed 
significant differences between and in the groups (vaccinated animals and control) in 
some sampling times. Data were all included in normal reference intervals typical of 
ovine specie except for RBC and MCV in the vaccinated group and MCH and 
MCHC in both groups (see Appendix 4). 
XIII.2.2.2.3 - VIRUS ISOLATION AND TITRE 
BTV-2 virus was isolated in the blood of all animals from day 3 to 14 p.i. in 
vaccinated group and from day 3 to 17 p.i. in control group, with peak titres observed 
on day 5 p.i. in both groups. Viraemia titres of vaccinated animals were lower respect 
to unvaccinated animals (P≤0.05) on day 10, 12 and 14 p.i.  Animals vaccinated with 
BTV-1 showed viraemia  for 11 days, while the control group for 14 days p.i. 
(Fig.28). 
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XIII.2.2.2.4 - SEROLOGICAL TESTS 
After challenge with virulent strain BTV-2, all animals showed neutralising antibody 
titres against BTV2 (Fig. 29). No significant differences were found between 
antibody titres of vaccinated and unvaccinated animals, except for day 12 when 
antibody titres were higher (P≤0.05)  in vaccinated animals.  
After inoculation with virulent strain BTV-2, in vaccinated animals an increase of 
antibody titres against BTV-1 was evidenced  starting from 5 days p.i. and peaking 
after 14 days when it appeared 4 logarithms-fold higher than day 0. Antibodies 
increase was similar to that in sheep vaccinated with the vaccine BTV-1 infected 
with the homologous serotype (Fig. 30).  
 
 
Fig. 27. Average evolution of rectal temperatures of sheep vaccinated (VAX) and unvaccinated 
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Fig. 28. Virus titres (± SD) in sheep vaccinated with BTV-1 modified-live virus vaccine and 





















Fig. 29.  Neutralising antibody titres against the serotype 2 in sheep vaccinated with BTV-1 modified-
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Fig. 30. Average of antibody titres against the serotype 1 of BTV found in groups of sheep vaccinated 
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XIV. - DISCUSSION 
Vaccination against BTV is an essential tool, not only for the control of the disease 
but more importantly, for ―safe‖ trade of live ruminants in accordance to OIE 
standards and EU legislation. To prevent BTV infection of ruminants, different types 
of vaccines, including modified live virus (MLV), inactivated vaccines, virus-like 
particles (VLP) produced from recombinant baculoviruses, and recombinant vaccinia 
virus vectored vaccines have been manufactured (Roy et al., 1992; Boone et al., 
2007). MLV vaccines tested in this study, when administered in adult Sarda sheep, 
resulted safe and effective in complete prevention of clinical signs and detectable 
viraemia after challenge using virulent homologous virus. However, the challenge 
with virulent strain BTV-2 showed that the vaccine is not able to cross-protect 
vaccinated sheep, confirming that protective immunity against BT is associated with 
the presence of type-specific neutralising antibodies. 
At the moment, only inactivated and MLV vaccines against BT are commercially 
available and used in the official vaccination campaigns. Although VLPs are safe and 
neat, their inconsistent efficacy when used in field trials (Roy et al., 1990, 1992, 
1994; Roy, 2004) and difficulties with commercial production, cost, and long-term 
stability make them ineligible for field use (Savini et al., 2007a). Similarly, 
recombinant vector vaccines expressing both VP2 and VP5, even though revealing 
some potential in terms of safety and protection, still require further development 
before being ready for field use (Lobato et al., 1997).  
Inactivated vaccines have been recently developed and marketed. The efficacy of an 
inactivated vaccine is fully dependent on the dose of virus, resulting in significantly 
higher virus mass than that of MLV. Two doses, in the presence of adjuvant, may 
often be required for inactivated vaccines considerably increasing the cost of 
vaccination. Inactivated vaccines for BTV-2 and/or BTV-4 have been developed, 
commercialized and successfully employed in the 2005–2006 BTV vaccination 
campaigns. In infected areas, when inactivated virus vaccines are used, it is 
recommended to wait for 60 days before moving the animals to take into 
consideration the risk that animals are infected at the moment of the vaccination. 
Conversely, live attenuated vaccines are cheap to produce in large quantities; they 
generate protective immunity after a single inoculation and have proven effective in 
preventing clinical BT disease in the areas where they are used (Patta et al., 2004; 
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Dungu et al., 2004). Stimulation of a strong antibody response by these vaccines is 
directly correlated to their ability to replicate in the vaccinated host. However, live 
attenuated BTV vaccines suffer from a variety of documented or potential 
drawbacks, including under-attenuation, the impact of which may vary with different 
breeds of sheep. Potential adverse consequences with the use of live attenuated 
vaccines are depressed milk production in lactating sheep, and abortion/embryonic 
death and teratogenesis in offspring from pregnant females that are vaccinated during 
the first third of gestation. Another risk associated is their potential for spread by 
vectors, with eventual reversion to virulence and/or reassortment of vaccine virus 
genes with those of wild-type virus strains (OIE, 2004f). The frequency and 
significance of these events remain poorly defined but natural and local 
dissemination of vaccine strains has already been documented in Europe (OIE, 
2004f). When MLV are used, it is recommended to take into consideration, before 
movements of animals, the duration of viremia induced by the vaccinal strain. In 
consequence, the waiting period before movement should be 60 days considering 
that it was determined that cattle could be moved after that period. 
When, in October 2006, BTV-1 was recorded in Sardinia, Ministry of Health has 
agreed that the use of vaccination is the only viable route to safeguard the livestock 
and to enable the movement of susceptible animals in accordance with national and 
European Union regulations. Since there was no inactivated BTV-1 vaccine yet 
available, it was decided to use a MLV vaccine as emergency measure (D.M. 
12.03.2007). The only attenuated vaccine against BTV-1 available on the market was 
manufactured by "Ondersterpoort Biological Products Ltd" (OBP) in South Africa. 
However, the OBP was not able to provide the vaccine (for times of production and 
delivery) for the next vaccination campaign that it would be started in March 2007. 
Therefore Ministry of Health, with D.M. 12.03.2007, authorized the ―IZS 
dell‘Umbria e del Molise‖ to produce the modified live vaccine against BTV-1 for 
2007 vaccination campaign. In attenuated vaccines the master or primary virus seed 
is prepared by BTV field isolates. Vaccine virus is attenuated by either passages in 
tissue culture, in embryonating chicken eggs or a combination of both. Vaccine virus 
manufactured by CESME has been obtained by cloning from South Africa 
tetravalent vaccine. and subsequently tested for the presence contaminant viruses of 
viable bacterial, fungal or mycoplasmal contamination. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
91 
 
In this work we have evidenced the safety of BTV serotype 1 MLV vaccine and its 
efficacy in protecting sheep against bluetongue infection. For this purpose various 
trials were performed, as described in the ―Manual of diagnostic tests and vaccines 
for terrestrial animals‖ by OIE (OIE, 2004f), to evaluate the innocuity and efficacy of 
this vaccine. 
Animal health status assessment and viraemia detection after vaccine inoculation 
performed to evaluate its safety has given a positive outcome. In fact, vaccine, both 
in normal dose and decuple dose, did not cause significant clinical effects and long-
term hyperthermia attributable to BT, proving that its use is safe. Analysis of 
laboratory data showed no changes in tested blood chemical parameters referable to 
the vaccine activity. Indeed, analysis of red cell parameters showed significant 
differences in some sampling times, but this were all included in normal reference 
intervals typical of ovine specie. As reported by OIE, MLV vaccines are teratogenic 
and should not be administered to pregnant sheep during the first half of pregnancy 
as this may cause fetal abnormalities and embryonal death. As shown by our results, 
BTV-1 vaccine did not show any adverse effects in pregnant ewes if administered in 
the second half of gestation. Virus titre was carried out to determine if attenuated 
virus can be transmitted by insects feeding on vaccinated animals. Our data indicated 
that laboratory-adapted viruses can be transmitted by insect vectors, as already 
reported by other authors  (Standfast et al., 1985). A suitable procedure to determine 
attenuated virus transmissibility should require that sheep are vaccinated and, during 
viraemia, that they are exposed to competent, uninfected Culicoides, which are then 
permitted to feed on uninfected animals that are monitored for the presence of BTV 
and anti-BTV antibody. Due to the fact that the titre of attenuated virus in the blood 
of vaccinated sheep is low, very large numbers of Culicoides would be needed and 
only a small proportion of these would become infected and live long enough to feed 
on and potentially transmit the virus to other uninfected sheep. It is difficult to design 
a laboratory experiment that takes account of the large numbers of vaccinated sheep 
and insects that would be present in field situations. However, in South Africa it is 
estimated that the minimum titre of virus circulating in the bloodstream of an animal 
must be at least 10
3
 TCID50 before feeding Culicoides become infected, although it 
has also been suggested that a lower titre may sometimes be infective. Only 
attenuated viruses that generate titres under 10
3
 TCID50 are deemed to be acceptable 
as vaccines (OIE, 2004f). In this work the administration of MLV vaccine caused a 
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transient viraemia in 8 animals (42.1%) of the group vaccinated with normal dose 
and in 4 (57.1%) of the group vaccinated with decuple dose. Measured viraemia was 
relatively modest in intensity and duration. However, 15,8% of animals vaccinated 
with single dose showed short-therm viraemia levels (>10
3
 TCID50) which are 
considered the threshold for possible Culicoides infection. Although for short time 
(48 hours), the possibility that insects could acquire vaccine virus by feeding on 
vaccinated animals and transmit it to other uninfected sheep or cattle cannot be 
prevented. 
Reversion to virulence test was executed to evaluate the possibility of vaccine virus 
to loose some of its characteristic of attenuation to acquire other more pathogenic. 
Validation studies confirm that attenuated viruses do not revert to virulence in 
vaccinated sheep (OIE, 2004f). However, if attenuated viruses can be transmitted 
from vaccinated animals, reversion to virulence during a number of sheep-insect 
replication cycles becomes a distinct prospect. In this trial vaccine virus, after three 
passages, caused a low increase of viraemia intensity and duration comparing to 
animals vaccinated with normal dose. Furthermore, clinical examinations together 
with biochemical analisys and CBC evidenced no severe health status alteration in 
inoculated animals. Our data suggest that virus vaccine after 3 passages on 3 groups 
of sheep has not changed its original features. 
The administration of BTV-1 MLV vaccine resulted to be safe, not causing in 
vaccinated animals significant clinical effects, not showing any adverse effects in 
pregnant ewes if administered in the second half of gestation and not changing its 
original features after 3 passages. However, titres and duration of viraemia 
recommend an awaiting period before shipment of vaccinated animals equal to 60 
days to prevent the spread of the virus. 
The efficacy test performed in this study evidenced how administration of BTV-1 
MLV vaccine was able to elicit significant neutralizing antibodies titres in all 
vaccinated animals and did not determine seroconversion against other serotypes. 
This vaccine has an appropriate balance between attenuation of virulence and ability 
to replicate in sheep. The antigenic stimulus provided by its replication elicits 
complete protection against challenge using a virulent homologous virus and does 
not cause any detectable viraemia in serologically positive vaccinated animals. These 
results show that at least 91.6% of vaccinated sheep will not develop a BT viraemia 
when challenged with virulent homologous virus seven months after immunisation. 
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Analysis of laboratory data showed in control group some changes in tested blood 
chemical parameters presumably referable to the virus activity. Indeed, analysis of 
red cell parameters showed significant differences in some sampling times, probably 
due to viral replication. Furthermore, it would appear that the risk of spreading BTV-
1 infection through the movement of vaccinated sheep will be very low. 
Furthermore, in the challenge test was performed the study of white blood cell 
subsets of immunised and non immunised sheep following BTV-1 experimental 
infection. Leukocytes subsets analisys showed no differences in CTL lymphocytes 
subsets between vaccinated and unvaccinated animals, although other authors 
reported how BTV infection caused CD8+ cells decrease. Jeggo et al. (1984) using 
cellular adoptive transfer demonstrated that CD8+ T cells could give a short-term 
heterotypic response able to protect sheep from different field strain BTV infection 
within a season. In our results we evidenced a CD4+ T cells depletion in 
unvaccinated sheep following virus inoculation. Being involved both in humoral and 
cell mediated immunity, CD4+ T-cells play a  fundamental role in eliciting a 
protective antiviral response. Our findings suggest that live modified BTV-1 vaccine 
used in this trial does protect animals against clinical signs and haematological 
modifications. Nevertheless, the absence of  any CD4+ cells decrease in vaccinated 
group confirm BTV-1 vaccine stimulation of cell mediated response immunity. 
Further studies are needed in order to better understand cell mediated immune 
response mechanisms involved in host defense response to BTV infection.  
Finally, in this study we performed a challenge trial with virulent strain BTV-2 in 
vaccinated sheep in order to verify evidence of crossprotection. The hypothesis on a 
correlation between the serotypes 1 and 2 of BT was born from the observation of the 
facts occurring in Sardinia when the disease appeared. In fact it is known that BTV-1 
and BTV-2 have a high pathogenic index and high epidemic potential (Saegerman et 
al., 2008). During the first two epidemic season of BT in Sardinia, BTV-2 caused the 
death about 120.000 sheep (www.izs.it). After, several vaccination campaigns were 
carried out to immunize the livestock. When in 2006 BTV-1 was identified in 
Sardinia, it was expected the death of numerous susceptible animals, while was 
recorded the death of only 4.500 sheep. These data suggested that sheep, previously 
immunized for serotype 2 of BT, were even protected for the serotype 1. However, 
after challenge with wild strain BTV-2, sheep have not shown cross-protection for 
serotype 2. Furthermore, vaccine has been able to reduce the duration of viraemia in 
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sheep infected with high titres of virulent strain of BTV-2. Moreover, infection with 
BTV-2 has produced an increase of antibody titres against serotype 1 similar to that 
obtained after challenge with homologous virus. It seems that infection with BTV-2 
exercises a booster effect in respect of serotype 1 of BTV. 
In conclusion, the administration of BTV-1 MLV vaccine was safe, not causing 
particular drawbacks, and effective, stimulating an adequate protection of animals in 
case of infection with wild strain of homologous serotype. 
Results obtained in this study were confirmed from the compaign vaccine 2007, from 
which were not found reports of negative effects due to inoculation of the vaccine 

























Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
95 
 
 Alba A., Casal J., Domingo M., (2004). Possible introduction of bluetongue into 
the Balearic Islands, Spain, in 2000, via air streams. The Veterinary Record, 
155: 460-461. 
 Anderson, R.M. & May, R.M., (1991). Infectious Diseases of Humans: 
Dynamics and Control, Oxford: Oxford University Press., 757. 
 Barratt-Boyes S.M. & MacLachlan N.J., (1995). Pathogenesis of bluetongue 
virus infection of cattle. J. Am. Vet. Med. Assoc., 206: 1322-1329. 
 Barratt-Boyes S.M. & MacLachlan N.J., (1994). Dynamics of viral spread in 
bluetongue virus infected calves, Vet. Microbiol., 40: 361-371. 
 Barratt-Boyes S.M., Rossitto P.V., Stott J.L., MacLachlan N.J., (1992). Flow 
cytometric analysis of in vitro bluetongue virus infection of bovine blood 
mononuclear cells, J. Gen. Virol., 73: 1953-1960. 
 Baylis M., O‘Connell L., Purse B.V., (2004). Modelling the distribution of 
bluetongue vectors. In Bluetongue, Part I (N. J. MacLachlan & J. E. Pearson, 
eds). Proc. Third International Symposium, Taormina, 26-29 October 2003. 
Veterinaria. Italiana, 40: 176-181. 
 Bonneau K.R., MacLachlan N.J., (2004). Genetic diversification of field strains 
of bluetongue virus. Veterinaria Italiana, 40: 446-447. 
 Bonneau K.R., DeMaula C.D., Mullens B.A., MacLachlan N.J., (2002). 
Duration of viraemia infectious to Culicoides sonorensis in bluetongue virus-
infected cattle and sheep. Veterinary Microbiology, 88: 115-125. 
 Bonneau K.R., Mullens B.A., MacLachlan N.J., (2001). Occurrence of genetic 
drift and founder effect during quasispecies evolution of the VP2 and NS3/3A 
genes of bluetongue virus upon passage between sheep and cattle. Journal of 
Virolology, 75: 8298-8305. 
 Bonneau K.R., Zhang N., Zhu J., Zhang F., Li Z., Zhang K., Xiao L., Xing W., 
MacLachlan N.J., (1999). Sequence comparison of the L2 and S10 genes of 
bluetongue viruses from the United States and the People‘s Republic of China. 
Virus Research, 61: 153-160. 
 Boone J.D., Balasuriya U.B., Karaca K., Audonnet J.C., Yao J., He L., et al., 
(2007). Recombinant canarypox virus vaccine co-expressing genes encoding the 
VP2 and VP5 outer capsid proteins of bluetongue virus induces high level 
protection in sheep. Vaccine; 25: 672-678. 
 Braverman Y. & Chizov-Ginsburg A., (1997). Repellency of synthetic and 
plant-derived preparations for Culicoides imicola. Medical and Veterinary 
Entomology, 11: 355-360. 
REFERENCES 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
96 
 
 Braverman Y., Chechik, F., (1996). Air streams and the introduction of animal 
diseases borne on Culicoides (Diptera, Ceratopogonidae) into Israel. Revue 
Scientifique et Technique – Office International des Epizooties, 15: 1037-1052. 
 Braverman Y., Wilamowsky A. & Chizov-Ginzburg A., (1995). Susceptibility of 
Culicoides imicola to cyhalothrin. Medical and Veterinary Entomology, 9: 443-
4. 
 Braverman, Y. (1989). Control of biting midges Culicoides (Diptera: 
Ceratopogonidae), vectors of bluetongue and inducers of sweet itch: a review. 
Israel Journal of Veterinary Medicine, 45: 124-9. 
 Bréard E., Sailleau C., Nomikou K., Hamblin C., Mertens P., Mellor P.S., El 
Harrack M., Zientara S., (2007). Molecular epidemiology of serotype 4 
bluetongue viruses isolated in the Mediterranean Basin between 1979 and 2004. 
Virus Research, 125: 191-197. 
 Bréard E., Pozzi N., Sailleau C., Catinot V., Durand B., Dumont P., et al., 
(2007). Transient effect of the attenuated bluetongue virus vaccine on the quality 
of the ram semen. Vet. Rec. 160(13): 431-435. 
 Bréard E., Hamblin C., Hammoumi S., Sailleau C., Dauphin G., Zientara S., 
(2004). The epidemiology and diagnosis of bluetongue with particular reference 
to Corsica. Res. Vet. Sci., 77: 1-8. 
 Brewer A.W., MacLachlan N.J., (1994).  The pathogenesis of bluetongue virus 
infection of bovine blood cells in vitro: ultrastructural characterization, Arch. 
Virol., 136: 287-298. 
 Brewer A.W. and MacLachlan N.J., (1992). Ultrastructural characterization of 
the interaction of bluetongue virus with bovine erythrocytes in vitro. Vet. 
Pathol., 29: 356-359  
 Brodie S.J., Wilson W.C., O‘Hearn P.M., Muthui D., Diem K., Pearson L.D., 
(1998). The effects of pharmacological and lentivirus-induced immune 
suppression on orbivirus pathogenesis: assessment of virus burden in blood 
monocytes and tissues by reverse transcription in situ PCR. J. Virol., 72: 5599–
5609. 
 Browne J.G. and Jochim M.M., (1967). Cytopathologic changes and 
development of inclusion bodies in cultured cells infected with bluetongue virus. 
Am. J. Vet. Res., 28: 1091-1105. 
 Caporale V., Giovannini A., Patta C., Calistri P., Nannini D., Santucci U., 
(2004). Vaccination in the control strategy of bluetongue in Italy. 
(Developments in biologicals, vol. 119). Control of infectious animal diseases by 
vaccination. Basel, Switzerland: S Karger AG, 113-127 [book chapter: 
Conference paper]. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
97 
 
 Caporale V., Di Emidio B., Nicolussi P., Piredda G., Salaris S., De Palmas S., et 
al., (2003). Experimental vaccination of sheep using a bluetongue attenuated live 
vaccine: a study of the effects on lactation. Vet. Ital. 39(4): 5-10. 
 Calistri P., Giovannini A., Conte A., Nannini D., Santucci U., Patta C., Rolesu 
S., Caporale V., (2004). Bluetongue in Italy: Part I. Veterinaria Italiana, 40: 243-
251. 
 Cannas E.A., Nicolussi P., Bonelli P., Dore S., Denti G., Marongiu E., 
Migliaccio P., Savini G., (2005). Live modified bluetongue vaccine viruses in 
Sarda sheep: effects of three different formulations on milk production. In: 
Proceedings of the 12th international symposium of the world association of 
veterinary laboratory diagnosticians, Montevideo, Uruguay, 16–19 November 
2005. 
 Chiang E.T., Persaud-Sawin D.A., Kulkarni S., Garcia J.G., Imani F., (2006). 
Bluetongue virus and doublestranded RNA increase human vascular 
permeability: role of p38 MAPK, J. Clin. Immunol., 26: 406-416. 
 De Mattos C.A., De Mattos C.C.P., Osburn B.I. and MacLachland N.J. (1994). 
Heterogeneity of the L2 gene of field isolates of bluetongue virus serotype 17 
from the San Joaquin Valley of California. Virus Res., 31: 67-87. 
 De Maula C.D., Leutenegger C.M., Bonneau K.R., MacLachlan N.J., (2002). 
The role of endothelial cell-derived inflammatory and vasoactive mediators in 
the pathogenesis of bluetongue, Virology,  296: 330-337. 
 De Maula C.D., Jutila M.A., Wilson D.W., MacLachlan N.J., (2001). Infection 
kinetics, prostacyclin release and cytokine-mediated modulation of the 
mechanism of cell death during bluetongue virus infection of cultured ovine and 
bovine pulmonary artery and lung microvascular endothelial cells, J. Gen. Virol., 
82: 787-794. 
 De Maula C.D., Heidner H.W., Rossitto P.V., Pierce C.M. and MacLachlan N.J., 
(1993). Neutralization determinants of United States bluetongue virus serotype 
10. Virology, 195: 292-296. 
 Della Porta A.J., Parsonson I.M. and McPhee D.A., (1985). Problems in the 
interpretation of diagnostic tests due to cross-reactions between orbiviruses and 
broad serological responses in animals. In Bluetongue and Related Orbiuiruses 
(Edited by Barber T. L. and Jochim M. M.), 445-453. Alan R. Liss, New York.  
 Della Porta A.J., McPhee D.A. and Snowdon W.A., (1979). The serological 
relationships of orbiviruses. In Arbouirus Research in Australia, (Edited by St 
George T. D. and French E. L.),  64-71. Proceedings of the second symposium 
17-19 July, Brisbane: CSIRO-QMIR.  
 Di Emidio B., Nicolussi P., Patta C., Ronchi G.F., Monaco F., Savini G., et al., 
(2004). Efficacy and safety studies on an inactivated vaccine against bluetongue 
virus serotype 2. Vet. Ital., 40: 640-644. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
98 
 
 Downes J. A., (1962). What is an arctic insect? Canadian Entomologist, 94: 143-
162. 
 Dragonas P., (1981). Fièvre catharrale au mouton. L‘Office International des 
Epizooties Monthly Circular. 9:10. 
 Dungu B., Gerdes T., Smit T., (2004). The use of vaccination in the control of 
bluetongue in southern Africa. Vet. Ital., 40: 616-622. 
 Dzhafarov S. M., (1964). Blood-sucking midges (Diptera, Heleidae) of the 
Transcaucasus. Akademija Nauk Azerbaidzanskoi SSR, Instituta 
Zoologicheskiy, 414. 
 Eaton B.T., Hyatt A.D. and White J.R., (1987). Association of bluetongue virus 
with the cytoskeleton. Virology, 157: 107-116. 
 Eksteen P.A., Huismans H., (1972). Interferon induction by bluetongue virus 
and bluetongue virus ribonucleic acid, Onderstepoort J. Vet. Res., 39: 125-131. 
 Ellis J.A., Luedke A.J., Davis W.C., Wechsler S.J., Mecham J.O., Pratt D.L. and 
Elliot J.D., (1990). T lymphocyte subset alterations following bluetongue virus 
infection in sheep and cattle. Vet. Immunol. Immunopathol., 24: 49-67.  
 Erasmus B.J., (1975). Bluetongue in sheep and goats. Aust. Vet. J., 51: 65-170. 
 European Commission, (2003). Aiuto di Stato No. 662/2001 – Italia (Sardegna). 
Aiuti a favore degli allevatori di bovini per i danni causati dall‘epizoozia Blue 
Tongue, C(2003) 2519fin, 27 July. EC, Brussels, 8 pp. 
(europa.eu.int/comm/secretariat_general/sgb/state_aids /agriculture/n662-01.pdf 
accessed on 28 July 2004). 
 European Commission, (2001). Decision of 9 February 2001 establishing 
protection and surveillance zones in the Community in relation with bluetongue 
(2001/138/EC). Off. J., L 050: 17-19. 
 European Council, (2000). Council Directive 2000/75/EC of 20 November 2000 
laying down specific provisions for the control and eradication of bluetongue. 
Off. J., L 327: 74-83. 
 European Council, (1992a). Council Directive 92/119/EEC of 17 December 
1992 introducing general Community measures for the control of certain animal 
diseases and specific measures relating to swine vesicular disease. Off. J., L 062: 
69-85. 
 European Council, (1992b). Council Directive 92/35/EEC of 29 April 1992 
laying down control rules and measures to combat African horse sickness. Off. 
J., L 157: 19-27. 
 Ferrari G., De Liberato C., Scavia G., Lorenzetti R., Zini M., Farina F., et al., 
(2005). Active circulation of bluetongue vaccine virus serotype-2 among 
unvaccinated cattle in central Italy. Prev. Vet. Med., 68: 10-13. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
99 
 
 Foster N.M., Luedke A.J., Parsonson I.M.,Walton T.E., (1991). Temporal 
relationships of viremia, interferon activity, and antibody responses of sheep 
infected with several bluetongue virus strains, Am. J. Vet. Res., 52: 192-196. 
 Fulton R.W., Pearson N.J., (1982). Interferon induction in bovine and feline 
monolayer cultures by four bluetongue virus serotypes, Can. J. Comp.Med., 46: 
100-102. 
 Gambles R.M., (1949). Bluetongue of sheep in Cyprus. Journal of Comparative 
Pathology, 59: 176- 190. 
 Gard G.P., (1984). Studies of bluetongue virulence and pathogenesis in sheep. 
Technical Bulletin No. 103, Department of Industries and Development, Darwin, 
Australia. 
 Gerbier G, Hendrikx P., Roger F., Zientara S., Biteau-Coroller F., Grillet C., 
Baldet T., Albina E., (2004). Bluetongue control using vaccines: an experience 
from the mediterranean islands in Europe. Veterinaria Italiana, 40: 611-615. 
 Gerbier G., Hendrikx, P., Roger F., Zientara S., Biteau-Coroller F., Grillet C., 
Baldet T., Albina E., (2003). Bluetongue control using vaccines: an experience 
from the mediterranean islands in Europe. In: Proceedings of the third OIE 
bluetongue international symposium, Taormina, Sicily, 26-29 October 2003. 
 Gibbs E.P. and Ellis C.G., (1994). The epidemiology of bluetongue. Comp. 
Immun. Microbiol. infect. Dis., 17: 207-220. 
 Gibbs E.P., Greiner E.C., (1994). The epidemiology of bluetongue. Comparative 
Immunology, Microbiology and Infectious Diseases, 17: 197-206. 
 Giovannini A., Calistri P., Conte A., Savini L., Nannini D., Patta C., Santucci U. 
& Caporale V.,  (2004a). Bluetongue virus surveillance in a newly infected area. 
Vet. Ital., 40 (3): 188-197. 
 Giovannini A., Conte A., Panichi G., Calistri P., Dessı` M., Foddis F., et al., 
(2004b). Effects of vaccination against bluetongue on milk production and 
quality in cattle vaccinated with live-attenuated monovalent type 2 vaccine. Vet. 
Ital. 40(4): 648-653. 
 Giovannini A., Conte A., Calistri P., Di Francesco C., Caporale V., (2004c). 
Risk analysis on the introduction into free territories of vaccinated animals from 
restricted zones. Vet. Ital. 40(4): 697-702. 
 Giovannini A., MacDiarmid S., Calistri P., Conte A., Savini L., Nannini D., et 
al., (2003). The use of risk assessment to decide the control strategy for 
bluetongue in Italian ruminant populations. J. Risk Anal., 24(6): 1737-1753. 
 Gould A.R., (1987). The complete nucleotide sequence of bluetongue virus 
serotype 1 RNA3 and a comparison with other geographic serotypes from 
Australia, South Africa and the United States of America, and with other 
orbivirus isolates. Virus Res., 7: 169-183. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
100 
 
 Hamers C., Werle-Lapostolle B., Rehbein S., Blanchet M., Mure-Ravaud K., 
Schumacher C., Hudelet P., (2006a).  Six month efficacy of an inactivated BTV-
2 industrial vaccine against a virulent BTV-2 challenge in sheep. In: Proceedings 
of the ninth international symposium on double-stranded RNA viruses, Cape 
Town, South Africa, 21–26 October 2006. 
 Hamers C., Hudelet P., Blanchet M., Werle-Lapostolle B., Sailleau C., Breard 
E., Zientara S., (2006b).  Efficacy of an inactivated bivalent BTV-2/BTV-4 
industrial vaccine against a BTV-2 or BTV-4 virulent challenge in sheep. In: 
Proceedings of the ninth international symposium on double-stranded RNA 
viruses, Cape Town, South Africa, 21–26 October 2006. 
 Hammoumi S., Breard E., Sailleau C., Russo P., Grillet C., Cetre-Sossah C., et 
al., (2003). Innocuity and activity of the monovalent bluetongue serotype 2 
vaccine. Specific detection of the genome of the vaccine strain by RT-PCR. J. 
Vet. Med., B50: 316-321. 
 Hewat E.A., Booth T.F. and Roy P., (1992). Structure of bluetongue virus 
particles by cryoelectron microscopy. J. Struc. Biol., 109: 61-69. 
 Holbrook, F.R., (1985). Research on the control of bluetongue in livestock by 
vector suppression. In Bluetongue and Related Orbiviruses, ed. Barber, T. L. & 
Jochim, M. M., New York: Alan R. Liss Inc., 617-20. 
 House J.A., Groocock C.M6., Campbell C.H., (1982). Antibodies to bluetongue 
viruses in animals imported into United States zoological gardens. Canadian 
Journal of Comparative Medicine, 46: 154-159. 
 Huismans H., Van Dijk A.A. and Els H.J., (1987a). Uncoating of parental 
bluetongue virus to core and subcore particles in infected L cells. Virology, 157: 
180-188. 
 Huismans H., Van der Walt N.T., Cloete M. and Erasmus B.J., (1987b). 
Isolation of a capsid protein of bluetongue virus that induces a protective 
immune response in sheep. Virology, 157: 172-179.   
 Huismans H., (1969). Bluetongue virus-induced interferon synthesis, 
Onderstepoort J. Vet. Res. 36: 181-185. 
 Hyatt A.D. and Eaton B.T., (1988). Ultrastructural distribution of the major 
capsid proteins within bluetongue virus and infected cells. J. gen. Virol., 69: 
805-815. 
 Italian Ministry of Health, (2005). Nota del 19 gennaio. Bluetongue—
provvedimenti ed impiego del vaccine sierotipo 16 nella IV campagna di 
vaccinazione 2004–2005, n.1720. 
 IZSAM, (2004). Istituto Zooprofilattico Sperimentale dell‘Abruzzo e del Molise 
‗G. Caporale‘. Vaccino e danni vaccinali, 
/http://gis2.izs.it:7777/bluetongue/doc_tec/danni_vacc/vaccini.pdfS. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
101 
 
 IZSAM, (2001). Istituto Zooprofilattico Sperimentale dell‘Abruzzo e del Molise 
‗G. Caporale‘. Safety and potency testing of bluetongue vaccines. Testing of 
monovalent bluetongue vaccine (serotype 2) for innocuity, potency and 
reversion to virulence. Contract DG Sanco 00/0127. Final report. Teramo, pp. 
19. /http://www.east-btnet.izs.it/document_r/research/final_report.pdfS. 
 Jackson H.C., (1989). Ivermectin as a systemic insecticide. Parasitology Today, 
5: 146-56. 
 Jameson P., Schoenherr C.K., Grossberg S.E., (1978). Bluetongue virus, an 
exceptionally potent interferon inducer in mice, Infect. Immun., 20: 321-323. 
 Jeggo M.H., Wardley R.C., Brownlie J. (1984). A study of the role of cell-
mediated Immunity in bluetongue virus infection in sheep, using cellular 
adoptive transfer techniques. Immunology, 52: 403-410. 
 Jeggo M.H., Gumm I.D. and Taylor W. P., (1983). Clinical and serological 
response of sheep to serial challenge with different bluetongue virus serotypes. 
Res. Vet. Sci., 34: 205-211.  
 Jeggo M.H. and Wardley R.C., (1982a). The induction of murine cytotoxic T 
lymphocytes by bluetongue virus. Archiv. Virol. 71: 197-206.  
 Jeggo M.H. and Wardley R.C., (1982b). Generation of cross-reactive cytotoxic 
T lymphocytes following immunization of mice with various bluetongue virus 
types. Immunology, 45: 629-635.  
 Jeggo M.H. and Wardley R.C., (1982c). Production of murine cytotoxic T 
lymphocytes by bluetongue virus following various immunization procedures. 
Res. Vet. Sci., 33: 212-215.  
 Jessup D.A., (1985). Epidemiology of two orbiviruses in California‘s native wild 
ruminants: preliminary report. In: Bluetongue and Related Orbiviruses, (eds 
Barber T.L. and Jochim M.M.), AR Liss, New York, 53-56. 
 Jiménez-Clavero M.A., Aguero M., San Miguel E., Mayoral T., Cruz Lopez M., 
Ruano M.J., et al., (2006). High throughput detection of bluetongue virus by a 
new real-time on clinical samples from current mediterranean outbreaks. J. Vet. 
Diagn. Invest., 18: 7-17. 
 Katz J., Alstad D., Gustafson G., Evermann J., (1994). Diagnostic analysis of the 
prolonged bluetongue virus RNA presence found in the blood of naturally 
infected cattle and experimentally infected sheep, J. Vet. Diagn. Invest., 6: 139-
142. 
 Lacey L.A. & Kline D.L., (1983). Laboratory bioassay of Bacillus thuringensis 
(H-14) against Culicoides spp. And Leptoconops spp. (Ceratopogonidae). 
Mosquito News, 43: 502-503. 
 Lecatsus G., (1968). Electron microscopic study of the formation of bluetonguc 
virus. Onderstepoort J. Vet. Res., 35: 139 150. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
102 
 
 Lelli R., Portanti O., Langella V., Luciani M., Di Emidio B., Conte A., (2003). 
Produzione di un Kit ELISA competitiva per la diagnosi sierologica della 
Bluetongue. Vet. Ital., 47: 5-13. 
 Luedke A.J., Jochim M.M., Bowne J.G. and Jones R.H., (1970). Observations on 
latent bluetongue virus infection in cattle. J. Am. Vet. Med. Assoc., 15: 1871-
1879  
 Leudke A.J., Jochim M.M. and Jones R.H., (1969). Bluetongue in cattle: 
viremia. Am. J. Vet Res. 30: 511-516.  
 Lobato Z.I., Coupar B.E., Gray C.P., Lunt R., Andrew M.E., (1997). Antibody 
responses and protective immunity to recombinant vaccinia expressed-expressed 
bluetongue virus antigens. Vet. Immunol. Immunopathol., 59: 293-309. 
 Lopez A.C., Botija C.S., (1958). Epizootie de fièvre catarrhale ovine en Espagne 
(blue tongue). Bull. Off. Int. Epiz., 50: 65-93. 
 Lucifora G., Rossi P., Calistri P., Giovannini A., (2004). Effects of bivalent 
bluetongue virus serotypes 2 and 9 vaccine on reproductive performance of 
cattle: a case study in Calabria, Italy. Vet. Ital., 40: 654-656. 
 Lunt R.A., Melville L., Hunt N., Davis S., Rootes C.L., Newberry K.M., et al., 
(2006). Cultured skin fibroblast cells derived from bluetongue virus-inoculated 
sheep and field-infected cattle are not a source of late and protracted recoverable 
virus, J. Gen. Virol., 87: 3661–3666. 
 MacLachlan N.J., Osburn B.I., (2006). Impact of bluetongue virus infection on 
the international movement and trade of ruminants. Journal of the American 
Veterinary Medical Association, 226: 1346-1349. 
 Maclachlan N.J., (2004). Bluetongue: pathogenesis and duration of viraemia. 
Vet. Ital., 40 (4): 462-467. 
 Maclachlan N.J., Pearson J.E. (2004). Bluetongue: Proceedings of the Third 
International Symposium. MacLachlan, N.J. and Pearson, J.E. (Eds.). 
Veterinaria Italiana, 40: 1-730. 
 MacLachlan N.J., (1994). The pathogenesis and immunology of bluetongue 
virus infection of ruminants. Comp. Immunol. Microbiol. Infect. Dis., 17: 197-
206. 
 MacLachlan N.J., Nunamaker R.A., Katz J.B., Sawyer M.M., Akita G.Y., 
Osburn B.I., Tabachnick W.J., (1994). Detection of bluetongue virus in the 
blood of inoculated calves: comparison of virus isolation, PCR assay, and in 
vitro feeding of Culicoides variipennis, Arch. Virol., 136: 1–8. 
 MacLachlan N.J., Rossitto P.V., Heidner H.W., Iezzi L.G., Yilma T., DeMaula 
C.D. and Osburn B.I., (1992). Variation amongst the neutralizing epitopes of 
bluetongue viruses isolated in the United States in 1979-1981. Vet Microbiol., 
31: 303-316.  
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
103 
 
 MacLachlan N.J., Barratt-Boyes S.M., Brewer A.W, and Stott J.G., (1991). 
Bluetongue virus infection of cattle. In Bluetongue, African Horse Sickness and 
Related Orbiviruses (Edited by Walton T. E. and Osburn B. l.) CRC Press, Boca 
Raton. 275-736. 
 MacLachlan N.J., Jagels G., Rossitto P.V., Moore P.F. and Heidner H.W., 
(1990). The pathogenesis of experimental bluetongue virus infection of calves. 
Vet. Pathol., 27: 223-229. 
 MacLachlan N.J., Heidner H.W. and Fuller F.J., (1987). Humoral immune 
response of calves to bluetongue virus infection. Am. J. Vet. Res., 48: 1031-
1035. 
 MacLachlan N.J., Thompson J., (1985a). Bluetongue virus-induced interferon in 
cattle, Am. J. Vet. Res., 46: 1238-1241. 
 MacLachlan N.J., Osburn B.I., Stott J.L., Ghalib H.W., (1985b). Orbivirus 
infection of the bovine fetus. Prog. Clin. Biol. Res., 178: 79-84. 
 Mahrt C.R. & Osburn B.I., (1986). Experimental bluetongue virus infection of 
sheep; effect of vaccination: pathologic, immunofluorescent, and ultrastructural 
studies. Am. J. Vet. Res., 47: 1198-1203. 
 Manso-Ribeiro J., Rosa-Azevedo J.A., Noronha F.O., Braco-Forte M.C., Grave-
Pereira C. & Vasco-Fernandez M., (1957). Fièvre catarrhale du mouton 
(bluetongue). Bullettin de l‘Office International des Epizooties, 48: 350-367. 
 MAPA, (2006). Report of the efficacy test performed in Spain with different 
commercially available vaccine against BTV4 in cattle and sheep. MAPA report.  
 Meiswinkel R., Gomulski L.M., Delécolle J.-C., Goffredo M., Gasperi G. 
(2004). The taxonomy of Culicoides vector Complexes – unfinished business. 
Veterinaria. Italiana, 40: 151-159. 
 Meiswinkel R., Baylis M. & Labuschagne K., (2000). Stabling and the 
protection of horses from Culicoides bolitinos (Diptera: Ceratopogonidae), a 
recently identified vector of African horse sickness. Bulletin of Entomological 
Research, 90: 509-15. 
 Meiswinkel R., (1992). Afrotropical Culicoides: C. (Avaritia) loxodontis sp. 
nov. a member of the Imicola group (Diptera: Ceratopogonidae) associated with 
the African elephant in the Kruger National Park, South Africa. Onderstepoort 
Journal of Veterinary Research, 59: 145-160. 
 Mellor P.S., Wittmann E.J., (2002). Bluetongue virus in the Mediterranean 
basin, 1998-2001. The Veterinary Journal, 164: 20-37. 
 Mellor P.S., Leake C.J., (2000). Climatic and geographic influences on arboviral 
infections and vectors. Revue Scientifique et Technique de l‘Office International 
des Epizooties, 19: 41-54.  
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
104 
 
 Mellor P.S., (1994). Bluetongue. State Veterinary Journal, 4: 7-10. 
 Mellor P.S., (1990). The replication of bluetongue virus in Culicoides vectors, 
Curr. Top. Microbiol. Immunol., 162: 143-161. 
 Mellor P.S., Pitzolis G., (1979). Observations on breeding sites and light-trap 
collections of Culicoides during an outbreak of bluetongue in Cyprus. Bullettin 
of. Entomological. Reseach., 69: 229-234. 
 Mertens P.P., Diprose J., Maan S., Singh K.P., Attoui H., Samuel A.R., (2004). 
Bluetongue virus replication, molecular and structural biology. Veterinaria 
Italiana, 40: 426-437. 
 Mertens P.P.C., Arella M., Attoui H., Belloncik S., Bergoin M., Boccardo G., 
Booth T.F., Chiu W., Diprose J.M., Duncan R., Estes M.K., Gorziglia M., Gouet 
P., Gould A.R., Grimes J.M., Hewat E., Hill C., Holmes I.H., Hoshino Y., Joklik 
W.K., Knowles N., López Ferber M.L., Malby R., Marzachi C., McCrae M.A., 
Milne R.G., Nibert M., Nunn M., Omura T., Prasad B.V.V., Pritchard I., Samal 
S.K., Schoehn G., Shikata E., Stoltz D.B., Stuart D.I., Suzuki N., Upadhyaya N., 
Uyeda I., Waterhouse P., Williams C.F., Winton J.R. & Zhou H.Z., (2000). 
Reoviridae. In Virus taxonomy. Seventh Report of the International Committee 
for the Taxonomy of Viruses (M.H.V. Van Regenmortel, C.M. Fauquet, D.H.L. 
Bishop, C.H. Calisher, E.B. Carsten, M.K. Estes, S.M. Lemon, J. Maniloff, M.A. 
Mayo, D.J. McGeoch, C.R. Pringle & R.B. Wickner, eds). Academic Press, 
London, 395-480. 
 Mertens P.P.C. & Sangar D.V., (1985). Analysis of the terminal sequences of the 
genome segments of four orbiviruses. Virology, 140: 55-67. 
 Monaco F., Cammà C., Serini S., Savini G., (2006). Differentiation between 
field and vaccine strain of bluetongue virus serotype 16. Vet. Microbiol., 116: 
45-52. 
 Monaco F., De Luca N., Spina P., Morelli D., Liberatore I., Citarella R., et al., 
(2004a). Virological and serological response of cattle following field 
vaccination with bivalent modified-live vaccine against bluetongue virus 
serotypes 2 and 9. Vet. Ital., 40(4): 657-660. 
 Monaco F., De Luca N., Morelli D., Pisciella M., Palmarini S., Di 
Giandomenico M., et al., (2004b). Field vaccination of cattle using a bivalent 
modified-live vaccine against bluetongue virus serotypes 2 and 9: effect on milk 
production. Vet. Ital., 40(4): 661-663. 
 Monaco F., Bonfini B., Zaghini M., Antonucci D., Pini A. & Savini G., (2004c). 
Vaccination of cattle using monovalent modified-live vaccine against 
bluetongue virus serotype 2: innocuity, immunogenicity and effect on 
pregnancy. Vet. Ital., 40(4):671-675. 
 Mortola E., Noad R., Roy P., (2004). Bluetongue virus outer capsid proteins are 
sufficient to trigger apoptosis in mammalian cells, J. Virol., 78: 2875-2883. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
105 
 
 Moss S.R., Jones L.D., Nuttal P.A., (1992). Comparison of the major structural 
core proteins of tick-borne and Culicoides - borne orbiviruses. J. gen. Virol., 73: 
2585-2590. 
 Murphey F.A., Borden E.C., Shope R.E., Harrison A., (1971). Physiochemical 
and morphological relationships of some arthropod-borne viruses to bluetongue 
virus--a new taxonomic group: electron microscopic studies. J. gen. Virol., 13: 
273-288.  
 Murray P.K., Eaton B.T., (1996). Vaccine for bluetongue. Aust. Vet. J., 73: 207-
210. 
 Nevill E.M., Erasmus B.J., Venter G.J., (1992). A six-year survey of viruses 
associated with Culicoides biting midges throughout South Africa (Diptera: 
Ceratopogonidae). In: Bluetongue, African horse sickness, and related 
orbiviruses: (eds. Walton TE and Osburn BI), Proceedings of the Second 
International Symposium, Paris, France. 314-319. 
 Nevill E.M., (1978). The use of cattle to protect sheep from bluetongue 
infection. Journal of the South African Veterinary Association 49: 129-30. 
 O‘Connell L., (2002). Entomological aspects of the transmission of arboviral 
diseases by Culicoides biting midges. PhD, Thesis, University of Bristol. 
 OIE. World Organisation for Animal Health (2006a). Bluetongue in Italy. 
Disease Information, 9 November, 19: 775-776. 
 OIE. World Organisation for Animal Health (2006b). Bluetongue in Belgium. 
Disease Information, 24 August, 19: 616-617. 
 OIE. World Organisation for Animal Health (2006c). Bluetongue in The 
Netherlands. Disease Information, 24 August, 19: 612-613. 
 OIE. World Organisation for Animal Health (2006d). Bluetongue in Germany. 
Disease Information, 24 August, 19: 618. 
 OIE. World Organisation for Animal Health (2006e). Bluetongue in France. 
Disease Information, 31 August, 19: 636-637. 
 OIE. World Organisation for Animal Health (2006f). Bluetongue in 
Luxembourg. Disease Information, 7 December, 19: 852. 
 OIE. World Organisation for Animal Health (2006g). Bluetongue in Bulgaria. 
Disease Information, 19 October, 19: 736. 
 OIE. Terrestrial animal health code, (2005). World Animal Health Organization. 
 OIE. World Organisation for Animal Health (2004a). Bluetongue in Morocco. 
Disease Information, 24 September, 17: 273. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
106 
 
 OIE. World Organisation for Animal Health (2004b). Bluetongue in Spain: 
serological findings in the peninsular territory, in sentinel animals. Disease 
Information, 15 October, 17: 302. 
 OIE. World Organisation for Animal Health (2004c). Bluetongue in Portugal. 
Disease Information, 26 November, 17: 353. 
 OIE. World Organisation for Animal Health (2004d). Bluetongue in Cyprus. 
Disease Information, 19 March, 17: 83-84. 
 OIE. World Organisation for Animal Health (2004e). Bluetongue in France, in 
the island of Corsica. Disease Information, 17 September, 17: 266-267. 
 OIE. World Organisation for Animal Health (2004f). Bluetongue, Chapter 2.1.9. 
In Manual of diagnostic tests and vaccines for terrestrial animals, Paris.  
 OIE. World Organisation for Animal Health (2003a). Bluetongue in Italy. 
Circulation of virus serotype 4 in Sardinia. Disease Information, 26 September, 
16: 209.  
 OIE. World Organisation for Animal Health (2003b). Bluetongue in France, in 
the island of Corsica. Disease Information, 31 October, 16: 242-243. 
 OIE. World Organisation for Animal Health (2003c). Bluetongue in Albania. 
Disease Information, 14 February, 16: 47. 
 OIE. World Organisation for Animal Health (2002). Bluetongue in Bosnia and 
Herzegovina. Disease Information, 6 September, 15: 171. 
 OIE. World Organisation for Animal Health (2001a). Bluetongue in Yugoslavia. 
Disease Information, 2 November, 14: 252. 
 OIE. World Organisation for Animal Health (2001b). Bluetongue in Former 
Yugoslav Republic of Macedonia. Disease Information, 12 October, 14: 234. 
 OIE. World Organisation for Animal Health (2001c). Bluetongue in Kosovo 
(FRY), territory under United Nations interim administration. Disease 
Information, 12 October, 14: 242. 
 OIE. World Organisation for Animal Health (2001d). Bluetongue in Croatia. 
Disease Information, 21 December, 14: 291. 
 OIE. World Organisation for Animal Health (2000a). Bluetongue in Tunisia. 
Disease Information, 7 January, 13: 1. 
 OIE. World Organisation for Animal Health (2000b). Bluetongue in Algeria. 
Disease Information, 28 July, 13: 109. 
 OIE. World Organisation for Animal Health (2000c). Bluetongue in Italy. 
Disease Information, 1 September, 13: 150. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
107 
 
 OIE. World Organisation for Animal Health (2000d). Bluetongue in Spain: in 
the Balearic Islands. Disease Information, 13 October, 13: 181. 
 OIE. World Organisation for Animal Health (2000e). Bluetongue in France: in 
the island of Corsica. Disease Information, 3 November, 13: 195. 
 OIE. World Organisation for Animal Health (1998). Bluetongue in Greece. 
Disease Information, 27 November, 11: 166. 
 Ortega M.D., Mellor P.S., Rawlings Pro M.J., (1998). Seasonal and geographical 
distribution of Culicoides imicola, C. pulicaris group and C. obsoletus group 
biting midges in central and southern Spain. Archives of Virology [Suppl.], 14: 
85-91. 
 Panagiotatos D.E., (2004). Regional overview of bluetongue viruses, vectors, 
surveillance and unique features in Eastern Europe between 1998 and 2003. 
Veterinaria Italiana, 40: 61-72. 
 Parker A.H., (1949). Seasonal and daily incidence of certain biting midges 
(Culicoides Latreille: Diptera, Ceratopogonidae). Transactions ofthe Royal 
Entomological Society London (A). 
 Patta C., Giovannini A., Rolesu S., Nannini D., Savini G., Calistri P., et al., 
(2004). Bluetongue vaccination in Europe: the Italian experience. Vet Ital, 40(4): 
601-610. 
 Pedley S., Mohamed M.E.H., Mertens P.P.C., (1988). Analysis of genome 
segments from six different isolates ofbluetongue virus using RNA RNA 
hybridization: a generalized coding assignment for bluetongue viruses. Virus 
Res., 10: 381-390. 
 Pierce C.M., Balasurya B.R., MacLachlan J., (1998). Phylogenetic analysis of 
the S10 gene of field and laboratory strains of bluetongue virus from the United 
States. Virus research, 55: 15-27. 
 Pini A., (1976). Study on the pathogenesis of bluetongue: replication of the virus 
in the organs of infected sheep. Onderstepoort J. Vet. Res., 43: 159-164. 
 Prasad B.V.V., Yamaguchi S. Roy P., (1992). Three-dimensional structure of 
single-shelled bluetongue virus. J. Virol., 66: 2135-2142. 
 Pritchard L.I., Sendow I., Lunt R., Hassan S.H., Kattenbelt J., Gould A.R., 
Daniels P.W., Eaton B.T., (2004). Genetic diversity of bluetongue viruses in 
south East Asia. Virus Research, 101: 193- 201. 
 Reddington J.J., Reddington G.M. and MacLachlan N.J., (1991). A competitive 
ELISA for detection of antibodies to the group antigen of bluetongue virus. J. 
Vet. Diagn. Invest., 3: 144-147. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
108 
 
 Richards R.G., MacLachlan N.J., Heidner H.W. and Fuller F.J., (1988). 
Comparison of virologic and serologic responses of lambs and calves infected 
with bluetongue virus serotype 10. Vet. Microbiol., 18: 233-242  
 Rinaldo C.R. Jr., Overall J.C. Jr., Glasgow L.A., (1975). Viral replication and 
interferon production in fetal and adult ovine leukocytes and spleen cells, Infect. 
Immun., 12: 1070-1077. 
 Ronchi G.F., Franchi P., Battistini L., Di Emidio B., (2003). Stability study of 
bluetongue attenuated live vaccine serotype 2 after rehydration. Vet. Ital., 39(2): 
11-14. 
 Rossitto P.V. & MacLachlan N.J., (1992). Neutralizing epitopes of the serotypes 
of bluetongue virus present in the United States. J. Gen. Virol., 73: 1947-1952. 
 Roy P., (2004). Genetically engineered structure-based vaccine for bluetongue 
disease. Vet. Ital., 40: 594-600. 
 Roy P., Bishop D.H., LeBlois H., Erasmus B.J., (1994). Long-lasting protection 
of sheep against bluetongue challenge after vaccination with like-like particles: 
evidence for homologous and partial heterologous protection. Vaccine,12: 805-
811. 
 Roy P., French T., Erasmus B.J., (1992). Protective efficacy of virus-like 
particles for bluetongue disease. Vaccine, 10: 28-32. 
 Roy P., Urakawa T., Van Dijk A.A., Erasmus B.J., (1990). Recombinant virus 
vaccine for bluetongue disease in sheep. J. Virol., 64: 1998-2003. 
 Saegerman C., Berkvens D., Philip S.M., (2008). Bluetongue epidemiology in 
the european union. Emerging Infectious Diseases, 40: 539-544. 
 Samal S.K., Lviingstone C.W., McConnell S., Ramig R.F., (1987a). Analysis of 
mixed infection of sheep with bluetongue virus serotypes 10 and 17; evidence of 
genetic reassortment in the vertebrate host. Journal of Virology, 61:1086-1091. 
 Samal S.K., El-Hussein A., Holbrook F.R., Beaty B.J., Ramig, F., (1987b). 
Mixed infections of Culicoides variipennis with bluetongue virus serotypes 10 
and 17: evidence for high frequency reassortment in the vector. Journal of 
General Virology, 68: 2319-2329. 
 Savini G., MacLachlan N.J., Sanchez-Vizcaino J., Zientara S., (2007). Vaccines 
against bluetongue in Europe. Comparat. Immunol. Microbiol. Infect Dis., 
doi:10.1016/j.cimid.2007.07.006. 
 Savini G., Hamers C., Migliaccio P., Leone A., Hudelet P., Schumacher C., 
Caporale V., (2006a). Assessment of efficacy of a bivalent inactivated vaccine 
against bluetongue virus serotypes 2 and 4 in cattle. In: Proceedings of the 24th 
world buiatrics congress, Nice, France, 15-19 October 2006. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
109 
 
 Savini G., Conte A., Di Gennaro A., Leone A., Migliaccio P., Bonfini B., Di 
Ventura M., Monaco F., (2006b). Virological and serological responses in cattle 
following vaccination with modified-live vaccine against bluetongue virus 
serotypes 2, 4, 9 and 16. In: Proceedings of the ninth international symposium 
on ds-RNA viruses, Cape Town, South Africa, 21-26 October 2006. 
 Savini G., Cannas E.A., Bonelli P., Petruzzi M., Fresi S., Dimauro C., Di 
Gennaro A., Nicolussi P., (2005a). Live modified bluetongue vaccine viruses in 
sarda sheep: clinical signs, haematology and chemistry. In: Proceedings of the 
12th international symposium of the world association of veterinary laboratory 
diagnosticians, Montevideo, Uruguay, 16–19 November 2005. 
 Savini G., Goffredo M., MonacoF., Di Gennaro A., Cafiero M.A., Baldi L., De 
Santis P., Meiswinkel R., Caporale V., (2005b). Bluetongue virus (BTV) 
isolations from the Obsoletus Complex (Culicoides, Diptera: Ceratopogonidae) 
in Italy. Vet Rec., 157: 133-139.  
 Savini G., Monaco F., Facchinei A., Pinoni C., Salucci S., Cofini F., et al., 
(2004a). Field vaccination of sheep with bivalent modified-live vaccine against 
bluetongue virus serotypes 2 and: effect on milk production. Vet. Ital., 40(4): 
627-630. 
 Savini G., Monaco F., Citarella R., Calzetta G., Panichi G., Ruiu A., et al., 
(2004b) Monovalent modified-live vaccine against bluetongue virus serotype 2: 
immunity studies in cows. Vet. Ital., 40(4): 664-667. 
 Savini G., Monaco F., Calistri P., Panichi G., Ruiu A., Leone A., et al., (2004c). 
Neutralising antibody response in cattle after vaccination with monovalent 
modified-live vaccine against bluetongue virus serotype 2. Vet. Ital., 40(4): 668-
670. 
 Savini G., Tittarelli M., Bonfini B., Zaghini M., Di Ventura M., Monaco F., 
(2004d). Serological response in cattle and sheep following infection or 
vaccination with bluetongue virus. Vet. Ital., 40(4): 645-647. 
 Savini G., Monaco F., Conte A., Migliaccio P., Casaccia C., Salucci S., et al., 
(2004e). Virological and serological response of sheep following field 
vaccination with bivalent modified-live vaccine against bluetongue virus 
serotypes 2 and 9. Vet Ital 2004;40(4):631–4. 
 Schreck C.E., Smith N. & McGovern T.P., (1979). Repellency of selected 
compounds against two species of biting midges (Diptera: Ceratopogonidae: 
Culicoides). Journal of Medical Entomology, 16: 524-527. 
 Sellers R.F., Maarouf A.R., (1991). Possible introduction of epizootic 
hemorrhagic disease of deer virus (serotype 2) and bluetongue virus (serotype 
11) into British Columbia in 1987 and 1988 by infected Culicoides carried on 
the wind. Canadian Journal of Veterinary Research, 55: 367-370. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
110 
 
 Sellers R.F., Maarouf A.R., (1989). Trajectory analysis and bluetongue virus 
serotype 2 in Florida 1982. Canadian Journal of Veterinary Research 53: 100-
102. 
 Sellers R.F., Pedgley D.E., (1985). Possible windborne spread to western Turkey 
of bluetongue virus in 1977 and of Akabane virus in 1979. Journal of Hygiene 
(London) 95: 149-158. 
 Sellers R.F., Gibbs E.P.J., Herniman K.A.J., Pedgley D.E., Tucker M.R. (1979). 
Possible origin of the bluetongue epidemic in Cyprus, August 1977. Journal of 
Hygiene (Cambridge) 83: 547. 
 Sellers R.F., Pedgley D.E., Tucker M.R., (1978). Possible windborne spread of 
bluetongue to Portugal, June-July 1956. Journal of Hygiene, Cambridge 81: 189. 
 Sellers R.F., Pedgley D.E., Tucker M.R., (1977). Possible spread of African 
horse sickness on the wind. Journal of Hygiene, Cambridge 79: 279-297. 
 Sellers R.F., (1975) Bluetongue in Cyprus. Australian Veterinary Journal 51: 
198-203. 
 Shad G., Wilson W.C., Mecham J.O., Evermann J.F., (1997). Bluetongue virus 
detection: a safer reversetranscriptase polymerase chain reaction for prediction 
of viremia in sheep, J. Vet. Diagn. Invest., 9: 118–124. 
 Shapiro H.M., (1995). Practical flow cytometry: Third Edition. Wiley-Liss, pp. 
542.   
 Shimshony A., (2004). Bluetongue in Israel – a brief historical overview. 
Veterinaria Italiana, 40: 116-118. 
 Spreull J., (1905). Malarial catarrhal fever (bluetongue) of sheep in South 
Africa. J. Comp. Pathol. Therapy, 18: 321-337. 
 Stallnecht D.E., Howerth E.W., (2004). Epidemiology of bluetongue and 
epizootic disease in wildlife: surveillance methods. Veterinaria Italiana, 40: 203-
207. 
 Standfast, H.A., Muller, M.J. & Wilson, D.D., (1985). Mortality of Culicoides 
brevitarsis fed on cattle treated with Ivermectin. In Bluetongue and Related 
Orbiviruses, ed. T. L. Barber & M. M. Jochim. New York: Alan R. Liss Inc., 
611-616. 
 Stott J.L., Barber T.L., Osburn B.I., (1985). Immunologic response of sheep to 
inactivated and virulent bluetongue virus. Am. J. Vet. Res., 46:.1043-1049. 
 Studdert M.J., Pangborn J. and Addison R.B., (1966). Bluetongue virus 
structure. Virology, 29: 509 511. 
 Tabachnick W.J., (2004). Culicoides and the global epidemiology of bluetongue 
virus infection. Veterinaria Italiana, 40: 145-150. 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
111 
 
 Takamatsu H., Mellor P.S., Mertens P.P., Kirkham P.A., Burroughs J.N., 
Parkhouse R.M., (2003). A possible overwintering mechanism for bluetongue 
virus in the absence of the insect vector, J. Gen. Virol., 84: 227–235. 
 Takamatsu H., Burroughs J.N., Wade-Evans A.M., Mertens P.P., (1992). 
Analysis of bluetongue virus serotype-specific and cross reactive ovine T-cell 
determinants in virus structural proteins, In: Walton T.E., Osburn B.I. (Eds.), 
Bluetongue, African horse sickness and related orbiviruses, CRC Press, Boca 
Raton, FL, USA, 491–497. 
 Takamatsu H., Burroughs J.N., Wade-Evans A.M. and Mertens P.P.C., (1990). 
Identification of a bluetongue virus serotype l-specific ovine helper T-cell 
determinant in outer capsid protein VP2. Virology, 177: 396-400.  
 Takamatsu H. and Jeggo M.H., (1989). Cultivation of bluetongue virus-specific 
ovine T cells and their crossreactivity with different serotype viruses. 
Immunology, 66: 258-263.  
 Vassalos M., (1980). Cas de fièvre catharrale du mouton dans l‘ile de Lesbos 
(Grece). Bullettin de l‘Office International des Epizooties, 92: 547-555. 
 Venter G.J., Gerdes G.H., Mellor P.S., Paweska J.T., (2004). Transmission 
potential of South African Culicoides species for live-attenuated bluetongue 
virus. Vet. Ital., 40: 198-202. 
 Veronesi E., Hamblin C., Mellor P.S., (2005). Live attenuated bluetongue 
vaccine viruses in Dorset Poll sheep, before and after passage in vector midges 
(Diptera: Ceratopogonidae). Vaccine, 23(48/49): 5501-5509. 
 Verwoerd D., Erasmus B.J., (2004). Bluetongue. In: Coetzer J.A., Tustin R.C. 
(Eds). Infectious Diseases of Livestock, 2nd ed. Oxford University Press, Cape 
Town, 1201-1220. 
 Wade-Evans A.M., Mertens P.P.C. and Belsham G.J., (1992). Sequence of 
genome segment 9 of bluetongue virus (serotype 1, South Africa) and expression 
analysis demonstrating that different forms of VP6 are derived from initiation of 
protein synthesis at two different sites. J. Gen. Virol., 73: 3023-3026.  
 Whetter L.E., Maclachlan N.J., Gebhard D.H., Heidner H.W., Moore P.F., 
(1989). Bluetongue virus infection of bovine monocytes, J. Gen. Virol., 70: 
1663-1676. 
 White D.M., Wilson W.C., Blair C.D., Beaty B.J., (2005). Studies on 
overwintering of bluetongue viruses in insects, J. Gen. Virol., 86: 453-462. 
 Wirblich C., Bhattacharya B., Roy P., (2006). Nonstructural protein 3 of 
bluetongue virus assists virus release by recruiting ESCRT-I protein Tsg101, J. 
Virol., 80: 460-473. 
 Zientara S., Bréard E., Sailleau C. (2006). Bluetongue: Characterization of Virus 
Types by Reverse Transcription-Polymerase Chain Reaction. Vannier P, 
Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 
studies in sheep”, Tesi di Dottorato in ―Scienze e Tecnologie Zootecniche‖ – Università degli Studi di Sassari 
112 
 
Espeseth D (eds): New Diagnostic Technology : Applications in Animal Health 
and Biologics Controls, Basel, IABs/Karger series, Developments in 


















































Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 





I owe special thanks to: 
 
 my tutors Doctor Paola Nicolussi and Doctor Piero Bonelli 
 the Laboratorio di Diagnostica Clinica (Dipartimento Direzione, Istituto 
Zooprofilattico Sperimentale della Sardegna “G. Pregreffi”): Doctor Rossana 
Re, Doctor Paolo Colorito, Doctor Giovanni A. Pilo, Mrs. Sandra Fresi and Mrs. 
Luciana Pais 
 Doctor Giovanni Savini of ―Centro Studi Malattie Esotiche‖ (CESME), ―Istituto 





















Dott. Marco Canalis, “Monovalent modified-live vaccine against Bluetongue serotype 1: Safety & Efficacy 




Analysis of variance (ANOVA) between groups: different superscripts (a, b, c) 
denote statistically significant differences  P≤ 0.05. 
Analysis of variance (ANOVA) within groups: different superscripts (single dose= *, 
decuple dose= + and control= #) denote statistically significant differences  P≤ 0.05 
respect to prevaccination value. 
 
v.n.: normal value 




Number Data  Number Data   
1 05/01/2007 12 11/04/2007 
2 17/01/2007 13 18/04/2007 
3 24/01/2007 14 26/04/2007 
4 31/01/2007 15 02/05/2007 
5 07/02/2007 16 09/05/2007 
6 14/02/2007 17 16/05/2007 
7 07/03/2007 18 23/05/2007 
8 14/03/2007 19 30/05/2007 
9 21/03/2007 20 07/06/2007 
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Analysis of variance (ANOVA) within groups: different superscripts (a, b, c) denote 
statistically significant differences  P≤ 0.05. 
 
v.n.: normal value 




Number Data  Number Data   
1 26/01/2007 8 14/03/2007 
2 31/01/2007 9 21/03/2007 
3 07/02/2007 10 28/03/2007 
4 14/02/2007 11 04/04/2007 
5 21/02/2007 12 11/04/2007 
6 28/02/2007 13 18/04/2007 
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Analysis of variance (ANOVA) between groups: superscript (*) denote statistically 
significant differences  P≤ 0.05. 
Analysis of variance (ANOVA) within groups: different superscripts (letters) denote 
statistically significant differences  P≤ 0.05. 
 
v.n.: normal value 




Number Data  Number Data   
1 01/08/2007 6 05/09/2007 
2 08/08/2007 7 12/09/2007 
3 17/08/2007 8 19/09/2007 
4 22/08/2007 9 26/09/2007 
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Analysis of variance (ANOVA) between groups: superscripts (*) denote statistically 
significant differences  P≤ 0.05. 
Analysis of variance (ANOVA) within groups: different superscripts (letters) denote 
statistically significant differences  P≤ 0.05. 
 
v.n.: normal value 




Number Data  Number Data   
1 12/10/2007 5 07/11/2007 
2 17/10/2007 6 14/11/2007 
3 24/10/2007 7 21/11/2007 
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